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Infectious Laryngotracheitis Virus (ILTV) is an Alphaherpesvirus of the domesticated 
chicken and other economically important fowl such as pheasants, peafowl and turkeys.  It 
causes an upper respiratory disease that is clinically characterised by dyspnoea, rales and 
expulsion of a thick, sometimes hemorrhagic, tracheal exudate.  Incidences of mortality 
range from 10 – 70 % whilst morbidity ranges from 50 – 100 %.  The disease causes 
significant financial losses to the poultry industry through bird death, stunted growth and a 
marked decrease in egg production.  Due to its economic importance, attenuated live-
vaccines have been developed by serial passage of virus either in eggs or tissue culture.  
These have the ability to protect birds against ILTV however they do not stop latent infection 
which can result in reactivation of the virus termed ‘vaccinal laryngotracheitis’.  The 
molecular biology underlying virus-host interactions for ILTV is poorly understood and 
there are large gaps in knowledge regarding the pathogenesis of ILTV infection. 
MicroRNAs (miRNAs) are short, non-coding RNAs that post-transcriptionally regulate gene 
expression through targeting of specific mRNAs.  Several herpesviruses have been shown to 
encode miRNAs that have the ability to regulate both viral and cellular gene expression 
which can impact virus-host interactions.  Previous work in the literature has shown that 
ILTV encodes for 10 miRNAs with sparse data on what they may be regulating.  
It was hypothesised that the virus-encoded miRNAs may have an effect upon the 
pathogenesis of the virus by targeting both cellular and viral mRNAs.  To investigate this 
hypothesis initially, the biochemical technique CLASH (Cross-Linking and Sequencing of 
Hybrids) was attempted however a lack of suitable reagents such as physiologically relevant 
cell lines of chicken origin made this technically challenging and this approach was halted.  
Instead, a bioinformatic approach was developed and split into two avenues of research.   
Firstly, it was hypothesised that miRNAs encoded by ILTV would target virally derived 
transcripts.  As the virus genome is poorly annotated, transcripts for all 79 open reading 
frames (ORFs) were created manually using an arbitrary system of 1000 bp upstream of the 
ATG start site and 50 bp downstream of the designated PolyA tail.  These were then fed into 
the online algorithm RNA Hybrid alongside sequences for all 10 virus-encoded miRNAs.  
Results from the bioinformatic predictions were then sorted and filtered using pre-defined 
conditions.  This left a total of 227 predicted interactions.  These were then filtered again 
leaving 28 novel targets that were screened in a reporter based system.  Three of the 
predicted interactions showed a decrease in luciferase-reporter activity compared to the 
siRNA control (UL24, UL29 and UL46/48), however only the latter two showed statistically 
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significant decreases in activity of 15 % and 20 % respectively.  Mutation of the seed 
sequences in both UL29 and UL46/48 targets abrogated the effects of the miRNA mimic.  
Further work on UL29 and its interaction with ILTV-miR-I2 looked at validating this 
interaction by western blotting however these results were inconclusive.  Investigations into 
the interaction between UL46/48 and ILTV-miR-I6-5p first confirmed by RT-PCR that 
UL46 was targeted by ILTV-miR-I6-5p.  Validation of the interaction between UL46 and 
ILTV-miR-I6-5p by western blotting was inconclusive.  Investigations into the interplay 
between UL46, UL48 and the ICP4 promoter were also characterised with UL46 able to 
negatively modulate the effects of UL48 on ICP4 promoter activity in a reporter-based 
system. 
Secondly, the same viral transcripts were then used in conjunction with high confidence 
chicken miRNAs as per MiRBase (Release 21, Jun 2014).  The sorting and filtering of 
results mirrored that of the viral transcript study giving a final list of 103 predicted targets.  
From the list, three targets were picked that were all targeted by the cellular miRNA gga-
miR-133a-3p and tested using the same reporter system.  Two targets, one in UL20 and one 
in the coding region of ICP4 showed no statistical difference between the miRNA mimic and 
siRNA control.  In contrast, one target, located in the 5’UTR of ICP4 and confirmed by RT-
PCR to be within the expressed mRNA transcript was found to cause a 55 % reduction in 
luciferase activity.  This effect was then abrogated upon mutation of the miRNA seed 
sequence.  Further investigations found that this miRNA can cause an apparent reduction in 
virus titer and a statistically significant decrease in plaque size morphology when virus is 
harvested from cells transfected with the miRNA mimic and used to infect naïve cells.  
Moreover, a combination RT-qPCR and sequencing was used to confirm the sequence of 
gga-miR-133a-3p in several tissues of the chicken including the Dorsal Root Ganglia (DRG) 
and Harderian gland (HG).  These are of importance to ILTV biology as the DRG is a site of 
latent infection and the HG is a secondary lymphoid organ (SLO) in the bird which monitors 
the upper respiratory tract, the site of lytic replication/clinical symptoms.   
Finally, CRISPR-Cas9 genome editing was used to delete a cluster of five miRNAs from the 
viral genome. Guide RNAs (sgRNAs) were designed to target the miRNA cluster and shown 
to efficiently direct cleavage of target DNA in an in vitro system.  Following 
transfection/infection of cells, virus was harvested and subsequent sequencing showed that 
this approach was successful in creating a recombinant ILTV.  This was detectable after 
passage of the virus through naïve cells although a pure population of recombinant virus was 




Infectious Laryngotracheitis (ILT) is a deadly disease of chickens caused by a virus called 
Infectious Laryngotracheitis Virus (ILTV).  The disease is financially important all over the 
world due to how much chicken is eaten.  If birds catch this virus, they have symptoms such 
as shortness of breath and produce a thick, sometimes bloodied mucus that they cough up.  
Birds also do not grow properly and egg laying birds do not lay as many eggs as healthy 
animals would.  Many birds recover from the virus but it can establish a life-long infection in 
the neurons of animals.  Because of this, vaccines have been developed to protect animals 
from developing the symptoms of the virus but they currently do not stop the virus setting up 
a life-long infection.  There is still not much known about how the virus interacts with 
chickens when they are infected. 
All life depends upon the making of new proteins from the DNA blueprint found within cells 
of the body.  The middle step in the process, known as messenger RNA (mRNA) carries the 
instructions from DNA to make new proteins.  Small molecules known as microRNAs 
(miRNAs) affect how much protein is produced by targeting these mRNAs and binding to 
them.  Viruses can also make miRNAs and they have the ability to target both virus mRNAs 
and cellular mRNAs.  To date, ILTV is known to make 10 miRNAs but very little is known 
about what they do.  The hypothesis is that these virus-encoded miRNAs, as well as cellular 
miRNAs can alter levels of specific virus mRNAs which will affect how the virus interacts 
with its host.   
The first aim was to predict virus mRNA targets of the virus-encoded miRNAs using 
computer software.  These predictions were analysed and initially 227 possible targets were 
identified.  Further analysis gave a final list of 28 targets that were tested in the laboratory.  
Three of these targets showed a change in virus mRNA levels but further work to validate 
these interactions was inconclusive.  
The second aim was to predict virus mRNA targets of chicken miRNAs.  These were also 
filtered and gave a total of 103 predicted targets.  Three of the targets of the chicken miRNA 
miR-133a were tested in the lab and one was found to affect an essential virus mRNA called 
ICP4.  Further work showed that this miR-133a is found in chicken tissues that are important 
to the virus lifecycle in the chicken.  
Finally, genome editing was used to make a mutant virus that lacked 5 of the virus-encoded 
miRNAs.  To do this, guide RNAs (sgRNAs) were designed that instruct a protein called 
Cas9 to cut at specific points in virus DNA.  Experiments showed that these sgRNAs were 
successful in cutting the virus DNA at the specific points and a mutant virus was made. 
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1.1 – Herpesviruses 
Herpesviruses are large, double-stranded DNA (dsDNA) viruses that are found throughout 
the animal kingdom.  Most animal species are thought to be infected with at least one 
herpesvirus and it is generally considered that most vertebrate species are infected with 
several herpesviruses (Pellet and Roizmann, 2007, Fenner et al., 2011).  There are now over 
130 characterised viruses contained within the herpesvirus family with many more likely to 
be identified in species that are generally not as well studied (Brown and Newcomb, 2011).  
Herpesviruses are considered to have co-evolved with their main, natural host over several 
millennia.  In the case of herpes simplex viruses this can be traced back to the common 
ancestor of old and new world apes around 44.2 million years ago (Wertheim et al., 2014).  
At the genomic level, this can be seen in the divergence but conserved functionality of open 
reading frames (ORFs) found across different species and families of herpesviruses (Fossum 
et al., 2009)  
Herpesviruses cause a diverse range of disease manifestations from an asymptomatic 
infection through to cancer and even death.  The latter are typically associated with 
immunocompromised hosts, neonates and non-natural hosts.  Some members of the family 
have also been linked with life limiting illnesses such as Alzheimer’s disease however these 
findings were and still are controversial (Readhead et al., 2018).   
There are four common biological properties that all herpesviruses share.  Firstly, all encode 
a number of enzymes that are involved with DNA synthesis, nucleic acid synthesis and 
metabolism.  Secondly, viral genome replication and capsid assembly occurs in the host 
nucleus.  Thirdly, the production of infectious progeny leads to the destruction of the 
infected host cell and finally, herpesviruses have the ability to set up a lifelong, latent 
infection in their natural host.  In this latent state, the viral genome exists as an episome with 
little to no viral gene expression occurring.  Latent virus is also able to reactivate and allow 
for the production of infectious progeny (Roizmann et al., 1992).  
1.1.1 – Herpesvirus Structure 
Structurally, herpesvirus virions are extremely similar.  At the core of the virion is a linear, 
non-segmented dsDNA genome that is packed into an icosahedral shaped capsid of T = 16 
symmetry.  The size of the capsid is estimated to be between 100 nm and 110 nm in 
diameter.  Surrounding the capsid is a loosely arranged protein layer called the tegument.  It 
is now well established that tegument proteins play important roles in initiating lytic gene 
expression, regulating viral gene expression and virus assembly (Owen et al., 2015).  The 
tegument links the capsid to the envelope that is a lipid bilayer derived from the infected cell.  
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It is studded with a number of viral glycoproteins that play a number of important roles, 
particularly in virus entry and attachment (reviewed in section 1.3.1).  The overall size of the 
virion can vary between 120 nm to 300 nm due to changes in the thickness of the tegument 
(Pellet and Roizmann, 2007).  A typical herpesvirus virion is shown alongside a 
diagrammatic representation of a virion (Figure – 1.1).  
1.1.2 – Herpesvirus Genomes 
Herpesvirus genomes are split into 6 categories, labelled A-F depending upon the presence, 
number and the genomic location, of repeat regions within the genome (Roizmann et al., 
1992).  The six categories are shown in Figure 1.2.  ‘A’ viruses have a long region that is 
flanked by repeat regions that are termed left terminal repeat (LTR) and right terminal repeat 
(RTR).  Category B viruses have a long region that is flanked by repeat regions at both ends 
that vary in number.  Likewise, category C viruses have repeat regions at the ends of the 
genome however these repeat regions are often smaller than that of category B viruses.  
Within the category C viruses, there are also unrelated repeat regions over 100 nt in length 
that subdivide the genome.  Category D viral genomes are split into two unique regions that 
are the Unique Long (UL) and Unique Short (US) regions.  These regions are separated by an 
inverted repeat region (IR) that is also found as a terminal repeat (TR) region at the end of the 
US genome segment.  Likewise, category E viruses also have UL and US genomic segments 
however they are both flanked by their own inverted repeat regions (termed RL and RS).  
Finally the genomes of category F viruses have been found to contain no repeat regions 
(Roizmann et al., 1992). 
The actual length of herpesvirus genomes vary from around 125 kb up to 240 kb with a GC 
content ranging from 32 to 75 % dependent upon the virus species (Davidson, 2007).  The 
minimum number of ORFs encoded by the viruses is around 70 with the upper limit not well 
defined (McGeoch et al., 2006).  The genome of Human Cytomegalovirus (HCMV) is 
thought to encode around 169 ORFs though some studies have suggested that there could be 
an additional 604 ORFs (Van Damme and Van Loock, 2014).  Between the three 
subfamilies, there are a collection of genes that are defined as ‘core genes’ and in total there 
are 43 genes that are shared between the Herpesviridae family (Davidson, 2007).  These 
genes tend to encode for proteins that are necessary for DNA replication, and structural 
elements of the virion such as the capsid and tegument proteins.  Subfamilies (alpha, beta 
and gamma) may also have conserved genes between them that are unique to that subfamily.  
In addition, individual genes may be restricted to a genera or individual species.  As well as 
having ORFs that are protein coding, many herpesviruses genomes also contain non-coding 
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RNAs.  These include long, non-coding RNAs (lncRNAs), specific examples include the 
four major HCMV lncRNAs named RNA2.7, RNA1.2, RNA4.9, and RNA5.0 respectively 
(Hancock, 2017).  Moreover, a number of herpesviruses have also been shown to encode for 
MicroRNAs (miRNAs) which are discussed in detail in section 1.7 (Pfeffer et al., 2004a, 
Kincaid and Sullivan, 2012).     
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Figure – 1.1. A Typical Herpesvirus Virion 
A – An electron micrograph of a Herpes Simplex 1 virion.  Image taken from 
http://web.stanford.edu/group/virus/herpes/2000/herpes2000.html  
(accessed: 15/11/2017) 
B – A diagrammatic representation of a Herpes virion showing major structural features: 
Capsid, Envelope, Tegument and Glycoproteins.  
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Figure – 1.2. Diagrammatic representation of the genomes found in the 
family Herpesviridae  
Schematic drawings of the six different types of genomes found within the 
Herpesviridae family.  Solid black horizontal lines represent genomes and 
rectangles depict repeat regions.  Arrows indicate the relative orientation of the 
repeat regions.  Genomes of group A (e.g. Ictalurid herpesvirus 1) viruses have 
a large terminal repeat region at both the left and right end of the genome.  
Group B viruses (e.g.  Saimirine herpesvirus 2) have terminal sequences 
repeated numerous times at both ends of the genome.  Group C viruses (e.g. 
Human gammaherpesvirus 4) harbour both terminal repeats and also 4 
unrelated repeat regions that subdivide the genome.  The genomes of group D 
(e.g. Gallid alphaherpesvirus 1) viruses are divided into a long and short 
segment by an inverted repeat of the terminal region of the short (U
S
) region.  
Group E viruses (e.g. Human alphaherpesvirus 1) are similar to Group D 
viruses in terms of genome segmentation and inversion of the repeat regions 
flanking both the long and short regions.  No terminal or inverted regions have 
been described for group F viruses (e.g. Tupaiid betaherpesvirus 1). 
Image adapted from (Roizmann et al., 1992)    
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1.2 – Herpesvirus Classification 
The Herpesvirales order is split into three distinct families; Alloherpesviridae, Herpesviridae 
and Malacoherpesviridae.  Within the Alloherpesviridae family there are 12 species split 
across 4 genera.  Viruses found in this family typically infect fish and amphibians (Waltzek 
et al., 2009).  Likewise, the 2 species split into 2 separate genera in the Malacoherpesviridae 
family infect molluscs such as oysters (Davison et al., 2009).  Finally, the Herpesviridae 
family is the largest and split into three subfamilies; Alphaherpesvirinae, Betaherpesvirinae 
and Gammaherpesvirinae.  In total, 89 species are found across the 3 subfamilies split into a 
total of 12 genera (King et al., 2018).  Classification of herpesviruses was originally based 
upon rudimental conditions including host range, cell tropism and site of latency however 
this was changed in favour of classification based upon genome arrangement and sequence 
homology (Roizmann et al., 1992).  This change in classification conditions lead to the 
movement of some viruses from one subfamily to another.      
1.2.1 – Alphaherpesviruses 
The Alphaherpesvirinae subfamily is the largest of the 3 subfamilies containing 38 virus 
species across 6 genera.  The Iltovirus genus contains 2 species and includes Gallid 
alphaherpesvirus 1, commonly referred to as Infectious Laryngotracheitis Virus (ILTV), this 
is discussed in detail in sections 1.4 and 1.5.  The Mardivirus genus also contains species 
that infect birds with Gallid alphaherpesvirus 2, commonly known as Marek’s disease virus 
1 (MDV1) the type species of the genus. Only 1 species is found in the Scutairus genus and 
that is Chelonid alphaherpesvirus 5.  There are 12 species in the Simplexvirus genus with 
Human alphaherpesvirus 1, also referred Herpes Simplex 1 (HSV-1) the type species for the 
genus.  Finally there are 17 species in the Varicellovirus genus which contains Human 
alphaherpesvirus 3, commonly known as Varicella zoster virus (VZV) whilst there is one 
virus species in the unassigned genus which is Chelonid alphaherpesvirus 6 (King et al., 
2018).    
The first two human herpesviruses identified were HSV-1 and HSV-2.  As evidenced by 
their naming they are highly similar in terms of pathogenesis and clinical symptoms however 
phylogenetic analysis suggests HSV-2 jumped species and is more closely related to 
Chimpanzee Herpesvirus (ChHV) than HSV-1 (Wertheim et al., 2014, Pimenoff et al., 
2018).  Infection by HSV-1 and HSV-2 typically occurs at the oral and genital regions and 
initial infection is typically asymptomatic.  Latency is established in the ganglia which 
innervates the initial site of infection.  Outcome of infection varies from small localised 
lesions to invasion of the brain resulting in encephalitis and in some cases, even death.  
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Reactivation of HSV-1 and HSV-2 from latency causes disease.  Symptoms tend to include 
blisters on epithelial surfaces such as the lips which develop into ulcerated lesions that 
pustulate (commonly referred to as cold sores).  In addition, clinical manifestations include 
conjunctivitis, eczema and as previously mentioned, encephalitis.  Congenital infection is 
common and could be considered vertical transmission and there have been reports of this in 
the literature (Conrady et al., 2010). 
Aujeszky's disease, commonly called pseudorabies, is caused by the virus Suid 
alphaherpesvirus 1 (SuHV-1) of the Varicellovirus genus.  It is universally considered to be 
one of the most important swine pathogens and it is highly contagious possessing the ability 
to infect several other species such as cattle, cats, dogs and sheep.  In pigs, SuHV-1 causes a 
variety of clinical symptoms including coughing, sneezing, fever and depression with more 
severe signs such as abortions, seizures and death also seen.  Mortality of animals is near 100 
% in piglets under 4 weeks of age yet is as low as 10 % in older piglets.  Infection can cause 
pregnant sows to abort litters or can cause stillbirths and mummifications. Non-natural hosts 
that can be infected also show a large range of clinical signs and almost always die from 
infection (Fenner et al., 2011). 
Marek’s disease virus 1 (MDV1) is caused by Gallid alphaherpesvirus 2 and is a deadly 
disease of poultry.  It is highly virulent and can cause widespread death in a chicken shed.  
Symptoms include paralysis of the legs, neck and wings, weight loss, depression and lumps 
on the skin.  The latter of these is caused by numerous T cell lymphomas that are induced by 
the virus infecting lymphocytes (Swayne et al., 2013).  Due to the oncogenic potential and 
the preferential infection of lymphocytes by MDV1, it was originally classed as a 
gammaherpesvirus however the genome organisation is more similar to the alphaherpesvirus 
subfamily and was reclassified (Roizmann et al., 1992).  Related viruses, such as Marek’s 
disease virus 2 (MDV2) or Gallid alphaherpesvirus 3 is clinically benign and has been used 
extensively as a vaccine against MDV1.               
1.2.2 – Betaherpesviruses 
There are 5 genera in the Betaherpesvirinae subfamily totalling 18 species, making it the 
smallest of the subfamilies.  The Cytomegalovirus genus is the largest containing 8 species 
including Human betaherpesvirus 5, also known as Human cytomegalovirus (HCMV).  
Similarly, the Muromegalovirus genus contains the murine equivalent of HCMV, Murid 
betaherpesvirus 1, commonly called Murine cytomegalovirus (MCMV).  Within the 
Proboscivirus genus is 1 species, Elephantid betaherpesvirus 1.  3 virus species are 
contained in the Roseolovirus genus including Human betaherpesvirus 6A (HHV6A).  
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Finally, there are 3 species that are classed as unassigned such as Suid betaherpesvirus 2 
(King et al., 2018). 
HCMV is ubiquitous throughout the human population with estimates on infection levels 
somewhere between 60 – 70 % for industrialised nations and nearer 100 % for developing 
countries.  De novo infection is typically asymptomatic however a very small proportion of 
individuals can develop infectious mononucleosis (commonly referred to as glandular fever) 
as a result of HCMV infection (Pellet and Roizmann, 2007).  HCMV complications occur 
during pregnancy and it is the leading cause of congenital birth defects.  It is estimated that 1 
in 100-500 babies born worldwide have congenital HCMV, 1 in 300 babies present with 
congenital symptoms and 1 in 7000 will die as a result (Butler, 2016).  Babies born with 
congenital HCMV that survive have a number of symptoms including liver, lung or spleen 
damage, mental retardation as well as hearing and vision loss.  In addition to congenital birth 
defects, HCMV is a problem in the immunocompromised individual.  This group of people 
include recipients of solid organ transplants and individuals infected with human 
immunodeficiency virus (HIV).  Associated diseases in the immunocompromised include 
increased risk of death, HCMV associated hepatitis, severe colitis and pneumonia (Sager et 
al., 2015, Navarro, 2016).      
1.2.3 – Gammaherpesviruses 
The final subfamily found within the Herpesviridae family is Gammaherpesvirinae.  It is the 
second largest subfamily containing 33 viruses across 5 genera.  Contained within the 
Lymphocryptovirus genus is Human gammaherpesvirus 4, more commonly called Epstein-
Barr virus (EBV).  The Macavirus genus contains viruses such as Ovine gammaherpesvirus 
2 (OvHV-2) whilst the Percovirus genus has 3 species including Equid gammaherpesvirus 2.  
There are a total of 8 species in the Rhadinovirus genus which includes Saimiriine 
gammaherpesvirus 2 (also known as Herpesvirus Saimiri, HVS) and Human 
gammaherpesvirus 8 which is also referred to as Kaposi’s sarcoma associated herpesvirus 
(KSHV).  3 viruses are currently unassigned and they include Equid gammaherpesvirus 7 
(King et al., 2018).     
Epstein-Barr virus (EBV) is one of two human Gammaherpesviruses that has oncogenic 
potential.  It is highly prevalent in the human population and similar to HCMV, can cause 
infectious mononucleosis (glandular fever) and is responsible for around 90 % of cases 
reported.  Infection with EBV is commonly asymptomatic if it happens during childhood but 
primary infection in adolescents can lead to glandular fever.  EBV is heavily associated with 
several cancers such as Hodgkin’s lymphoma, Burkitt’s lymphoma, and gastric cancers 
Chapter 1  Introduction 
10 
 
(Maeda et al., 2009).  This is because EBV latency occurs in B lymphocytes.  These diseases 
and cancers are linked more with the immunocompromised individual but can also happen in 
the immunocompetent.  As well as cancers, EBV is linked with autoimmune diseases too 
including systemic lupus erythematosus (Lupus) and rheumatoid arthritis (Toussirot and 
Roudier, 2008). 
KSHV (HHV-8) is the other human gammaherpesvirus with oncogenic potential.  Its 
prevalence varies between continents with approximately 10 % of people in Mediterranean 
countries infected compared to 40 % in sub-Saharan countries (Fu et al., 2009).  
Malignancies associated with KSHV include Kaposi’s sarcoma, primary effusion lymphoma 
and Castleman’s disease (Goncalves et al., 2017).  Similar to EBV, immunocompromised 
patients are at a higher risk of developing these malignancies compared to a healthy 
individual.  Moreover, AIDS patients in Sub-Saharan Africa are at the highest risk of having 
a Kaposi’s sarcoma diagnosis (Boshoff and Weiss, 2002).  Primary infection of KSHV is 
thought to occur through the oral/salivary routes with latency establishment in B 
lymphocytes similar to other Gammaherpesviruses.  
Both Alcelaphine gammaherpesvirus 1 and Ovine gammaherpesvirus 2 are causative agents 
of the fatal lymphoproliferative disease malignant catarrhal fever (MCF) in their non-natural 
host.  In their natural reservoir host, wildebeest and sheep respectively, no disease is 
apparent (Russell et al., 2009).  Animals susceptible to MCF include cattle, deer, buffalo and 
other ungulates.  Clinically the disease manifests with symptoms including fever, depression, 
opacity of the cornea and a thick mucopurulent discharge from the nose.  The outcome of 
infection in these non-natural hosts is typically death but some animals have been shown 
to recover from the infection (O'Toole and Li, 2014).  Infected animals are dead-end 
hosts with no known transmission between cattle and other MCF susceptible animals.                    
1.3 – Herpesvirus Lifecycle  
The lifecycle of herpesviruses can be split into two distinctly separate stages.  Lytic infection 
with herpesviruses is associated with the temporal expression of the majority of virus-
encoded ORFs and subsequent release of infectious, daughter progeny.  In stark contrast, the 
latent infection of herpesviruses is highly regulated with tight controls on gene expression 
with the viral genome existing in the nucleus of infected cells as an episome.  The transition 
from latency to lytic replication is known as reactivation and it is generally associated with a 
stimuli that results in cellular stress.  Upon reactivation, the full temporal cascade of gene 
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expression is seen along with any associated clinical symptoms.  The end result is the 
assembly and egress of infectious virus particles.    
1.3.1 – Cellular Attachment and Entry  
The process of herpesvirus cellular attachment and entry are distinctly separate complex 
mechanisms that require both cellular and viral factors.  As the lifecycle can be split into two 
stages also (lytic and latent replication) in addition to the large breadth of cellular tropism 
across the family, it is not surprising to learn that this process is also complex giving the 
viruses the ability to enter this large variety of cell types.  First and foremost, the herpesvirus 
genome encodes for a number of glycoproteins that allow for attachment to a cell utilising a 
number of different receptors found upon the cell surface.  There are 10 glycoproteins 
encoded for by HSV-1 however this number can vary depending on the virus species 
however it is widely reported that only 4 glycoproteins, gB, gD, gH and gL, are essential for 
HSV-1 entry into host cells (Agelidis and Shukla, 2015). 
To begin the process of attachment, the glycoproteins gB and/or gC interact with heperan 
sulphate proteoglycans (HSPG) which are found on the cell surface.  The latter is not 
essential as shown by recombinant viruses lacking gC but there is an overall reduction in 
binding without gC (Herold et al., 1994, Shukla and Spear, 2001).  Following attachment, 
fusion occurs.  This involves several glycoproteins including gB, gD, gH and gL.  As well as 
viral factors, cellular factors are also necessary to facilitate fusion and these are nectin-1, 
herpes virus entry mediator (HVEM) or 3-O-sulfated HS (3-OS HS) (Shukla and Spear, 
2001).  When gD binds to one of these cellular receptors it undergoes a conformational 
change recruiting gB, gH and gL to form a fusion complex causing the merging of the lipid 
bilayers.  Once this has happed, the viral capsid along with the tegument proteins are 
released into the cytoplasm of the cell (Agelidis and Shukla, 2015). 
Following entry of the viral capsid and the tegument into the cytoplasm, directed transport to 
the nucleus is required due to the fact that molecules larger than 500 kDa have restricted 
diffusion movement in the cytoplasm, therefore a transport system is essential.  This is 
especially true for cells like neurons which have very long axons linking the site of infection 
to the cell nucleus meaning virions have to travel long distances (Enquist et al., 1998, 
Campadelli-Fiume and Menotti, 2007).  Microtubules found within the cell act as the 
“molecular motorways” on which the capsid travels to the nucleus from the cell periphery.  
They are polarised structures with the positive end located towards the cell membrane and 
the negative end found near the nucleus at the microtubule organizing centre (MTOC) 
(Dohner and Sodeik, 2005).  Once the viral capsids coated with the inner tegument are in the 
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proximity of the nucleus, filaments protruding from the nuclear pores are used for binding.  
This binding is thought to enable the release of the viral DNA and allow for translocation 
into the nucleus (Campadelli-Fiume and Menotti, 2007).           
1.3.2 – Lytic Replication 
During lytic replication, gene expression occurs in a highly controlled temporal manner.  The 
initial stage of this begins with immediate-early genes (also commonly referred to as alpha 
or α genes).  The second stage in the cascade are early genes (also known as beta or β genes), 
these are typically enzymes and the viral replication machinery.  Once these early genes have 
been transcribed, viral DNA (vDNA) replication occurs.  By definition, anything transcribed 
following viral DNA  replication is referred to as a late gene (gamma or γ genes).  This tends 
to include structural genes such as the capsid.  A simplified diagrammatic representation of 
the lytic (and latent) lifecycle is shown in Figure 1.3. 
Translocation of viral DNA is the beginning of the lytic replication cycle.  In the case of 
HSV-1 replication, there are 6 immediate-early genes (ICP4, ICP0, ICP22, ICP27, US1.5, 
and ICP47) that do not require de novo protein synthesis for their expression (Pellet and 
Roizmann, 2007).  Instead, all have a response element termed the ‘TAATGARAT’ 
sequence upstream of their respective coding regions.  A cellular protein, OCT-1 binds to 
this sequence and functions as a transcription factor.  This however is not enough to induce 
IE gene synthesis.  To initiate expression, the viral tegument protein VP16 (UL48 gene) 
binds to Host Cell Factor 1 (HCF-1) and this complex is then carried into the nucleus of the 
infected cell (LaBoissière and O'Hare, 2000).  The VP16/HCF-1 complex then binds to 
OCT-1 forming a complex that can initiate transcription.  This binding causes high levels of 
IE gene transcription kick starting the temporal cascade of gene expression (Thomas et al., 
1998). 
Once the temporal cascade of gene expression has begun, it is irreversible unless inhibited 
artificially.  Immediate-early gene expression, in particular that of ICP4 is absolutely 
required for progression beyond this stage, other IE genes have been shown to be 
dispensable for infection however an extremely high multiplicity of infection (MOI) is 
necessary.  One such example of an IE gene that can be removed is ICP0.  Studies have 
shown that is not necessary for replication (with a high MOI) however it is multifunctional 
and one such function is to decrease the total amount of histone H3 associated with viral 
promoters suggesting it helps early gene expression by counteracting epigenetic silencing of 
the genes (Leib et al., 1989, Cliffe and Knipe, 2008).  Early genes do not contain a specific 
response element akin to the TAATGARAT sequence found within the IE-genes but there is 
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evidence suggesting some have binding sites for transcription factors such as SP1 (Pellet and 
Roizmann, 2007).  Proteins encoded for by the early genes include the viral DNA replication 
machinery thus preparing the infected cell for vDNA replication.  
The full mechanisms of vDNA replication has not been fully elucidated however it is widely 
accepted that UL9 which encodes for the origin binding protein initiates replication by 
binding to an origin of replication.  HSV-1 contains 3 origins of replication, two copies of 
OriS in the IRS/TRS and one copy in the UL region (Summers and Leib, 2002).  Replication 
follows a rolling circle model which produces long head to tail concatamers of vDNA 
(Boehmer and Lehman, 1997).   
In the first instance, replication is thought to initiate at one of the origin of replication sites 
with both UL29 and UL9 been shown to be present in a complex surround an OriS site 
which is negatively supercoiled (Makhov et al., 2003).  This complex is thought to facilitate 
unwinding of the DNA as well help form the pre-replicative and mature replication sites 
(Darwish et al., 2016).  These replication sites are punctate within the nucleus and take up 
significant space once vDNA synthesis is underway.  The viral proteins then undergo a 
hypothesised conformational changes within the UL29/UL9 complex to form the DNA 
hairpin and breaking of the dsDNA to form ssDNA whereby UL29 acts to stop reannealing 
of the two complementary strands (Weller and Coen, 2012).  Folowing this, the 
helicase/primase (H/P) complex consisting of UL5, UL8 and UL52 is recruited for several 
functions.  Firstly, it unwinds duplex DNA and subsequently synthesise short RNA primers 
to allow for the initiation of DNA replication.  In an in vitro system, Chen et al. (2011), 
showed that a minimum of 6 bp of ssDNA is necessary for the H/P complex to unwind 
duplex DNA.  The last of the essential viral proteins recruited to the replication fork are the 
proteins that make up the viral polymerase; UL30 and UL42.  For the recruitment of 
polymerase to the replication site, an active form of the primase must be present.  Several 
mechanisms for this have been suggested including a conformational change in the H/P 
complex, changes in the RNA primer and also the possibility of UL29 interacting with the 
polymerase directly (Weller and Coen, 2012).  In total, 7 viral proteins along with as yet 
unidentified cellular factors are required for vDNA replication and they are; UL5, UL8, 
UL9, UL29, UL30, UL42 and UL52 (Pellet and Roizmann, 2007). 
Finally, the last set of genes are transcribed and these are designated as late genes.  They on 
the whole encode for genes necessary for virion assembly and egress from the cell.  The first 
stages of capsid assembly happen in the cytoplasm though the final stages of capsid 
assembly including the insertion of vDNA happen in the nucleus of the cell (Pellet and 
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Roizmann, 2007).  Once capsids contain vDNA, the first stage of egress occurs.  This 
happens through the inner nuclear membrane with capsids budding with the assistance of 
UL31 and UL34 proteins into the perinuclear space (Mettenleiter, 2002).  Subsequent steps 
of virion maturation have been hotly disputed in the literature with differing models 
proposed.  The model with the most data, and generally the most accepted, is the 
envelopment–de-envelopment–re-envelopment model. To move out of the perinuclear space, 
de-envelopment occurs by the capsid envelope fusing with the outer nuclear membrane 
facilitating the release of the capsid and tegument proteins into the cytoplasm.  The tegument 
of the herpesvirus capsid is typically described as a loose structure however there is evidence 
suggesting at least the inner tegument follows the same icosahedral symmetry; most likely 
due to the large tegument protein interacting with major capsid protein (Zhou et al., 1999).  
With this scaffold, tegumentation can occur with both the inner and outer tegument 
occurring in the cytoplasm.   
The final stage in assembly and egress is the addition of a final envelope which is studded 
with glycoproteins which are necessary to facilate entry into cells.  This is thought to occur 
through the trans-golgi vesicles whereby assembled glycoproteins are in such an orientation 
that their cytoplasmic tails interact with tegument proteins.  Interactions between both 
glycoprotein E (gE) and glycoprotein M (gM) and the tegument protein UL49 has been 
shown in SuHV-1 (Fuchs et al., 2002b).  These interactions are thought to drive the final 
envelopment as well as unidentified mechanisms as all three of these proteins have been 
shown to be dispensible for replication (Mettenleiter, 2002).  Release of virions from the cell 
is carried out by exocytosis (Pellet and Roizmann, 2007).                          
1.3.3 – Latency 
Latency is the second stage of the herpesvirus lifecycle and it is the one by which they are 
able to establish lifelong infections in their host.  The viral genome in latent cells exists as an 
episome and no viral replication is seen with viral gene expression tightly regulated.  The 
level of gene expression varies between species and in this section, HSV-1 latency will be 
reviewed with mention of other species from other subfamilies. 
The site of latency for Alphaherpesviruses is the sensory neurons that innervate the initial 
site of infection.  Following lytic replication, virions track up the axon of the neuron by 
retrograde transport.   Upon reaching the neuronal cell body, the herpesvirus genome forms a 
closed circle or episome.  No known protein-encoding genes are transcribed during this 
period.  In contrast however, a long viral RNA referred to as the latency associated transcript 
(LAT) is heavily expressed.  It is encoded antisense to the IE-gene ICP0, a transactivator of 
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viral gene expression (discussed in section 1.3.2) (Pellet and Roizmann, 2007).  The function 
of the LAT is to repress lytic gene expression thus blocking reactivation of the virus (Nicoll 
et al., 2016).  No proteins are produced from the LAT however the 8.3 kb primary transcript 
is spliced into two major LAT introns of 1.5 and 2 kb size respectively along with a 6.3 kb 
minor LAT exon that is further processed into 8 mature microRNAs (Pellet and Roizmann, 
2007).  Numerous studies have been undertaken elucidating the role of the LAT and its 
associated miRNAs.  Umbach et al. (2008b), showed that the LAT encoded miRNAs were 
able to suppress expression of the viral genes ICP0 and ICP4.  As well as repressing viral 
gene expression the LAT can also block apoptosis.  Two small RNA products from the 1.5 
kb LAT intron were shown to be able to block cold shock induced apoptosis in latently 
infected neuroblastoma cells (Shen et al., 2009).  
Moreover, it is not only the LAT that works to help maintain latency.  Whilst the 
TAATGARAT response element can kick start lytic replication in permissive cells, in 
neuronal cells, the opposite effect is seen (Lillycrop and Latchman, 1992).  OCT-2, the 
neuronal version of OCT-1 can bind to these response elements in IE-genes and repress lytic 
gene expression.  In addition, cellular miRNAs can also target essential IE-genes thus 
blocking reactivation (discussed more in section 1.7.3) (Pan et al., 2014). 
Numerous other mechanisms have also been reported to help maintain latency across the 
virus family.  Latency in the gammaherpesvirus EBV is much more complex involving 3 
stages defined by the viral transcripts that can be detected (Rowe et al., 1992).  Recent 
reports investigating KSHV latency implicated that chromatin remodelling controls 
reactivation (Hopcraft et al., 2018).  Epigenetic regulation has also been implicated in 
controlling latency of cytomegaloviruses found in the Betaherpesvirus subfamily (Liu et al., 
2013).           
1.3.4 – Reactivation  
Similar to latency and other life stages of the virus, reactivation is tightly controlled.  The 
causes of reactivation are still mysterious and wide ranging but the molecular control of 
reactivation has been elucidated for several virus species.  The outcome of reactivation is 
dependent upon the virus subfamily, for example Alphaherpesvirus reactivation leads to 
clinical symptoms such as cold sores in the case of HSV-1 whilst reactivation of 
Betaherpesviruses and Gammaherpesviruses is more complex especially owing to the 
oncogenic nature of the latter.    
Reactivation requires the virus to overcome all of the mechanisms that are in place to 
maintain latency.  As discussed in the previous section (1.3.3), both cellular and viral factors 
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contribute to the maintenance of latency.  The end goal of reactivation is the production of 
infectious daughter progeny in a similar fashion to de novo lytic infection however there are 
two major differences.  Firstly, the genome exists as an episome that is epigenetically 
modified with chromatin and other factors.  Secondly, VP16, necessary to facilitate IE-gene 
transcription is most likely not present however there is little evidence surrounding this 
(Cliffe and Wilson, 2017).   
The process of reactivation is broken down into two separate stages.  In the first instance, a 
burst of viral transcription happens following a reactivation stimulus typically defined as a 
‘stressor’.  These stressors have been found to include heat shock, mental tension, fatigue, 
and exposure to UV light amongst others (Grinde, 2013).  Studies observed the transcription 
of VP16 upon inhibition of some cell signalling pathways such as those downstream of nerve 
growth factor (NGF) (Wilcox and Johnson, 1987, Kim et al., 2012).  Even on the production 
of viral transcripts, these then have to overcome the RNAi pathway including the LAT 
associated miRNAs that are known to target ICP4 and ICP0 suggesting there is some 
redundancy in this mechanism.  Not all latently infected cells exposed to a stressor will 
undergo reactivation but rather a subset.  One theory surrounding this is a threshold of lytic 
protein production that must be reached in phase I in order to trigger full blown reactivation 
(Cliffe and Wilson, 2017).  If this threshold is surpassed, phase II reactivation which results 
in the synthesis of infectious particles occurs. 
  





Immediate Early IE (α)  
Early (β) 
Late (γ)  
DNA replication 
Infection  
Latency Lytic/productive cycle 
Reactivation 
Figure – 1.3. Diagrammatic representation of the Herpesvirus gene expression cascade 
Following de novo infection, gene expression follows a temporal pattern with immediate-early 
genes (IE) (also known as alpha or α genes) expressed initially.  Following IE gene expression, 
early genes (E) (also referred to as beta or β genes) are activated.  Following early gene 
expression, viral DNA replication typically occurs.  Finally, late genes (L) (also called gamma 
or γ genes) are expressed prior to virion assembly and nuclear egress. Completing the lytic or 
productive viral cycle. Conversely, herpesviruses also have a latent cycle whereby no infectious 
progeny are produced.  Upon certain triggers, reactivation can occur resulting in a lytic or 
productive cycle  
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1.4 – Infectious Laryngotracheitis 
Infectious Laryngotracheitis (ILT) is a fatal respiratory disease of poultry.  It is caused by the 
Alphaherpesvirus Gallid alphaherpesvirus 1 (Infectious Laryngotracheitis Virus [ILTV]).  
Endemic worldwide, it can be a significant burden on poultry producers both in the broiler 
and laying industries.  The virus and its properties are discussed in greater detail in section 
1.5.   
1.4.1 – Occurrence and Significance  
The first reports of ILT came from Canada in 1925 with the USA reporting it a year later.  
By the early 1960’s, over 40 countries had reported the disease (Menendez et al., 2014).  
Even in the earliest reports, it was described as a ‘major problem’ for the poultry industry 
with researchers also reporting of ‘chronic carrier’ birds that survived the initial infection 
and possessed the ability to pass the virus onto other birds (Brandly and Bushnell, 1934).  
Today, it is still a major economic problem for the global poultry industry though it is 
confined to certain geographic regions/areas.  This tends to be where the highest population 
density of poultry is seen (Bagust et al., 2000).        
Vaccination is commonly used to protect birds but this prevents the clinical symptoms as 
opposed to preventing infection.  The first vaccine for ILT was developed in 1934 by 
inoculating birds with infected tissue in the cloaca (Brandly and Bushnell, 1934).  This is 
generally considered as the first effective vaccine against a major avian pathogen (Swayne et 
al., 2013).  More recently, the USDA labels licensed vaccines as ‘Prevention of 
Laryngotracheitis’ instead of ‘Prevention of infection’ due to the fact that a latent infection is 
still established (Koski et al., 2015).  The majority of vaccines used are live-attenuated 
through serial passage of virus either in tissue culture or chicken embryos (Coppo et al., 
2013b).  However, attenuated vaccine viruses have the ability to recombine and the 
emergence of vaccine derived virulent strains has become more common (Lee et al., 2012).  
A study carried out in 2008 found that 94 % of the strains circulating in Europe over the last 
35 years were related to the vaccine strain (Neff et al., 2008).  Recently, there have been 
efforts to create vectored vaccines using Herpesvirus of Turkeys (HVT) and Fowl pox virus 
(FPV) expressing ILTV glycoproteins to confer protection.  As well as this, recombinant 
vaccines are also been developed which lack the genes for some viral glycoproteins (Devlin 
et al., 2007, Schneiders et al., 2018).     
1.4.2 – Clinical Signs  
Clinically, there are two forms of ILT recognised: the more severe epizootic form and a 
milder enzootic form.  The former is characterised by dyspnoea, gasping, coughing and 
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expulsion of thick, sometimes haemorrhagic, tracheal exudate.  The milder form presents 
with marked decreases in egg production, watery eye, conjunctivitis, swelling of the 
infraorbital regions and nasal discharge (Bagust et al., 2000).  Some of the symptoms are 
shown in Figure – 1.4.  There have been some reports of other clinical symptoms such as 
esophagitis and pharyngitis in some backyard flocks but this is not typically common and 
has only been reported in a handful of cases (Sary et al., 2017).  Symptoms present in the 
animal after a 6 – 12 day incubation period or after 2 – 4 days incubation in birds 
experimentally inoculated with the virus (Fuchs et al., 2007).  After the onset of clinical 
signs, most chickens tend to recover in around 10 – 14 days (Bagust et al., 2000).  Typical 
outbreaks see morbidity reach around 90 – 100 % whilst mortality ranges greatly, usually 
between 5 – 70 % although mortality is generally around 10 - 20 % (Devlin et al., 2011, 
Coppo et al., 2013b).  
1.4.3 – Gross Pathology 
Post mortem examinations reveal extensive pathological findings.  Lesions can be observed 
in the conjunctiva and throughout the respiratory tract of infected animals, commonly 
located in the larynx and trachea of the bird (Bagust et al., 2000).  Swelling and 
inflammation of the respiratory tract coupled with necrosis and haemorrhage can also be 
seen (Ou and Giambrone, 2012) (Figure – 1.5A).  Thick tracheal exudate and caseous plugs 
also line the lumen of the trachea and can cause complete occlusion of the lumen as shown in 
Figure – 1.5B.  Virus can also disseminate throughout the body of the bird with a number of 
internal organs including throat, trachea, lung, cecum, kidney, pancreas, thymus and 
oesophagus, testing positive for the virus via quantitative PCR analysis (qPCR) (Wang et al., 
2013).  Work carried out by another lab group in the same year detected ILTV in a larger 
number of organs with a more widespread dissemination throughout the body.  Zhao et al. 
(2013), found ILTV in 17 different locations including the heart, liver, spleen, lung, kidney, 
larynx, tongue, thymus, glandular stomach, duodenum, pancreatic gland, small intestine, 
large intestine, cecum, cecal tonsil, bursa of Fabricius, and brain of chickens.  This pattern of 
detection was seen across both the directly infected and contact exposed group of birds up to 
28 days post infection (DPI).     
At the histopathological level, intranuclear inclusion bodies are typical, though only present 
in the early stages of infection.  Infected epithelial cells start to form large, multinucleated 
cells (syncytia).  The loss of goblet cells and invasion of the mucosa by inflammatory cells is 
also seen.  In later stages, the loss of the epithelial layer through cell death can expose the 
blood capillaries leading to rupture and haemorrhage (Bagust et al., 2000).       






Figure – 1.4. Clinical Signs of Infectious Laryngotracheitis Virus infection 
A – Animal is showing conjunctivitis and open-mouthed breathing 
B – Central bird is showing open-mouthed breathing and craning of the neck 
C – Animal is displaying signs of conjunctivitis and nasal discharge 
D – The animal has exuded bloodied, tracheal exudate coming from the mouth 
Images adapted from Buckles (2009).  










Figure – 1.5. Gross Pathology of Chickens infected with ILTV 
A – Image depicts the trachea of infected animals with the bottom showing the fewest lesions and 
haemorrhage and the top displaying the more severe haemorrhage and lesions 
B – Cross sections of trachea from birds infected with ILTV showing complete occlusion of the 
lumen with tracheal exudate.  On the right a healthy trachea is shown for comparison 
C – Tracheal exudate lining the lumen of the trachea from an infected animal.  In some cases this 
can also be haemorrhagic 
 
Images adapted from Buckles (2009). 
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1.4.4 – Poultry as a worldwide food source 
At a global level, just over 118 thousand tonnes of poultry meat was eaten in 2017.  The 
United States of America accounted for around 18 thousand tonnes of this total last year 
(OECD et al., 2017).  When broken down into amount of poultry eaten per capita, Israel eats 
the most with 56.9 Kg of poultry eaten per head.  This is over double the amount the 
combined EU28 eat per person which is at 24.2 kg per head (OECD et al., 2017). 
Chickens and other birds are a staple source of protein in the average British household with 
91 % of consumers reporting that they ate chicken and of these, 70 % eat chicken at least 
once per week (Mintel, 2017).  Economically, chicken in particular is valuable to the British 
economy with figures from 2016 showing unprocessed poultry sales equated to £2,894 
million rising to an estimated £3,405 million by 2022 (Mintel, 2017).  In addition, 
government figures show that approximately 112 million hens (including spent laying hens 
and surplus breeder stock) were slaughtered in the UK during the month of July 2018 
(DEFRA, 2018).  These figures underline the importance of chicken and other poultry as a 
valuable food source and how food security lapses and pathogen outbreaks can have serious 
financial consequences at a governmental level right down to the individual farmer.   
1.5 – Infectious Laryngotracheitis Virus 
Infectious Laryngotracheitis Virus (ILTV) is a member of the Iltovirus genus in the 
Alphaherpesvirinae subfamily.  It is also sometimes referred to as Gallid alphaherpesvirus 1.  
It is the etiological agent of Infectious Laryngotracheitis (ILT).     
1.5.1 – Genome Structure  
The genome of ILTV is consistent with a category D genomic structure with a UL region and 
a US region that is flanked by both an internal and terminal inverted repeat regions (IR/TR) (as 
outlined in Figure – 1.2.).  The genome is ~150 kb in length and it encodes for a predicted 80 
ORFs.  Eight of these ORFs are unique to the Iltovirus genera.  Sixty five of these ORFs are 
found within the UL with a further 9 encoded for in the US.  Three ORFs (ICP4, US10 and 
sORF4/3) are found within the internal inverted and terminal repeat regions (IR/TR) flanking 
the US region (Piccirillo et al., 2016).  Of the predicted 80 ORFs, 63 are homologous to the 
HSV-1 genome (McGeoch et al., 1988).  Within the UL region there is a lack of UL16 
homologue and large inversion of the genomic arrangement from UL22 to UL44 genes 
(Ziemann et al., 1998a).  Moreover, the UL47 gene, termed sORF1 in ILTV is translocated 
from the UL to the US region however its function is generally considered to be the same 
(Helferich et al., 2007).  Flanking the ends of the UL region are the eight unique genes to the 
iltovirus genera.  Six are found at the left hand end of the region and are designated ORF F 
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followed by ORF A through E in that genomic order (displayed on Figure – 1.7) (Veits et al., 
2003b, Garcia et al., 2013).  Previous work stated that ORFs A-E were dispensable for 
replication in vitro but more recent work has found that deletant ORF C recombinant viruses 
are heavily attenuated in vivo compared to wild type and the deletant virus is now a possible 
vaccine candidate (Veits et al., 2003b, Garcia et al., 2016, Schneiders et al., 2018).  At the 
other end of the UL region are another two unique ORFs termed UL0 and UL-1 (Thureen and 
Keeler, 2006, Ziemann et al., 1998b).  The former of these, UL0 has been shown to be 
dispensable for replication in vitro however recombinant viruses lacking UL0 have been 
observed to be attenuated in vivo (Veits et al., 2003a).  In comparison, UL-1 has recently 
been shown to be essential for ILTV replication suggesting it plays an important role in the 
ILTV lifecycle (Nadimpalli et al., 2017).     
1.5.2 – Transmission 
Natural infection of birds with ILTV primarily occurs through the nasal, oral or ocular route 
(Bagust et al., 2000).  The source of this infection can come from other infected animals, 
contaminated dust, litter, drinking water and fomites (Ou and Giambrone, 2012).  Other 
indirect sources of transmission have also been reported including cats, crows and dogs 
(Kingsbury and Jungherr, 1958).  Infected birds that are actively shedding virus can do so 
through a number of routes.  This includes both respiratory and ocular routes as described 
above but also through faeces with high levels of virus detected between 2 and 7 DPI and 
lower but sustained presence of virus until 28 DPI (Roy et al., 2015).  The virus itself is 
relatively hardy with a series of experiments showing that virions could survive on wooden 
surfaces, away from light, for up to three months.  In the same experiments, it was shown 
virus could survive in deep litter for 20 days and that carcasses of birds that had succumbed 
to the virus harboured infective virions up to three weeks after death (Bagust et al., 2000).  
Due to the large number of potential transmission routes, biosecurity controls are considered 
to be paramount in helping to stem the spread of the virus alongside vaccination efforts.      
1.5.3 – Replication 
The site of initial replication for ILTV is widely believed to be the epithelial cells lining both 
the trachea in the upper respiratory tract and the conjunctival mucosal surfaces (Reddy et al., 
2014).  Different strains of ILTV have been shown to also have differing virulence and 
tropisms to the trachea or conjunctival surfaces (Kirkpatrick et al., 2006).  The highest level 
of viral titres in experimentally infected animals is seen in the trachea and conjunctiva 
around 4 – 6 days post infection (DPI) (Oldoni et al., 2009).  Following initial replication, it 
is believed that ILTV then invades the basement membrane to disseminate into the lamina 
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propria.  This mechanism is not well studied for ILTV however it is well characterised in 
other Alphaherpesviruses and so is inferred (Reddy et al., 2014).  Viral DNA is detected in a 
large number of an infected animals organs suggesting systemic spread of the virus through 
an unknown mechanism (Wang et al., 2013, Zhao et al., 2013).  Infection of leucocytes, in 
particular macrophages in vitro has been suggested as the possible mechanism of systemic 
spread in the bird (Calnek et al., 1986).  This is also purported as a possible mechanism of 
resistance and susceptibility to ILTV in different bird lines (Loudovaris et al., 1991a, 
Loudovaris et al., 1991b). 
During the initial, acute infection phase, invasion of the neurons and latency establishment 
occurs.  Viral DNA is detectable in the trigeminal ganglia (TG) from three to six days post 
onset of acute infection from both field and vaccine strains (Bagust, 1986).  The tracheal 
ganglion has been shown to be the main site of latency however dorsal root ganglia (DRG) 
have also been shown to harbour ILTV DNA (this study) (Bagust et al., 2000).  Reactivation 
of virus in latently infected birds has been put down to a number of different factors.  It is 
generally reported that stress factors such as the mixing of unfamiliar birds and even the 
onset of lay can trigger reactivation of the virus (Coppo et al., 2012, Coppo et al., 2013a).       
The kinetics of ILTV replication have previously been studied in vitro to determine the 
expression pattern of the viral transcripts (Mahmoudian et al., 2012).  Many of the viral 
transcripts with homologs in other Alphaherpesviruses were classified in a similar pattern, 
for example ICP4 as a designated immediate-early gene however they were some exceptions 
such as US4 (Glycoprotein G [gG]), which is typically classed as a late gene however it was 
only partially inhibited with the addition of Cycloheximide (CHX).     
1.5.4 – Pathogenesis 
Pathogenesis of ILTV has been studied using a number of different techniques.  The initial 
attempts to measure pathogenicity revolved around looking at the microscopic pathology 
induced in the trachea following infection (Guy et al., 1990).  This was then replaced with a 
more comprehensive approach taking into account clinical signs, body weight gain and the 
presence of vDNA in the trachea.  This was considered to be a more precise measure of 
pathogenicity compared to the trachea pathology index (Kirkpatrick et al., 2006).  As well as 
this, in vitro growth characteristics have been evaluated in a number of studies however 
these do not link to pathogenicity (Mahmoudian et al., 2012, Oldoni et al., 2009).   
The pathology and clinical symptoms associated with ILTV have been well documented in 
the literature and until recently, the underlying pathogenesis was not well characterised but 
in recent years a number of papers have looked at varying aspects of the immune response to 
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ILTV infection.  The initial barrier to ILTV infection is the mucus that lines both the 
respiratory and conjunctival tracts.  This innate barrier is the first hurdle for ILTV to 
overcome prior to infection.  Within the mucus, there are a number of innate immune 
mediators including interferons, collectins, IgA, defensins and lactoferins though there has 
been no research into the effects of these on ILTV (Coppo et al., 2013a).  Following 
infection of epithelial cells 789 genes were differentially expressed compared to uninfected 
chicken embryo lung cells in vitro with 54 of these genes linked to inflammatory response 
pathways (Lee et al., 2010).  More recently, cytokine profiling in a number of different 
tissues in infected animals revealed peak pro-inflammatory and anti-inflammatory cytokine 
transcription 5 DPI (Vagnozzi et al., 2018).  In the same study, it was shown that interferon-
beta (IFN-β), is not induced in the trachea of birds suggesting ILTV mediates and blocks the 
type 1 interferon response.  
At the initial infection sites, a small infiltration of what is presumed to be Heterophils is 
observed in the lamina propria.  This infiltration persists and between 3 to 5 DPI, more 
infiltrate is seen with macrophage and other lymphocytes observed (Purcell, 1971).  CD4+ 
and CD8+ cells are seen throughout the mucosa as revealed by immunohistochemistry 
(Devlin et al., 2010).  It was also reported that the types of inflammatory cells present at this 
stage of infection influences the outcome of infection as well as the balance of the adaptive 
immune response (Devlin et al., 2010).   
Virus neutralising antibodies against ILTV are detectable in the serum of infected animals 
around 5 – 7 DPI and continually raise until a peak at around 21 DPI.  These antibodies 
levels then wane over time and are detectable at low levels for several months (Bagust et al., 
2000).  Glycoproteins expressed by the virus are considered to be the most immunogenic and 
can elicit both a humoral and cell mediated response (Coppo et al., 2013a).  Early work 
showed vertical transmission of passive immunity to offspring in vaccinated birds though 
this was found to offer no greater protection than parents who were non-vaccinated when the 
animals were challenged (Hayles et al., 1976, Coppo et al., 2013a).  This work suggested that 
cell-mediate immunity was the most important response to infection and outcome of 
infection compared to humoral immunity (Coppo et al., 2013a).   
A great deal of work has been carried out on glycoprotein G (US4) and its role in 
pathogenesis.  Original studies showed that gG is a broad spectrum viral chemokine binding 
protein (Bryant et al., 2003).  The first gG deficient knockout of ILTV was made in 2006 and 
it has subsequently undergone a number of different studies (Devlin et al., 2006).  Studies 
looking at the in vitro growth characteristics found no significant differences when compared 
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to wild-type virus however in vivo work showed extensive attenuation of clinical signs and 
weight changes in challenged birds (Devlin et al., 2007, Devlin et al., 2010).  From this work 
it was deduced that gG played a significant role in ILTV pathogenesis.  Recently, gG has 
been shown to alter the transcription of key inflammatory markers such as CXCL8 and IL-18 
both in vitro and in vivo (Coppo et al., 2018).  
1.6 – MicroRNAs 
MicroRNAs (miRNAs) are short, non-coding RNAs around ~22 nt in length.  They have 
been identified across the animal kingdom in a large number of species ranging from algae to 
humans (Berezikov, 2011).  Their main function is the post-transcriptional regulation of 
genes by guiding the RNA-induced silencing complex (RISC) to target mRNAs halting the 
translation of the target through a number of means (discussed in section 1.6.3).  The effects 
of miRNAs are seen in nearly every biological process from cell proliferation to disease 
development (Winter et al., 2009). 
MiRNAs were first identified around 25 years ago by two groups at the same time.  
Researching the genomes of Caenorhabditis elegans (C. elegans), the lin-4 gene was shown 
to encode for a small RNA as opposed to a protein.  It is encoded in the antisense orientation 
to the protein coding gene lin-14 and was shown to result in the repression of the lin-14 
protein (Lee et al., 1993, Wightman et al., 1993).  A further 7 years passed until a second, 
small RNA was identified again in C. elegans named let-7 (Reinhart et al., 2000).  This 
ignited the field of small RNA research and the coining of the term microRNA.  Since then, 
38589 miRNA entries have been added to the miRNA database MiRBase (release 22, March 
2018) (Griffiths-Jones et al., 2006).  Within the human genome, miRNAs are predicted to 
account for 1 – 5 % of the total genome and it is suggested that they can regulate at least 30 
% of the protein coding genes (Macfarlane and Murphy, 2010).   
As mentioned above, miRNAs can play a role in disease development.  This can be through 
the direct interaction between miRNAs and their targets but also through the levels of certain 
miRNAs changing.  Changes in miRNAs and disease development have been shown in a 
wide variety of complications including cancer and cardiovascular disease (Ha, 2011).  
Within cancer, miRNA expression is reduced or eliminated through deletions of miRNA 
coding regions in some cases.  This is the case with chronic lymphocytic leukemia (CLL) 
whereby a common deletion affects the levels of miR-15 and miR-16 and in this deletion is 
frequently the only abnormality seen in patients suggesting the loss of these miRNAs is the 
direct cause of CLL (Schetter et al., 2010).  On a similar note, miR-155 over expression can 
drive b-cell tumours and this strategy is utilised by MDV (discussed in section 1.7) 
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(Costinean et al., 2006).  Finally, following acute myocardial infarction (AMI) in both 
humans and mice, levels of several miRNAs are altered including miR-1, miR-133a and 
miR-133b withing the blood plasma.  This finding suggests that circulating miRNA levels 
can be used as possible diagnostic markers for prognosis of diease in patients presenting with 
cardiovascular symptoms (Ha, 2011).         
MicroRNAs are not the only non-coding RNAs (ncRNAs) that are found in nature.  There 
are several other species of ncRNAs that have a variety of different functions including small 
interfering RNAs (siRNAs), piwi interacting RNAs (piRNAs), long non-coding RNAs 
(lncRNAs) and circular RNAs (circRNA).  The latter two will be dicussed below.   
Firstly, there are long non-coding RNAs (lncRNAs) which are defined as transcripts longer 
than 200 nucleotides that are not protein coding (Perkel, 2013).  Around ~28,000 lncRNA 
transcripts have been identified in the human genome highlighting their importance in vital 
cellular processes (Hon et al., 2017).  Functionally, lncRNAs can affect the regulation of 
gene transcription right through to post-transcriptional regulation.  One such example of of a 
lncRNA affecting mRNA turnover is gadd7.  In response to damaging radiation, gadd7 
levels increase with the consequence of increased binding to TDP-43 at the detrement of 
cdk6 mRNA.  The result of the change in binding affinity of TDP-43 is a reduction of cdk6 
levels thus leading to cell cycle arrest (Liu et al., 2012).   
Secondly, a more recent discovery is the identification of circular RNAs (circRNAs).  
Instead of a typical RNA which is in a linear conformation, the 5’and 3’ of the RNA are 
joined together forming a circle.    Functionally, they have many possible functions as 
described in the literature including acting as miRNA sponges, transporting miRNAs in the 
cell and also binding to RNA-binding proteins (Wilusz and Sharp, 2013, Memczak et al., 
2013).  One such example of a circRNA acting as a miRNA sponge is circular RNA sponge 
for miR-7 (ciRS-7).  The circRNA has been shown to have over 60 seed sequence sites 
(discussed in section 1.6.3) aciting as anchor sites for miR-7 binding thus reducing the 
amount of ‘free’ miR-7 that can be used to target mRNAs (Hansen et al., 2013).   
This feature of circRNAs adds another layer of gene regulation as they can modulate the 
levels of other ncRNAs however circRNAs are not the only ncRNA species that effectively 
regulate the expression of other ncRNAs.  The lncRNA PTENP1 has been shown to act as a 
molecular decoy for miRNAs targeting the tumour suppressor protein PTEN.  The 3’UTR of 
PTENP1 was found to bind the same miRNAs as the 3’UTR of PTEN mRNA (Wang and 
Chang, 2011)                         
Chapter 1  Introduction 
28 
 
1.6.1 – MicroRNA Biogenesis 
MicroRNA biogenesis is a complicated process.  It involves several steps that starts at the 
genome (A diagrammatic flow chart of miRNA biogenesis is shown in Figure – 1.6).  The 
majority of miRNAs genes are transcribed by RNA polymerase II (RNA pol II) but in some 
cases, RNA polymerase III (RNA pol III) is also the starting point of transcription (Lee et al., 
2002).  In the case of human miRNAs, transcription factors such as p53, MYC ZEB1 and 
ZEB2 can positively or negatively regulate the transcription of miRNAs.  Likewise, DNA 
methylation and histone modification can also contribute to their regulation similar to protein 
encoding genes (Ha and Kim, 2014).  Once transcribed, these transcripts, known as primary 
miRNAs (pri-miRNAs) form a self-hairpin structure within which the mature miRNA 
sequence is embedded.  The pri-miRNAs can be over 1 kb in length and possess both a 5’ 
cap and a 3’ polyA tail.  They can encode for a single mature miRNA (monocistronic 
transcript) or several mature miRNAs (polycistronic transcript) either through a single 
promoter or through several promoters for each of the miRNAs in the pri-miRNA (Cai et al., 
2004).  Pri-miRNAs are spread throughout the genome, many are found in intergenic regions 
or in an antisense orientation to protein coding genes but in some cases, they are also found 
in introns and exons (Kim, 2005). 
Following transcription, the pri-miRNA undergoes the first stage of processing.  The RNase 
III enzyme Drosha and its co-factor DiGeorge syndrome chromosomal region 8 (DGCR8) 
form what is known as the microprocessor complex.  This complex cleaves the stem-loop 
structure from the pri-miRNA to form a ~65 nt precursor miRNA (pre-miRNA).  The models 
currently suggested in the literature propose that DGCR8 recognises the pri-miRNA at the 
ssRNA-dsRNA junction and directs Drosha to a precise cleavage point around 11 nt away 
from this single-stranded-double-stranded RNA junction (Macfarlane and Murphy, 2010).  
The Drosha and DCGR8 proteins are essential for normal development and function.  
Deficiency in Drosha is embryonically lethal whilst DCGR8 knockout mice have early arrest 
in development.  Lack of DGCR8 in humans is associated with DiGeorge syndrome which 
can cause a variety of congenital problems (Ha and Kim, 2014).    
Once the pre-miRNA is formed, it requires translocation to the cytoplasm for further 
processing.  For this to happen, the pre-miRNA requires 2 important structural features.  At 
the 5’ end, a phosphate group is required whilst at the 3’ end, a 2 nt overhang must be 
present (Zeng and Cullen, 2005).  This is to allow recognition by the Exportin/Ran complex 
that is made up of Exportin 5 and Ran-GTP co-factors that enables the export of the pre-
miRNA from the nucleus to the cytoplasm.  Following translocation to the cytoplasm, the 
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Ran-GTP is hydrolysed to Ran-GDP subsequently causing the complex to dissemble 
releasing the pre-miRNA into the cytoplasm (Wang et al., 2011). 
The second stage of miRNA processing revolves around the RNase III endonuclease Dicer.  
Dicer along with its co-factors TAR RNA-binding protein (TRBP), protein activator of PKR 
(PACT) and argonaute-2 protein (Ago-2) form the RISC loading complex (RLC).  Several of 
these proteins do not play a role in the processing of the pre-miRNAs but help to stabilise the 
complex as well as recruit the pre-miRNA and help form the RLC (Lee et al., 2006).  The 
pre-miRNA is recognised by several domains of the Dicer protein including the piwi-
argonaute-zwille (PAZ) domain, RNase IIIa and RNase IIIb allowing it to cleave the pre-
miRNA into a dsRNA duplex that is approximately ~22nt in length that still has a 5’ 
phosphate group and a 3’ 2 nt overhang that has a hydroxyl group.  The latter of which is 
necessary for Dicer to bind to the pre-miRNA (Ha and Kim, 2014, Macfarlane and Murphy, 
2010). 
This dsRNA duplex then interacts with Ago-2 to eventually form the RISC that has the 
ability to target specific mRNAs for silencing.  The PAZ domain of Ago-2 interacts with the 
2 nt overhang at the 3’ of the dsRNA duplex whilst the 5’ interacts with the middle domain 
(MID) of Ago-2.  These interactions help to anchor the duplex to Ago-2 (Gregory et al., 
2005, Kim, 2005).  The final stage is the unwinding of the dsRNA duplex by helicases.  One 
strand, termed the guide strand or mature miRNA remains in the RISC and goes on to target 
mRNAs.  The second strand or passenger strand is released from the complex and can follow 
two fates.  It is either degraded or can be incorporated into a separate RISC where it also can 
target mRNAs and act as a mature miRNA (Ha and Kim, 2014, Kim et al., 2009).  As both 
strands have the possibility of becoming the mature miRNA, a naming system was devised 
based upon which strand of the duplex the miRNA came from.  This feature is seen on 
miRNA naming system denoted by either a 5p or 3p at the end of the miRNA name 
(Griffiths-Jones et al., 2006).    
         
   
  





Figure – 1.6.  MicroRNA Biogenesis pathway 
Section 1.6.1 discusses the miRNA biogenesis pathway. 
Imaged adapted from Winter et al. (2009)  
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1.6.2 – MicroRNA Target Recognition 
Target recognition of miRNAs relies upon sequence complementarity between the miRNA 
and the mRNA target in a Watson-Crick manner.  In plants, perfect (or near perfect) 
complementarity is required along the full ~22 nt miRNA sequence for target recognition 
resulting the repression of the mRNA by degradation of the target (Bartel, 2009).  In 
comparison, animals as well as viruses do not require near perfect or perfect 
complementarity.  The nucleotide sequence at positions 2 – 8 nt at the 5’ end of the miRNA 
which is termed the seed sequence is considered to be the most important for target 
recognition (Gottwein et al., 2007).  The targeting by, and binding with the seed sequence is 
known as canonical binding and miRNAs that are conserved across different species use the 
same seed sequence (Lewis et al., 2005).  Non-canonical binding between a miRNA and 
mRNA can also occur.  This is where the seed sequence contains a mismatch, the miRNA 
only matches at the 3’ end or at the centre of the miRNA (Helwak et al., 2013).  
Mismatching of sequences can happen through G:U binding known as G:U wobble.  This 
was first thought to have a negative effect upon the miRNA targeting but binding can still 
happen though the specificity and activity of the miRNA can change (Macfarlane and 
Murphy, 2010).  Initial observations dating back the first identified miRNAs in C. elegans 
suggested that miRNAs only target the 3’UTR of mRNA transcripts however more recently 
they have been shown to target mRNAs both in the 5’UTR and the coding region in addition 
to the 3’UTR (Lee et al., 1993, Grey et al., 2010, Lytle et al., 2007) 
1.6.3 – Modes of Action of MicroRNAs 
There is general consensus in the literature that miRNAs negatively regulate gene 
expression.  A single miRNA can have multiple targets and conversely, several miRNAs can 
target a single mRNA transcript (Macfarlane and Murphy, 2010).  Reports in the literature 
suggest that there are two main methods of gene silencing by miRNAs; mRNA cleavage and 
translational repression.  As well as this, other methods have been reported such as mRNA 
cap inhibition and ribosomal drop-off causing premature termination of translation 
(Morozova et al., 2012).  A recent study in mice observed 48 % of mRNAs targeted by 
miRNAs are silenced by translational repression with only 29 % by mRNA degradation.  
The rest (23 %) have a combination of both (Jin and Xiao, 2015). 
Cleavage of the target mRNA is catalysed by Ago-2 and tends to require a large percentage 
of complementarity between the miRNA and its target however there is exceptions to this 
(Mallory and Vaucheret, 2004).  At the beginning of the process, the RISC complex recruits 
the GW182 family of proteins.  This provide a scaffold on which subsequent effector 
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proteins can be recruited (Behm-Ansmant et al., 2006).  Following miRNA-mRNA 
interactions, deadenylation of the poly(A) tail is carried out by the deadenylase enzymes 
PAN2/PAN3 and CCR4-NOT with the former initiating the process and the latter 
completing it (O'Brien et al., 2018).  Decapping of a target mRNA can follow this, primarily 
with decapping protein 2 (DCP2) alongside other related proteins (Valencia-Sanchez et al., 
2006).  For effective mRNA degradation, both the CCR4-NOT complex and DCP2 enzymes 
are necessary to facilitate deadenylation and decapping of the mRNA (Behm-Ansmant et al., 
2006) 
As well causing mRNA decay, miRNA target recognition can also employ a number of other 
post-transcriptional methods to effect protein expression.  These all broadly fall under the 
category of  translational repression however the miRNA target mRNA can have different 
fates (Morozova et al., 2012).  Translation occurs in three stages; initiation, elongation and 
termination and all three have been shown to be targeted in different aspects.  Inhibition of 
translation initiation can be caused by disassociation of eIF4A from the initiation complex 
(Fukaya et al., 2014).  During elongation, inhibition can occur through a decrease in the 
number of associated ribosomes thus lowering protein production potential (Morozova et al., 
2012).  Premature termination of of translation can also occur through ribosome drop off 
(Petersen et al., 2006).  The decision on which stage is targeting through this mechanism is 
also unclear but some research suggests that the promoter used to transcribe the mRNA 
influences the mechanism of silencing (Kong et al., 2008).      
In addition to repressing translation by the methods outlined above, target mRNAs can be 
sequestered into Processing bodies (P bodies) within the cytoplasm.  These lack translational 
machinery and so protein production is halted for the targeted mRNA.  P bodies have been 
shown to arise as a consequence of RNAi mediated gene silencing (Eulalio et al., 2007).  
mRNAs that are sequestered to P bodies are not always decayed and are simply repressed, 
thus can act as a storage of targeted mRNAs (Hubstenberger et al., 2017).  Stored mRNAs 
within the P bodies can then either be decayed or can by recycled and sent to the polysomes 
for protein synthesis (Yang and Bloch, 2007).        
1.6.4 – Approaches to Identify MicroRNA Targets  
Following the identification of miRNAs, an entirely new field in gene regulation opened up 
looking at miRNA target recognition and analysis of their targets.  MicroRNAs are small and 
consist of RNA making elucidation of targets tricky due to their size and stability.  Despite 
this, several approaches have been successfully used to identify their targets either through in 
silico approaches or more traditional in vitro laboratory techniques.  With the advent of next 
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generation sequencing and tumbling costs of this technology, a combination of 
bioinformatics and laboratory techniques is now more frequently used. 
Bioinformatics can be used to predict miRNA targets and a number of computer algorithms 
and programmes have been developed by independent groups.  These programmes include; 
miRTar (Hsu et al., 2011), miRanda (John et al., 2004), miRDB (Wong and Wang, 2015) 
and RNA Hybrid (Rehmsmeier et al., 2004).  They all work in slightly different manners to 
achieve the same end goal of target prediction.  Differences include sequence 
complementarity, thermo dynamic stability and data input methods.  Whilst bioinformatic 
prediction is a powerful tool, it does have several drawbacks.  Firstly, predictions generated 
can contain false positives which affects the confidence in the process and secondly, any 
predictions made in silico have to be validated experimentally in vitro. 
There are several in vitro approaches that can be taken to identify miRNA targets. They can 
be split into three distinct research strategies; transcriptomics, biochemical and proteomic 
analysis.  Transcriptomics measures changes in gene expression in the presence of a stimuli 
which can be either the presence or loss of a mature miRNA.  Microarrays are the most 
common approach for this method and they have the ability to test a few hundred to several 
thousand transcripts at once allowing for multiplexing and the testing of several potential 
targets on the same chip (Thomson et al., 2007).  RNA sequencing (RNA-seq) can also be 
applied in the same way using specific miRNAs but both techniques have limitations.  
Primarily, any specific changes in gene expression levels seen cannot be attributed to a 
specific miRNA and so further validation steps are required to match the gene target and the 
miRNA. 
There are a number of different biochemical approaches that have been developed since 
miRNAs were first discovered. They are more sensitive than transcriptomic approaches as 
they revolve around maintaining miRNA:mRNA interactions so as to identify specific 
targets through immunoprecipitation (IP) methods (Doelken et al., 2010).  IPs typically use 
the Ago-2 protein of the RISC complex as the main target as it is this protein that is anchored 
to the miRNA (RISC-IP).  These pull downs can then be processed further through 
microarray analysis or by next generation sequencing to determine targets.  If a known target 
is been pulled down, RT-qPCR can be used to determine the level of enrichment of a specific 
mRNA against a whole cell lysate sample (Pavelin et al., 2013).  Similar to transcriptomic 
approaches, RISC-IP does have some drawbacks.  One particular problem is the pulling 
down of indirect targets as the approach is not very stringent.  
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RISC-IP has been improved upon several times; each becoming more sensitive than its 
predecessor.  The development of high throughput sequencing of RNAs isolated by 
crosslinking and immunoprecipitation (HITS-CLIP) improved RISC-IPs by utilising UV 
crosslinking.  This crosslinked the RISC to the mRNA target at the miRNA:mRNA 
interaction.  By using this technique, the sensitivity increased which in turn made the 
approach more powerful (Chi et al., 2009).  HITS-CLIP has been used several times in a 
number of different herpesviruses to identify miRNA:mRNA interactions (Guo et al., 2015, 
Riley et al., 2012). 
Photoactivable-ribonucleoside-enhanced CLIP (PAR-CLIP) became the successor to HITS-
CLIP through improvements and efficiencies in the technique.  Incorporation of 
ribonucleoside analogues that are photoreactive, such as 4-thiouridine (4-SU) and 6-
thioguanosine (6-SG) into RNA transcripts allows for improved crosslinking efficiency 
when UV irradiated thus increasing the amount of mRNA pulled down compared to HITS-
CLIP (Hafner et al., 2010).  PAR-CLIP has been used numerous times to also identify 
miRNA:mRNA interactions (Pan et al., 2014, Benhalevy et al., 2017).  Whilst both HITS-
CLIP and PAR-CLIP are more stringent than RISC-IP, they still do not directly map out 
specific miRNA:mRNA interactions and downstream work is required to match miRNA 
sequences to their mRNA targets.   
The latest and most sensitive technique is known as cross linking and sequencing of hybrids 
(CLASH) (Helwak et al., 2013, Helwak and Tollervey, 2014).  It builds upon HITS-CLIP by 
adding an extra step whereby the miRNA and mRNA bound by UV crosslinking are ligated 
together to create a chimera.  These ligated miRNA:mRNA chimeras can then be identified 
in the sequencing stage.  Most recently, a quicker version of this approach has been 
developed called qCLASH that is essentially the same however a lower input quantity can be 
used (Gay et al., 2018).  Coupled with this approach is a bioinformatic pipeline that was 
specifically developed to partner CLASH to identify these interactions (Travis et al., 2014).        
In addition to the development of CLASH/qCLASH as described, the use of locked nucleic 
acids (LNAs) as bait to pull down specific miRNA interactions (Xu et al., 2017).  The 
experimental procedure referred to as Target-Link relies upon a LNA with a sequence 
antisense to the miRNA of interest.  This LNA can have a protein attached such as biotin 
which can be used to purify the miRNA:mRNA complexes of interest that have been UV 
crosslinked together.  Due to the high affinity binding between the LNA and miRNA, 
purification steps can be more stringent reducing the number of false positives that are seen 
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with some other methods.  This approach maybe of use when looking at specific 
miRNA:mRNA interactions that have been investigated by other experimental methods.    
Highlighting this combination of using both bioinformatics and the wet-lab based techniques 
described above are the number of new computer algorithms that take raw data reads 
generated from next generation sequencing of CLIP/CLASH experiments to identify 
miRNA:mRNA interactions.  These programmes include miRTarCLIP (Chou et al., 2013) 
and MiRTarget (Wang, 2016).       
The final method of identifying miRNA:mRNA interactions is using a proteomic approach.  
Stable isotope labelling by amino acids in cell culture (SILAC) can track the synthesis and 
degradation of proteins in a cell.  Addition of a miRNA to a sample will change the levels of 
specific proteins and this can be analysed by SILAC methods (Gallaher et al., 2013).  Whilst 
this approach can be used, it does have its downsides.  The major flaw in using proteomic 
approaches is that only one miRNA can be investigated at once which is much narrower than 
the global approaches of CLASH for example.  Secondly, protein deregulation may not 
necessarily be due to the addition of a particular miRNA and may be an indirect effect.   
1.7 – Virus-encoded MicroRNAs 
Viruses are obligate intracellular pathogens and it is well known that they modulate the 
cellular environment to their own advantage.  It is therefore no surprise that viruses were 
found to encode miRNAs considering that they are non-immunogenic and take up relatively 
little space in already compact genomes (Pfeffer et al., 2004a, Sarnow et al., 2006). 
The first virus-encoded miRNAs were identified in cells latently infected with EBV.  It was 
found that these miRNAs were differentially expressed depending upon the latent stage of 
the virus life cycle (Pfeffer et al., 2004a).  The latest release of MiRBase (Release 22, March 
2018) lists 530 mature miRNAs from 35 viruses (shown in Table – 1.1).  Most virus-encoded 
miRNAs discovered thus far have been identified in large DNA viruses with the majority 
identified in herpesviruses (Grey, 2015).  Some such as poxviruses however have not been 
shown to encode for miRNAs and this most likely due to the location of replication.  
Herpesviruses and adenoviruses both replicate in the nucleus of infected cells whereas 
poxviruses replicate in the cytoplasm so lack access to critical components of the miRNA 
processing machinery (Cullen, 2010). 
Furthermore, RNA viruses have also been shown to encode for miRNAs although there has 
been some controversy regarding whether or not they are real.  This was the case for HIV-1 
which is still listed to encode for 4 mature miRNAs from 3 precursors on MiRBase 
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(Bennasser et al., 2004, Pfeffer et al., 2005).  The retroviruses bovine foamy virus (BFV) and 
simian foamy virus (SFV) have both been shown to encode for 4 and 13 mature miRNAs 
respectively (Whisnant et al., 2014, Kincaid et al., 2014). Both of these studies observed that 
these miRNAs were generated via non-canonical pathways as the primary miRNA (pri-
miRNA) transcripts are transcribed by RNA pol III as opposed to RNA pol II.  Another 
retrovirus virus that has been shown to encode for miRNAs is bovine leukaemia virus (BLV) 
which encodes for 10 mature miRNAs from 5 precursors (Rosewick et al., 2013).   
Similar to their hosts, viruses can also encode for other types of ncRNA in addition to 
miRNAs.  There are several instances of viruses encoding for lncRNAs and there is an 
emerging field documenting the identification of circRNAs encoded for within viruses.  
Possibly the most well studied virally encoded lncRNA is the HSV-1 encoded latency 
associated transcript (LAT).  It has been strongly implicated in the epigenetic regulation of 
HSV-1 gene regulation during latency and directly influences reactivation of the virus 
(Nicoll et al., 2016).  HCMV has also been shown to encode for at least 4 lncRNAs, one of 
which, lncRNA 2.7, is the most abundant transcript found during the early stages of HCMV 
infection and it has numerous roles including binding to retinoid/interferon-induced 
mortality-19 subunits of the mitochondrial enzyme complex 1 to prevent stress induced 
apoptosis and allowing continued ATP production (Reeves et al., 2007).  lncRNAs can also 
be used to subvert the host cell antiviral response.  KSHV encodes for the lncRNA PAN 
which during the lytic phase of infection can reduce the expression of IFN-α, IFN-γ and 
ISGs (Qiu et al., 2018). 
In addition to lncRNAs, viruses have been recently shown to also encode for circRNAs.  
Both KSHV and EBV have been shown to have circRNAs (Tagawa et al., 2018, Huang et 
al., 2019).  As this is a very emerging field, information regarding the function of the 
circRNAs is still sparse however the study by Huang et al. (2019), explored the regulation of 
host miRNAs by the virus-encoded circRNAs.  The study found several host miRNAs 
including miR-28-5p, miR-151a-5p and miR-1248 were down regulated by EBV-
circRPMS1.  As previously mentioned in section 1.6, circRNAs have the ability to regulate 
other ncRNAs.  This adds another dimension and layer of complexity when one is 
investgating the role of non-coding RNAs during virus infection and no doubt this emerging 
field will rapidily expand with the identification of circRNAs in other virus families also.          
  




Table – 1.1. List of Virus-encoded MicroRNAs adapted from MiRBase 
Family Subfamily Virus No. of mature 
miRNAs 
Herpesvirus α-herpesvirus Bovine Herpesvirus 1 12 
Bovine Herpesvirus 5 5 
Duck enteritis virus 33 
Herpes B virus 15 






Pseudorabies virus 18 
β-herpesvirus HCMV 26 
Murine CMV 29 
γ-herpesvirus EBV 44 
HSV 6 
KSHV 25 
Rhesus lymphocryptovirus 70 
Papillomavirus   BPCV1  1 
BPCV2 1 
Polyomavirus Simian virus 40 2 
Raccoon polyomavirus  2 
Gorilla polyomavirus 1 2 
Retrovirus Bovine Leukaemia virus 10 
Bovine Foamy virus 4 
Adapted from MiRBase (release 22, March 2018).  Some have been omitted from the full list. 
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1.7.1 – Cellular Targets of Virus-encoded miRNAs 
It is no surprise that many of the characterised virus-encoded miRNAs found in 
herpesviruses regulate cellular pathways that are key to survival including apoptosis, 
immune evasion and cell cycle.  All of these are crucial for the maintenance of latency but 
by regulating these pathways, viral pathogenesis and in the case of some herpesviruses, 
oncogenic development can be controlled.  
Firstly, there a number of reported viral miRNAs that target genes associated with apoptosis.  
By blocking this pathway, the virus promotes cell survival which is naturally beneficial to 
the invading pathogen.  EBV encodes several miRNAs that target several parts of this 
pathway. A report observed that 12 EBV miRNAs tested in silico against the 3’UTR of 
caspase 3 showed one or more binding sites.  When tested in in a reporter based system, 9 of 
these showed a statistically significant reduction in caspase 3 expression (Harold et al., 
2016).  Caspase 3 is known to be the mediator of apoptosis and by targeting this, EBV can 
help maintain a persistent infection.  EBV miRNAs have also previously been shown to 
target genes upstream of caspase 3.  EBV-miR-BART5 has been shown to target the pro-
apoptotic gene P53 upregulated modulator of apoptosis (PUMA).  Deletion of this miRNA 
from the EBV genome caused increased levels of PUMA mediated cell death suggesting that 
this miRNA helped to protect EBV infected cells from apoptosis (Cullen, 2009).  Taken 
together, the literature surrounding viral miRNAs and apoptosis avoidance suggests that 
several genes in the apoptotic pathway are targets of these viral miRNAs and by reducing 
their expression it promotes cell survival and thus survival of the virus.          
Viral miRNAs can also target genes associated with the triggering of the immune system 
thus promoting the chance of immune evasion.  HCMV miRNA HCMV-miR-UL112 has 
been shown to target the major histocompatibility complex class I–related chain B (MICB) 
gene, firstly through bioinformatic prediction and then with more traditional laboratory 
methods.  The consequence of this targeting is a reduced number of activated natural killer 
cells (NK) as MICB is the ligand for natural killer cell activating receptor (NKG2D) which 
causes NK cell activation (Stern-Ginossar et al., 2007).  This targeting of MICB expression 
by herpesviral miRNAs is somewhat conserved with both EBV and KSHV encoding 
miRNAs that also target this gene indicating that this pathway of NK cell activation 
shutdown is crucial in the herpesviral lifecycle (Nachmani et al., 2009). 
Finally, the cell cycle can be targeted by virus-encoded miRNAs.  One such report observed 
that HCMV encodes the miRNA HCMV-miR-US25-1 that was found to target several genes 
associated with cell cycle control including cyclin E2, BRCC3, EID1, MAPRE2, and CD147 
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and deletion of this miRNA caused an over expression of cyclin E2 with regards to viral 
infection (Grey et al., 2010).  Similarly, a miRNA encoded by herpesvirus saimiri (HVS), 
HVS-miR-HSUR5-3p targets WEE1 which is a negative regulator of the cell cycle.  This 
downregulation leads to the reduced phosphorylation of one of its substrates, cyclin 
dependent kinase 1 (CDK1) (Guo et al., 2015). 
Overall, targeting of cellular transcripts with virus-encoded miRNAs helps viruses to survive 
in a hostile environment.  It allows for the regulation of specific targets and pathways in a 
non-immunogenic way thus assisting in the completion of the viral life cycle.    
1.7.2 – Viral Targets of Virus-encoded miRNAs 
As well as targeting cellular transcripts, virus-encoded miRNAs have the ability to target 
other viral transcripts.  As previously stated, the majority of virus-encoded miRNAs 
identified to date have been in the herpesvirus family.  The ability to set up a life-long 
infection requires precise control of gene expression and miRNAs are a method of regulation 
during these latent periods (Goodrum et al., 2012).  There is a large body of evidence in the 
literature that herpesviruses use miRNAs as a means to maintain and promote latency.  This 
is achieved by targeting viral genes that are typically necessary for lytic replication and/or 
reactivation.  For example, KSHV mature miRNAs are produced from 12 stem-loops and are 
all encoded for in the latency associated locus.  This complex region allows for the 
expression of the miRNAs and the latency associated nuclear antigen (LANA) in a co-
ordinated manner (Gottwein, 2012).  Both KSHV-miR-K12-7 and KSHV-miR-K12-9 target 
ORF50 (RTA), a protein that is required for the induction of lytic replication (Qin et al., 
2017).  Similarly, miRNAs found in HSV-1, HCMV and OvHV-2 target essential 
immediate-early gene transcripts (Duan et al., 2012, Grey et al., 2007, Riaz et al., 2014). 
Control of gene expression is a major part of the viral life cycle and by utilising virus-
encoded miRNAs to regulate viral gene expression as well as endogenous targets, it helps the 
virus gain a competitive edge against the cellular immune system.  This in turn can drive 
pathogenesis of the virus or as is the case with herpesviruses, help to maintain a life-long 
infection in the host.    
1.7.3 – Viral Targets of Cellular-encoded miRNAs 
As the targeting of transcripts is dictated by the miRNA sequence, any transcript containing 
the corresponding sequence can be silenced.  As previously explored in section 1.7.2, viral 
targets can be silenced by virus-encoded miRNAs however there is a growing body of 
evidence that endogenous miRNAs are also able to target viral transcripts thus affecting vital 
viral processes.  The first reports of endogenous miRNAs targeting viral transcripts came out 
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just over a decade ago and they have been found to both promote and inhibit virus 
replication (Cullen, 2011).  The liver specific miRNA miR-122 was reported to bind to two 
sites in the 5’UTR of Hepatitis C virus (HCV).  It was observed that this miRNA is essential 
for HCV replication and also enhanced HCV mRNA translation (Jopling, 2008, Jopling et 
al., 2005).  Introduction of a locked nucleic acid (LNA) antisense to the miRNA caused a 
reduction of HCV viral burden in vivo (Cullen, 2011).  
Conversely, endogenous miRNAs also have the ability to inhibit virus replication.  This has 
been reported for several viruses with the introduction of artificial miRNA target sites into 
the viral genome but there is no reason why cellular miRNAs cannot natively target viral 
transcripts.  An early report showed that the miRNA miR-32 was able to inhibit the 
replication of primate foamy virus (PFV) in the 293T human kidney cell line however the 
physiological relevance of this was trivial considering PFV does not replicate in the kidneys 
in vivo (Lecellier et al., 2005).   One such study that showed physiological relevance as well 
as the inhibition of viral transcripts was carried out with HSV-1.  The report by Pan et al. 
(2014), found the neuronal specific miRNA miR-138 was able to target ICP0 and repress its 
expression.  The ICP0 gene functions as a transactivator of lytic gene expression and 
suppression by miR-138 promoted host survival and latency in mouse models. Similar 
reports of miRNA targeting of essential genes for reactivation from latency have been 
reported in other herpesviruses.   
These interactions add another layer of complexity in understanding virus-host interactions 
and the regulation of viral gene expression with regards to viral pathogenesis.  As 
approaches to identify miRNA interactions become more sensitive and powerful (reviewed 
in section 1.6.4) the number of reports describing cellular miRNAs targeting virus transcripts 
will undoubtedly increase.      
1.7.4 – ILTV-encoded miRNAs 
Initially, 8 miRNAs were identified in the ILTV genome by deep-sequencing with four of 
these then validated by northern blot analysis (Waidner et al., 2009).  In the same year, a 
second lab group, also using sequencing, identified the previously published 8 miRNAs plus 
an extra 2 novel miRNAs.  They went onto confirm the expression of all 10 miRNAs by 
PCR using small-RNA enriched libraries (Rachamadugu et al., 2009).  To date, these are the 
only identified and validated miRNAs within the ILTV genome.  Figure – 1.7 shows the 
position of the miRNAs relative to the ILTV genome in a representative diagrammatic 
format.    
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Little work has been carried out regarding the role of these ILTV-encoded miRNAs with 
only one paper to date identifying one target of the miRNAs ILTV-miR-I5 and ILTV-miR-
I6.  Both of these miRNAs are encoded anti-sense to the major immediate-early gene ICP4 
and previous work identified ICP4 as a target of both ILTV-miR-I5 and ILTV-miR-I6.  
Using a luciferase based reporter system, the group found the addition of miR-I5 caused a 
statistically significant 60 % reduction in luciferase activity whilst the addition of miR-I6 
caused a reduction of 23 % that was not significant.  The effects observed were alleviated 
upon addition of an antagonist to the respective miRNAs or by mutating the miRNA seed 
sequence.  Further work went on to identify that miR-I5 reduced ICP4 transcript levels by 50 
% and it did this by cleavage of the mRNA at the miRNA binding site as validated by 
modified RACE analysis (Waidner et al., 2011).      
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ILTV-miR-I1-5p AGACUGAUUGGGGAAUGAUUGG MIMAT0012723 
ILTV-miR-I1-3p AAUUCCAUUCCUCUUUCUGUCUCC MIMAT0012724 
ILTV-miR-I2 GGAAGGCUGUGCGAUAGGAGCCGA MIMAT0012725 
ILTV-miR-I3 UCUUGUCUCUGGGUGGGUUCGGA MIMAT0012726 
ILTV-miR-I4 AUGUAUAGCGAGCAAUGACCGUGU MIMAT0012727 
ILTV-miR-I5-5p CUUCUCGUCCCCGUCUUCUUCAGA MIMAT0012728 
ILTV-miR-I5-3p UGAAGAAGACGACGACGAGGAGCAU MIMAT0012729 
ILTV-miR-I6-5p GUCUCCUGUACCCUCAUCGUCG MIMAT0012730 
ILTV-miR-I6-3p ACGCUGAGGGGCCAUGAGACAGU MIMAT0012731 
ILTV-miR-I7 UUUUAAUACUGAGGUGCGAAUG MIMAT0012861 
Adapted from MiRBase (Release 22, March 2018) 
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Figure – 1.7. Genome Layout of ILTV 
Genomic layout of ILTV showing each of the 79 ORFs in the genome (solid black arrows).  Direction of arrows depicts orientation of the ORF 
coding in either a left to right or right to left orientation.  Red arrows show locations of the virus-encoded miRNAs.  Adapted from Thureen and 
Keeler (2006). 
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1.8 – Genome Editing 
Genome editing is a natural occurrence in nature through spontaneous mutations to DNA 
causing deletions, substitutions and insertions in the genome.  Early work on genome editing 
showed that these mutations could be increased with the use of radiation or chemical 
treatment (Muller, 1927, Auerbach et al., 1947).  It took a further 30 years or so for genome 
editing to be targeted using a process of homologous recombination; something which is still 
in use today (Smithies et al., 1985).  This approach however, is highly precise but very 
inefficient and so it takes a large amount of time and patience to generate the desired 
mutations.  Currently, there are three separate approaches that  all revolve the ability to make 
double stranded breaks in DNA at a precise location to induce a programmable change in the 
genome either through non-homologous end joining (NHEJ) or homology directed repair 
(HDR) which relies upon the cell to repair DNA damage (Carroll, 2017).  Discussed below 
are three systems, zinc-finger nucleases (ZFNs), transcription activator like effector 
nucleases (TALENs) and clustered interspaced short palindromic repeats (CRISPR).  All 
three are in use today however the latter is now the most dominant.  The systems have all 
been employed in a number of different species across the natural kingdom for a wide 
variety of different applications.  In future, these systems have the ability to affect the natural 
world profoundly.  This includes applying to system to agriculture, germline editing and the 
control of invasive species through gene drives (Carroll, 2017). 
1.8.1 – Zinc Finger Nucleases (ZFN) 
Genome editing using Zinc finger nucleases (ZFNs) relies upon a fusion between a zinc 
finger DNA binding domain and a DNA cleavage domain.  By modifying the former of these 
domains, it allows for the targeting of specific sequences in a genome (Carroll, 2011).  Each 
zinc finger (ZF) comprises around 30 amino acids and can bind to 3 nucleotides (nts) of 
DNA in a modular fashion.  Subsequently, it was shown that by altering these ZFs, different 
sequences of DNA could be targeted (Pabo et al., 2001). 
The DNA cleavage domain of ZFN is a type 2 restriction endonuclease called Fok1.  Early 
work on the proteolytic fragments of Fok1 showed that it contained both a DNA-binding 
domain and a non-specific DNA-cleavage domain (Kim et al., 1996).  By combining the ZFs 
with the Fok1 restriction endonuclease, ZFN were synthesised.   
Following the synthesis and successful testing of ZFNs in vitro it was soon applied to a 
variety of different species with different targets using both NHEJ and HDR.  Activity in 
animals was first shown in Drosophila melanogaster with higher order animals such as 
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zebrafish following (Carroll, 2011).  ZFNs have since been succeeded by more specific and 
easier systems that offer more precision and greater flexibility in targeting of genomes.     
1.8.2 – Transcription Activator-Like Effector Nucleases (TALENs) 
The successor to ZFNs, transcription activator like effector nucleases (TALENs) are an 
advancement on ZFNs as they still rely upon the Fok1 restriction enzyme (nuclease domain) 
to cut the DNA however they use transcription activator like effectors (TALEs) which can be 
programmed to target any DNA sequence allowing for more flexibility.  By combining a 
TALE with a nuclease domain, precise genome editing can be carried out (Boch, 2011).  
TALE proteins were first identified in pathogenic bacteria that infect plants.  They were 
shown to contain a repeated ~34 conserved amino acid sequence with differing amino acids 
at positions 12 and 13 known as the repeat variable diresidue (RVD) (Boch and Bonas, 
2010).  TALEs work on the basis of amino acid sequence recognising DNA sequence and by 
altering this ~34 amino acid sequence with appropriate RVDs allows for the targeting of 
specific DNA (Boch, 2011). 
TALENs have been applied to a large number of different organisms to efficiently modify 
their genomes including plants of economic importance and to generate knockout animals 
used in research (Tesson et al., 2011, Haun et al., 2014).  Their usage has been far reaching 
due to the ability to target individual nucleotides when compared to ZNF nucleotide triplets 
however with development of CRISPR-Cas systems as outlined below that are cheaper and 
offer greater flexibility in targeting, the usage of TALENs has in declined in recent years.             
1.8.3 – Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) 
The most recent advancement in precise genome editing is using the CRISPR system.  
Although its application and usage has exploded in recent years, CRISPR has been known 
about for over 30 years with the first observations of clustered repeats made in 1987 (Ishino 
et al., 1987).  A further 20 years passed before these clustered repeats were identified as 
derivatives of bacteriophage DNA and other viruses that had tried to attack the cells (Pourcel 
et al., 2005).  Previous to this however was the discovery of a set of genes termed CRISPR 
associated systems genes (Cas genes) that encoded proteins with both helicase and nuclease 
motifs which were suggested to have a functional relationship with the CRISPRs (Jansen et 
al., 2002).  It took until 2010 for the first publications to show the targeting and cleavage 
ability of the CRISPR-Cas system against fragments of bacteriophage and plasmid DNA in 
the bacteria Streptococcus thermophilus (Garneau et al., 2010).  Research into Cas systems 
rapidly increased and so far 93 individual cas genes split into 35 families have been 
discovered (Makarova et al., 2015).  To date, cas genes have been identified that can cleave 
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single stranded DNA (ssDNA), double-stranded DNA (dsDNA) and also even RNA 
(Sinkunas et al., 2011, Gasiunas et al., 2012, Cox et al., 2017).  The simplistic system relies 
upon a guide RNA (sgRNA) that is homologous to the region targeted for cleavage and a 
small transacting RNA (tracrRNA) that helps to process the sgRNA and cleavage of the 
target when coupled with a single cas protein that carries out the cleavage of desired target 
(Carroll, 2017).       
The most utilised CRISPR system for genome editing is the CRISPR-Cas9 system which 
was shown to be programmable to cleave specific sequences in the human genome 
simultaneously by two independent research labs (Hsu et al., 2014, Mali et al., 2013).  It has 
now been applied to a large variety of organisms to make precise genomic changes as well as 
allowing researchers to activate and repress specific genes (Larson et al., 2013).          
 
  





Figure – 1.8. Genome Editing using the CRISPR-Cas9 System 
The CRISPR-Cas9 system relies upon a target sequence of 20 bp within a sequence of DNA 
(or RNA depending upon the Cas protein) that has a Photospacer Adjacent Motif (PAM) that 
is essential for Cas9 binding and cleavage.  Once DNA is cleaved by the Cas9 protein, host 
cell machinery repair the double stranded break (DSB) either through Non-Homologous End 
Joining (NHEJ) or Homology Directed Repair (HDR).  Figure adapted from Tu et al. (2015)  
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1.8.4 – Creation of Recombinant Viruses 
The first reports of targeted editing of viruses using homologous recombination came out 
some 40 years ago (Mocarski et al., 1980).  Since this report, a vast number of recombinant 
viruses have been created using this approach to aid investigations into viral gene function 
and inadvertently cell signalling amongst other things.  As stated previously homologous 
recombination is very precise but highly inefficient even on large animal genomes.  
Anecdotal reports suggest successful homologous recombination in viruses is as low as 1 in 
a million virions produced.  This approach was updated in 1996 when it was shown that 
inducing double stranded breaks (DSBs) into the viral DNA greatly improved the efficiency 
of targeted recombination (Ryan and Shankly, 1996).  The downside to this was that it relied 
upon a unique restriction endonuclease site within the Suid Herpesvirus-1 genome, thus 
greatly reducing the targeting ability of this approach with improved efficiency.   
Aside from homologous recombination, the development of the Bacterial Artificial 
Chromosome (BAC) system allowed for even more control over the production of mutant 
viruses.  First reported in 1997, the BAC system works by cloning the entire viral genome 
into an artificial chromosome of stable bacteria such as Escherichia coli (Messerle et al., 
1997).  This allows for mutations to be made in the viral DNA as if it were a plasmid 
however the drawback is that in the early uses, residual bacterial sequences were 
incorporated into the virion.  Another drawback to this approach was that not all viruses 
could have BACs created.  In particular, several attempts have been made to produce an 
ILTV BAC but to no avail.  This is thought to be down to the palindromic sequences found 
within the viral genome that are toxic to the bacteria.  More recently however, a cosmid 
system using yeast has been reported for ILTV using three plasmids to encode for the full 
genome (Spatz. et al., 2018). 
The advancement of precision genome editing has also affected the methods of creating 
recombinant viruses.  Reports of ZFNs being effectively used to create recombinant viruses 
are sparse however the technology was explored as a possible gene therapy to chronic viral 
infections as well as targeting cellular genes to confer resistance against HIV-1.  ZFNs 
targeting the genomes of HSV-2 and HIV-1 have been reported both with the conclusions 
that the approach could be used for gene therapy (Wayengera, 2011, Wayengera, 2012).  
Moreover, targeting of the cellular genome to confer protection against viral infection has 
also been reported using ZFNs.  Targeting of the CCR5 gene in CD4+ T cells conferred 
protection against HIV-1 infection both in vitro and in vivo (Perez et al., 2008).       
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TALENs have been used in some capacity to modify viral genomes.  Bi et al. (2014), 
reported the use of both TALENs and CRISPR-Cas9 systems to modify adenoviruses.  For 
proof of principle, a recombinant adenovirus was used that carried the enhanced green 
fluorescent protein (eGFP) with TALENs and sgRNAs designed against it. Results showed 
that both systems were able to competently cleave the target DNA however the CRISPR-Cas 
system was reported to be much more efficient at cutting the sequence (Bi et al., 2014).  The 
TALENs system has also been used to target the genome of Hepatitis B virus (HBV) 
genome.  Four sets of TALEs were designed against the episomal covalently closed circular 
HBV DNA (cccDNA).  Around 35 % of target cccDNA molecules had some form of 
mutation and replication was impaired (Bloom et al., 2013).  The findings also suggested that 
genome editing technologies could not only be used to create recombinant viruses but also to 
efficiently clear chronic viral infections.      
With the advent of the CRISPR-Cas system, it was soon applied to viruses.  In the first 
instance, sgRNAs were designed to target the LTR of HIV-1.  Loss of the LTR caused a 
reduction in HIV-1 gene expression (Ebina et al., 2013).  The following year it was applied 
to herpesviruses and since then a number of papers have come out detailing recombinant 
viruses created using the CRISPR-Cas system (Russell et al., 2015).  Since the first papers 
were published detailing that this system could be used to modify herpesviruses, a large 
number of recombinant viruses have been created and in the case of HSV-1, these 
modifications are detailed succinctly by Wang et al. (2018).  Across the reports there is a 
general consensus that for efficient editing of herpesviruses, two plasmids are transfected 
into cells prior to infection with virus.  These plasmids consist of the donor template 
containing the homologous repair arms with the desired mutations (gene knock out/fusion 
gene ETC.) and a second plasmid encoding for the sgRNA and cas9 protein.  Effieciency 
improvements vary but one report suggests a 10,000 fold increase in efficiency in HDR 
using CRISPR-Cas9 compared with homologous recombination (Lin et al., 2016).  Selection 
of viruses containing the desired mutations is variable and dependent upon the marker used 
for selection.  Typically, fluorescent markers are used such as eGFP/RFP as this allows for 
FACs processing but other methods have also been used such as plaque assays.  No doubt 
with these systems becoming cheaper and more accessible, the continuation of modifying 
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1.9 – Aims 
Elucidating the roles of ILTV-encoded miRNAs is an important step forwards in the 
understanding of ILTV biology in the broader area of virus-host interactions.  Previous work 
in the literature has already identified and validated these miRNAs however there is little 
knowledge on their targets both in the viral genome as well as the host genome.  
The major aims of this thesis were to: 
 
 Characterise the expression of viral genes and viral miRNAs in a temporal manner 
and investigate the tropism of ILTV in a number of different avian cell lines in 
vitro 
 Employ the use of the experimental procedure CLASH (outlined in section 1.6.4) to 
identify miRNA:mRNA interactions during ILTV infection   
 Use bioinformatics to predict viral targets of virus-encoded miRNAs and test a 
panel of these in a laboratory setting by a number of methods 
 Identify viral targets of high-confidence cellular miRNAs by bioinformatic analysis 
and investigate these interactions and validate them using laboratory methods 
 Explore the potential use of genome editing technology, specifically CRISPR-Cas9 
and whether it is a viable option to create recombinant viruses.  Efforts were 
focused upon the deletion of five miRNAs found at the left hand end of the genome 
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2.1 – Tissue Culture 
2.1.1 – Cell lines used  
HEK293T Cells (Graham et al., 1977) (A gift from Dr. N Smith, The Roslin Institute) were 
grown in T75 flasks with Dulbecco’s Modified Eagles Medium (DMEM) containing 8 % 
foetal bovine serum and 1 % penicillin-streptomycin.  Cells were incubated at 37 °C with 5 
% CO2.    
HEK293FT cells (Javanbakht et al., 2003) (A gift from Dr. N Smith, The Roslin Institute) 
were grown in T75 flasks with Dulbecco’s Modified Eagles Medium containing high 
glucose and high pyruvate.  Media was supplemented with 10 % foetal bovine serum, 1 % 
penicillin-streptomycin and 500 µg/ml Geneticin™ selective antibiotic (Invitrogen).  Cells 
were incubated at 37 °C with 5 % CO2.  
LMH cells (Kawaguchi et al., 1987) (A gift from Dr K. Russell, Roslin Institute) were grown 
in a T75 flask coated with 0.1 % gelatin in Waymouth’s media (Invitrogen, Paisley, UK [All 
reagents were obtained from Invitrogen unless otherwise stated]) supplemented with 10 % 
foetal bovine serum, 1 % chicken serum, 1 % sodium bicarbonate and 1 % penicillin-
streptomycin and incubated at 37 °C, 5 % CO2.     
CLEC213 cells (Esnault et al., 2011) (A gift from Dr P. Quéré, INRA, France) were grown 
in T75 flasks with Dulbecco’s Modified Eagles Medium containing F12 nutrient mix.  This 
was supplemented further with 8 % foetal bovine serum and 1 % penicillin-streptomycin.  
Cells were incubated at 37 °C at 5 % CO2.     
Primary Chicken kidney cells (CKC’s) were prepared fresh (as described previously by 
Barrow and Lovell (1989)) and maintained in Minimal Essential Medium (MEM).  Media 
was supplemented with 10 % foetal bovine serum and 1 % penicillin-streptomycin.  Cells 
were grown in T175 flasks and incubated at 38 °C, 5 % CO2. 
DF-1 cells (Himly et al., 1998) were grown in T75 flasks with Dulbecco’s Modified Eagle’s 
Medium supplemented with 10 % foetal bovine serum and 1 % penicillin-streptomycin.  
Cells were incubated at 37 °C at 5 % CO2.     
QT-35 cells (Cowen and Braune, 1988) (A gift from Miss C Conceicao, Roslin Institute) 
were grown in T75 flasks with Dulbecco’s Modified Eagle’s Medium (DMEM) which was 
supplemented with 10 % foetal bovine serum and 1 % penicillin-streptomycin.  Cells were 
kept in a 37 °C at 5 % CO2.    
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QM-7 (Rong et al., 2014) cells were grown in T75 flasks with Dulbecco’s Modified Eagles 
Medium containing F12 nutrient mix.  This was supplemented further with 8 % foetal bovine 
serum and 1 % penicillin-streptomycin.  Cells were incubated at 37 °C at 5 % CO2.    
HD-11 cells (Beug et al., 1979) (A gift from Miss K Miedzinska, Roslin Institute) were 
grown in a T75 flask with Dulbecco’s Modified Eagles Medium containing; 36 ml tryptose 
phosphate broth (TSB), 10 % foetal bovine serum and 1 % penicillin-streptomycin-
glutamate.  Cells were incubated at 38 °C, 5 % CO2.     
Primordial Germ Cells (PGCs) (Glover and McGrew, 2012) (A gift from Dr M McGrew, 
Roslin Institute) were grown in 24-well plates with serum free media.  They were maintained 
at 38 °C, 5 % CO2.    
2.1.2 – Propagation of adherent cells 
Cells were passaged every 2-3 days depending upon the cell line.  Media was removed from 
cells and cells washed with sterile PBS.  Once washed, cells (except HD11) were detached 
from the plastic using trypsin-EDTA (Sigma Aldrich, Dorset, UK).  They were then seeded 
out into fresh flasks with appropriate media.   
For growth of LMH cells, flasks coated with gelatin were prepared prior to cell passage.  5 
mL of 0.1 % gelatin (10 mL for T175) was pipetted into T75 flasks and shaken to coat the 
bottom of the flask evenly.  Prior to the addition of cells, excess gelatin was removed. 
HD-11 cells were detached using a sterile scraper.  Cells were transferred to a falcon tube 
and centrifuged at 435 x g for 5 minutes.  Supernatant was removed and fresh media 
containing the appropriate supplements was added.  Cells were resuspended, counted and 
seeded out in fresh T75 flasks. 
2.1.3 – Propagation of suspension cells 
PGCs were monitored every day.  Media was changed every 48 hours by removing half of 
the media (~ 250 µl) using a pipette.  Fresh media was then added to the cells.  Cells were 
passaged by transferring well contents to a falcon tube and centrifuging cells for 5 minutes at 
435 x g.  Supernatant was replaced with fresh media and cells were counted before been 
seeded out into a clean 24-well plate. 
2.1.4 – Preparation of cells for long term storage 
Cells were resuspended to 5 x 106 cells/ml and centrifuged at 500 x g for 5 minutes.  Cell 
supernatant was removed and 1 ml of freezing medium (90 % FBS, 10 % [v/v] dimethyl 
sulphoxide) was used to resuspend the cell pellet.  Samples were then transferred to cryovials 
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and placed in a Mr. Frosty® (Thermo Scientific, Loughborough, UK) which was stored at -
80 °C overnight.  Samples were put into liquid nitrogen the following day for long term 
storage.   
2.1.5 – Growth of cells from long term storage 
Vials of cells were removed from liquid nitrogen and placed in a 37 °C water bath to thaw 
quickly.  Cells were then added to a 25 cm2 tissue culture flask (T25) and an appropriate 
quantity of pre-warmed media was added.  The flasks were then transferred to the applicable 
incubator (temperature dependent) and left overnight.  The following day, the growth 
medium was replaced. 
2.1.6 – Transfection of cells using Lipofectamine 2000® 
HEK293T cells were seeded at a density of 2x105 cells per well in a 12 well plate and left for 
24 hours prior to transfection.  100ng of plasmid DNA and 100 nanomolar (nM) miRNA 
mimic were added to Opti-MEM to a final volume of 50 μl and left to incubate for 5 minutes 
at room temperature. 5 μl of Lipofectamine 2000 was added to 45 μl of Opti-MEM and also 
left to incubate for 5 minutes at room temperature.  After incubation, the 
Lipofectamine/Opti-MEM mix was added to the plasmid DNA/miRNA mimic mix and 
reactions were left to incubate for 15 minutes at room temperature.  The total 100 μl 
Lipofectamine/DNA mixture was added to the cells which were subsequently left to incubate 
for 48 hours at 37°C with 5% CO2 before harvesting. 
2.1.7 – Transfection of cells using Xfect™ Polymer 
The day before transfection, HEK293T cells were seeded at a density of 2x105 cells per well 
in a 12 well plate.  100 ng of Plasmid DNA and 100 nM of miRNA mimic were mixed to a 
final volume of 50 μl of Xfect reaction buffer and gently mixed.  0.3 μl of Xfect polymer 
was added to the mixture and the reaction was mixed gently before been incubated at room 
temperature for 20 minutes.  Following incubation, the total 50.3 μl mixture was added to the 
cells which were incubated for 48 hours at 37°C with 5% CO2 before harvesting. 
LMH cells were seeded out at density of 1x105 cells per well in a 24 well plate and left to 
adhere overnight.  100 nM of miRNA mimic was then added to Xfect reaction buffer to a 
final total volume of 25 μl and mixed gently.  0.3 μl Xfect polymer was added to the reaction 
and mixed once again before a 20 minute incubation period at room temperature.  The total 
25.3 μl reaction was then added to the cells which were then placed in a 37°C with 5% CO2 
incubator for 12 hours before infection with ILTV virus.   
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24 hours before transfection, LMH cells were seeded out at a density of 5x105 cells per well 
in a 6-well plate and left to adhere.  2.5 μg of plasmid DNA was added to a final volume of 
100 μl of Xfect reaction buffer and gently mixed.  0.75 μl of Xfect polymer was added to the 
reaction and mixed again and subsequently incubated at room temperature for 20 minutes.  
All of the reaction mixture was then added to the cells, which were then incubated for 48 
hours at 37°C with 5% CO2 before harvesting. 
For CRISPR-Cas9 transfections, LMH cells were seeded out at density of 5x105 cells per 
well in a 6 well plate and left for 24 hours to adhere.  Once adhered, 5 μg of repair template 
DNA and 5 μg of cas9 plasmid DNA which also encoded for the specific sgRNAs were 
mixed with Xfect reaction buffer to a final volume of 100 μl.  Reactions were mixed and 
then 3 μl of Xfect polymer was added to the samples and mixed again before a 20 minute 
incubation period at room temperature.  The total reaction volume was then added to the 
cells which were incubated for 5-6 hours at 37°C with 5% CO2 before cells were infected 
with ILTV.                 
2.2 – PCR Methods 
2.2.1 – DNA isolation 
Total DNA was isolated from cell lines at a maximum density of 5 x 106 cells per sample 
using the DNeasy Blood and Tissue Kit (Qiagen) as per the manufacturer’s protocol.  
Extracted DNA concentrations were determined using a NanoDrop ND-100 
Spectrophotometer (Thermo Scientific) and samples stored at – 20 °C. 
2.2.2 – RNA isolation 
Total RNA was isolated from cell lines at a maximum density of 1 x 107 cells per sample 
using the RNeasy Mini Kit (Qiagen) as per the manufacturer’s protocol.  RNA concentration 
was then determined using a NanoDrop ND-100 Spectrophotometer and samples stored at – 
80 °C. 
Total small RNA was isolated from tissues using the miRNeasy Mini Kit (Qiagen).  Before 
isolation of total RNA, tissue was disrupted using stainless steel beads (Qiagen Cat: 69989) 
in a TissueLyser II machine (Qiagen, Cat: 85300).  Samples were shaken for 2 minutes at 
27.5 shakes per second and then rotated on the machine and the process repeated.  Once 
tissue was disrupted, the miRNeasy Mini Kit was used as per the manufacturer’s protocol.  
Purified RNA was then determined using a NanoDrop ND-100 Spectrophotometer and 
samples stored at – 80 °C until used.  
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2.2.3 – DNase treatment of RNA 
DNase treatment of RNA was carried out using the TURBO DNA-free™ Kit (Life 
Technologies).  1 µg of sample was treated with 2 µl TURBO DNase and 5 µl 10 x TURBO 
buffer into a final reaction volume of 50 µl.  Reactions were placed in a 37 °C water bath for 
30 minutes.  6 µl DNase STOP was then added and left to stand at room temperature for 5 
minutes. 
2.2.4 – RNase treatment of DNA 
2 µl of RNAsecure (Thermo Scientific Fisher AM7005) was added to the extracted DNA and 
samples were vortexed.  They were then incubated at 60 °C for 20 minutes in a heat block. 
Samples were stored at – 20 °C until further use. 
2.2.5 – Reverse transcription of RNA 
DNase treated RNA was primed with either Oligo (DT) primer or random primers (Both 
Promega, Southampton, UK).  10 µl of DNase treated RNA was added to 1µl of either Oligo 
(DT) primer or random primers and incubated at 70 °C for 5 minutes.  Samples were then 
placed on ice.  5 µl of supplied buffer, 30 U Avian Myeloblastosis Virus Reverse 
Transcriptase (AMV RT) and 2.5 µl dNTPs (10nM) (all Promega) were added to the DNase-
treated RNA – Primer mix to a total volume of 50 µl and incubated at 37 °C for 1 hour.  
cDNA concentrations were determined using a NanoDrop ND-100 Spectrophotometer and 
samples stored at – 20 °C.     
2.2.6 – PCR  
All Polymerase Chain Reactions (PCR) were carried out in a Veriti 97-well thermal cycler 
(Life Technologies).  Primer3 (http://primer3.ut.ee/) was used for primer design.  Sample 
reactions contained 1 U of Taq DNA Polymerase (Qiagen), 2 µl 10x reaction buffer 
(supplied with the Taq DNA Polymerase), 0.4 µl dNTPs (10nM) (Promega), 8 pmols 
forward and reverse primer in  a final volume of 20 µl.  Cycling conditions were as follows: 
95 °C for 15 minutes, 35 cycles of 95 °C for 30 seconds, 55 – 60 °C for 1 minute 
(temperature dependent upon the Tm of Primers), 72 °C for 1 – 5 minutes (depending upon 
length of product amplifying) followed by a final  cycle of 72 °C for 7 minutes. 
2.2.7 – Colony PCR 
Colonies were picked and individually spread over a fresh Luria-Bertani (LB)/agar plates 
containing appropriate antibiotic (100 µg/ml Carbenicillin or 50 µg/ml Kanamycin) that was 
divided and numbered with a grid.  The spreader was then agitated in 20 l of dH2O in a tube 
labelled with the same number.  Numbered plates were incubated at 37 C overnight. 
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Samples agitated in water were boiled at 95 C for 10 minutes.  A conventional PCR (section 
2.2.7) was used to screen for positive colonies.  PCR products were analysed on a 2 % 
Agarose gel as described in section 2.2.12.  One positive colony was then selected and 
grown in 5 ml LB broth containing appropriate antibiotic, plasmid DNA purified (section 
2.3.9) and sent for sequencing (see section 2.3.7).  Large cultures were then prepared of 
positive colonies that contained the correct insert (see section 2.3.10.) 
2.2.8 – Mutagenesis PCR 
Mutagenesis PCR was carried out using the Quik-Change Lightning Site-Directed 
Mutagenesis Kit (Agilent Technologies, Manchester, UK).  Primers for mutagenesis were 
designed using the QuikChange Primer Design Program 
(http://www.genomics.agilent.com/primerDesignProgram.jsp) and primers can be 
found in appendix 2.  Site-Directed Mutagenesis reactions, PCR cycling conditions and 
Dpn1 digestion were carried out as per the manufacturer’s protocol. 
2.2.9 – Quantitative PCR  
Quantitative PCR (both RT-qPCR and qPCR) were carried out in a Rotor Gene RG-3000 
(Qiagen).  SensiFAST SYBR Hi-ROX Kit (Bioline) was used for reactions that were set up 
follows:  10 µl SensiFAST SYBR Hi-ROX reaction buffer, 8 pmols of both forward and 
reverse primer, 2 µl DNA (or 500 ng cDNA template for RT-qPCR) template topped up to 
20 µl using dH2O.  Primers were designed using primer3 (http://primer3.ut.ee/) and 
amplified no more than 200 bp.  Cycling conditions were as per the 3-step cycle outlined in 
the manufacturer’s protocol.  
2.2.10 – Synthesis of RNA from a DNA template 
To synthesise RNA, the NEB Quick High Yield Kit (New England Bio labs, E2050s) was 
used as per the manufacturer’s protocol.  A total of 100 ng DNA template was used in a final 
reaction volume of 30 µl.  Reactions were set up and incubated at 37 °C overnight.  Once 
incubated, samples were treated with 2 µl of DNase as per the instructions in the 
manufacturer’s protocol.  
2.2.11 – Agarose gel electrophoresis 
DNA was analysed by electrophoresis using 0.5 – 3 % agarose gels containing 1 x SYBR® 
Safe DNA Gel stain (Life Technologies) in Tris-acetate (TAE) buffer.  Samples were mixed 
with 6 x loading dye (New England Biolabs, #B7024S).  Electrophoresis was carried out in 
tanks with gels submerged in TAE buffer at 80 – 100 V for an appropriate length of time for 
band separation.  Estimation of DNA size was carried out using 1 kb, 100 bp or 50 bp 
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GeneRuler DNA Ladders (Thermo Scientific).  Gel images were captured using an alpha UV 
imager.      
DNase treated guide RNA (sgRNA) was then extracted as per section 2.2.2.  RNA was 
eluted using 50 µl of nuclease free water and stored at – 80 °C until needed.  Two aliquots of 
RNA (each 2 µl in volume) were taken and left at room temperature for 1 hour to check for 
degradation.  After the incubation period, samples were tested on a NanoDrop ND-100 
Spectrophotometer for RNA quantification.  In addition to this, an aliquot of RNA was 
analysed on a 3 % agarose gel to qualify any RNA degradation and to ensure correct size of 
RNA.  Equipment used for gel electrophoresis was treated with 0.5 M NaOH for 1 hour prior 
to use to remove any RNases.   
2.2.12 – DNA extraction from agarose gels 
DNA was extracted from agarose gels using the QIAquick Gel extraction Kit (Qiagen) 
according to the manufacturer’s protocol.  Extracted DNA concentration was determined 
using a NanoDrop ND-100 Spectrophotometer and samples stored at – 20 °C.  
2.2.13 – PCR Purification 
PCR products were extracted from reactions using the QIAquick PCR purification kit 
(Qiagen) according to the manufacturer’s protocol.  Extracted DNA concentration was 
determined using a NanoDrop ND-100 Spectrophotometer and samples stored at – 20 °C.  
2.3 – Cloning Methods 
2.3.1 – PCR purification 
PCR products were purified using the QIAquick Purification kit (Qiagen) as per the 
manufacturer’s protocol. 
2.3.2 – Annealing of oligonucleotides 
Oligonucleotides up to 120 bases in length were manufactured by Sigma-Aldrich (Sigma-
Aldrich) along with the equivalent reverse complement counterpart.  Oligonucleotides were 
then resuspended in dH2O to a concentration of 100 M.  1 l of each pair was mixed with 5 
l of 10 x Buffer 2 (New England Biolabs) to a final volume of 50 l.  Samples were heated 
to 95 C for 5 minutes in a heat block and allowed to cool slowly to room temperature.    5 l 
of annealed oligonucleotides were then digested with appropriate restriction endonucleases 
before been ligated into a vector cut with the same endonucleases.   
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2.3.3 – DNA ligation 
When PCR products required sequencing, the TOPO TA Cloning Kit (Life 
Technologies) was used for cloning.  4 l of PCR product mixed with 1 l of salt solution 
and 1 l of TOPO 4 vector and left to stand at room temperature for 10 minutes. 
For cloning DNA/annealed oligonucleotides cut with restriction endonucleases into 
expression vectors the LigaFast™ Rapid DNA Ligation System (Promega) was used.  100 
ngs of vector was used to 2 l of DNA insert along with 3 U of T4 DNA ligase (supplied in 
the LigaFast™ kit) in a final volume of 15 l.  Ligations were placed on ice overnight to 
gently warm to room temperature.     
2.3.4 – Transformation of chemically competent cell lines 
5 l of ligated product was added to 25 l (or 30 l for STBL3 Cells) of TOP10 chemically 
competent cells (Life Technologies) and placed on ice for 30 minutes.  Samples were then 
heat shocked at 42 C for exactly 45 seconds before been placed back on ice for a further 5 
minutes.  150 l of pre-warmed SOC media was then added to each ligation.  Samples were 
then placed in a 37 C shaking (200 RPM) incubator for 1 hour.  After incubation, samples 
were spread on to LB plates containing appropriate antibiotic (100 g/mL Ampicillin or 50 
g/mL Kanamycin) and incubated overnight at 37 C.     
2.3.5 – Transformation of Ultracompetent cell lines 
2 µl of β-Mercaptoethanol was added to 45 µl of XL-10 Gold Ultracompetent Cells 
(supplied with Quik-Change Lightning Site-Directed Mutagenesis Kit, Agilent) and 
incubated on ice for 10 minutes with gentle, intermittent mixing.  2 µl of site-directed 
mutagenesis PCR product was added to the cells and incubated on ice for 30 minutes.  
Samples were then heat shocked at 42 °C for precisely 30 seconds before been placed back 
on ice for a further 2 minutes.  200 µl of pre-warmed SOC medium was added to the samples 
and placed in a 37 °C shaking incubator for 1 hour at 200 rpm.  Following incubation, 
samples were spread on LB plates and were left in a 37 °C incubator overnight. 
2.3.6 – Restriction digests 
DNA and annealed oligonucleotides were digested with restriction endonucleases (Afl2, 
Bbs1, BamH1, Bgl2, EcoR1, Kpn1, Not1, Pme1, Xho1, NEB) according to the 
manufacturer’s instructions using the supplied buffers. Restriction digests were incubated at 
37 C for 1 hour in a total volume of 30 l for double digests and 40 l total volume for 
sequential digests.  Oligonucleotides containing endonuclease sites were digested and 
purified using PCR purification as described in section (section 2.3.1).  Expression vectors 
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were treated with FastAP Thermosensitive Alkaline Phosphatase (Thermo Scientific) 
according to the manufacturer’s protocol before samples were analysed on a 1 % agarose gel.  
Bands were excised using a clean scalpel and purified as described in section 2.2.13.  The 
DNA concentration of cut expression vectors was then determined using a 
photospectrometer.  
2.3.7 – Sequencing of samples 
Plasmid DNA was sent to GATC biotech (GATC, London, UK) as per their instructions. 
2.3.8 – Sequencing analysis 
DNA sequences were analysed using NCBI nucleotide BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast).  NEBcutter (http://tools.neb.com/NEBcutter2/) was 
used for restriction digest mapping.     
2.3.9 – Plasmid DNA isolation from bacteria (small scale) 
A single bacterial colony was isolated from LB plates and placed into 5 ml LB broth 
containing appropriate antibiotic.  Cultures were incubated overnight in a 37 °C shaking 
incubator set at 200 RPM.  Plasmid DNA was extracted using the QIAprep Spin Miniprep 
Kit (Qiagen) as per the manufacturer’s protocol.  Eluted plasmid DNA concentration was 
determined using a NanoDrop ND-1000 spectrophotometer.  Samples were stored at – 20 °C.      
2.3.10 – Plasmid DNA isolation from bacteria (large scale) 
200 ml of LB broth containing appropriate antibiotic was inoculated with 1 ml of culture as 
set up in section 2.3.9.  Cultures were shaken overnight at 37 °C at 200 rpm.  Plasmid DNA 
was then extracted using the Qiagen EndoFree Plasmid Maxi Kit (Qiagen) as per the 
manufacturer’s protocol.  Eluted plasmid DNA concentration was determined using a 
NanoDrop ND-1000 spectrophotometer.  Samples were stored at – 20 °C. 
2.3.11 – Preparation of Bacterial stocks for long term storage 
Colonies that were confirmed to have the correct insert by sequencing were used to set up 
long term glycerol stocks.  500 µl of culture (a single bacterial colony grown in 5 ml LB 
broth containing appropriate antibiotic(100 µg/ml Carbenicillin or 50 µg/ml Kanamycin) 
was mixed with 500 µl 80 % glycerol in H2O and stored at – 80 °C. 
2.4 – Detection of Proteins by Chemiluminescence and Western 
Blotting 
2.4.1 – Sample preparation  
Laemmli buffer (Bio-Rad, Hemel Hempstead, UK) was prepared by adding 50 µl of β-
Mercaptoethanol to 950 µl Laemmli sample buffer.  Cells were harvested as per section 2.1.2 
Chapter 2  Materials and Methods 
61 
 
and transferred into a suitable Falcon tube and centrifuged at 435 x g before been 
resuspended in one volume of sterile PBS.  Once re-suspended, an equal volume of Laemmli 
buffer was added.  Samples were mixed by vortexing and placed in a dry hot plate at 95 °C 
for 10 minutes.  After boiling, samples were loaded on to a pre-cast SDS-PAGE gel (Bio-
Rad, UK).  
2.4.2 – SDS-Polyacrylamide gel electrophoresis 
Precast 4-20 % Mini-PROTEAN® TGX™ Gels (Bio-Rad) were used for SDS-PAGE.  
Samples were loaded into the gel along with Odyssey® Protein Molecular Weight Marker 
(LI-COR).  The gel was run in running buffer (Tris/Glycine/SDS buffer (Bio-Rad) for 90 
minutes at 100 volts.   
2.4.3 – Transfer of protein to nitrocellulose membrane 
For transfer of protein to nitrocellulose membrane (Bio-Rad nitrocellulose mini membranes), 
the Trans-Blot® Turbo™ Blotting System (Bio-Rad) was used.  The Trans-Blot Turbo 
Transfer Buffer was prepared as per the manufacturer’s protocol and then the transfer stacks 
and nitrocellulose membrane were soaked in the transfer buffer for 2 – 3 minutes.  Assembly 
of the transfer stack is as follows from bottom to top: bottom cassette electrode, bottom 
reservoir stack, blotting (nitrocellulose) membrane, gel, top reservoir stack and top cassette 
electrode.  To transfer the protein to the nitrocellulose membrane, the manufacturer’s 
protocol for Mini-PROTEAN TGX gels was followed.          
2.4.5 – Blocking of nitrocellulose membrane 
A blocking solution was made using 4 % w/v ECL Prime Blocking Agent (GE Healthcare 
Sciences)   in PBS-T (PBS containing 0.1 % v/v Tween 20 [Sigma-Aldrich]).  The 
membrane was incubated at room temperature in a dark box for 1 hour on a rocker using 50 
mL of blocking buffer. 
2.4.6 – Probing nitrocellulose membranes with antibodies 
Primary antibodies were added at a dilution of 1:1,000 into the blocking solution and left 
overnight on a rocker at 4 °C.  The membrane was then washed x 3 using PBS-T.  Secondary 
antibodies were added at a dilution of 1:10,000 in 4 % blocking solution.  Membranes were 
incubated for 1 hour before been washed x 3 using PBS-T.  Membranes were then analysed 
on the Li-Cor image analyser (LI-COR).  A list of antibodies used during this project can be 
found in table 2.1. 
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Table – 2.1. Antibodies and their appropriate dilutions 
Primary Antibodies Dilution Use Manufacturer 
Mouse anti-Actin 1:5000 WB Abcam (Cambridge, UK)  
(Cat #AB8226) 
Rabbit anti-Argonaute 2  1:1000 WB  A gift from Dr. finn Grey  
(The Roslin Institute) 
Rat anti-HA 1:1000 WB Roche (Burgess hill, UK) 
(Cat #11-867-423-001) 
6xHis 1:1000 WB Roche 
(Cat #11-922-416-001) 
tubulin 1:5000 WB Abcam (Cat #AB18251) 
Peroxidase Anti-Peroxidase 
Soluble Complex antibody 
1:1000 CHEM Sigma-Aldrich (Cat #P1291) 
Secondary Antibodies Dilution Use Manufacturer 
IRDye 680RD donkey anti-mouse 1:10000 WB Li-Cor (Cat #926-68072) 
IRDye 800CW donkey anti-rabbit 1:10000 WB Li-Cor (Cat #926-32213) 
IRDye 680RD donkey anti-rat 1:10000 WB Li-Cor (Cat #926-68076) 
CHEM = Chemiluminescence, WB = western blotting. 
2.4.7 – Detection of Protein by Chemiluminescence 
Detection using chemiluminescence used a peroxidase anti-peroxidase antibody (listed in 
Table - 2.1) following the running, transferring and blocking of a nitrocellulose membrane 
(as laid out in sections 2.4.2 – 2.4.5).  For detection, the Pierce™ ECL Western Blotting 
Substrate (ThermoFisher Scientific) was used as per the manufacturer’s protocol.  Blots were 
then analysed on a G-box imaging system (Syngene, Cambridge, UK).   
2.5 – Production of a cell line stably expressing tagged Ago2 
2.5.1 – Determining antibiotic resistance of cells 
LMH cells were seeded at a density of 1x104 per well on a 24 well plate and incubated 
overnight (section 2.1.2).  Puromycin (Sigma-Aldrich) was added to the cells with dilutions 
ranging from 0 µg/mL to 10 µg/mL.  The medium was replaced every 48 hours containing 
the appropriate concentration of antibiotic.  Cell viability was checked every 48 hours using 
trypan blue staining and determining the percentage of dead cells, this was carried out for 11 
days to determine the minimum concentration of antibiotic that caused complete cell death in 
4-6 days.   
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2.5.2 – Production of Lentivirus particles 
HEK293FT cells were seeded out for 70-90 % confluency in 100 mm plates using 
appropriate media containing no antibiotics or Geneticin.  24 hours after seeding out cells, 
media was replaced with 10 ml pre-warmed media.  Lentiviral media contained 150 µl 
Optimem (Invitrogen), 4 µg Vector plasmid, 2 µg Envelope plasmid and 6 µg Packaging 
plasmid.  Once mixed, it was left to stand for 5 minutes at room temperature.  Transfection 
media was also made containing 150 µl Optimem (Invitrogen) and 36 µl Lipofectamine 2000 
(Thermo Scientific) and left to stand for 5 minutes.  After standing, both lentiviral and 
transfection media were mixed together and left to stand for 20 minutes at room temperature.  
The mixture was then added to the seeded out plates.  Cells were then placed back into a 37 
°C, 5 % CO2 incubator.  16 hours post transfection, media was replaced with pre-warmed 
media containing appropriate supplements.  Supernatant was harvested from cells 3 Days 
Post Infection (D.P.I) by scrapping cells from the plate and centrifuging them at 435 x g for 
5 minutes.  The resulting supernatant was then filtered using a 0.45 µm filter.  At this point, 
supernatant was either aliquoted into 15 mL Falcon tubes and frozen at -80 °C or further 
concentrated.   
2.5.3 – Concentration of Lentivirus particles by ultra-centrifugation 
14 mL of supernatant was added to each 14 mL ultra-centrifuge tube (Beckmann Coulter, 
USA) (or sterile PBS for balancing).  Tubes were weighed and balanced to within +/- 0.1 g 
before been placed into corresponding buckets (Beckmann SW40 Swing-out Rotor).  The 
samples were loaded and then centrifuged for 2 hours at 19,500 RPM at 16 °C.  Once 
finished, supernatant was removed and the pellet was resuspended in 200 µl sterile PBS.  
2.5.4 – Transduction of LMH cells with Lentivirus particles  
Cells were seeded out on a 24 well plate at a density 1x105 per well and left overnight to 
adhere.  Polybrene (Millipore) was added to concentrated virus at a concentration of 8 
µg/mL and mixed by inversion.  Virus supernatant was then added to cells at 100 µl 
supernatant per well. Cells were incubated at 38 °C for 30 minutes.  Cells were then 
centrifuged for 2 hours at 625 x g at 30 °C.  18 hours after centrifugation, media was 
changed on the cells. 
2.6 – Other Methods 
2.6.1 – Infection of cells with ILTV 
All cells listed in section 2.1.1 with the exception of HEK293T cells were seeded out at the 
appropriate density on a 24-well plate.  Plates were placed back in the incubator for 24 hours 
to allow the cells to adhere. 
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Virus was retrieved from LN2 and thawed rapidly using a 37 °C water bath.  Cells were 
washed with sterile PBS before a virus suspension with an appropriate multiplicity of 
infection (MOI) was added.   Plates were rocked manually every 15 minutes to ensure 
complete coverage of the monolayer.  After 1 hour, the virus suspension was removed from 
cells and replaced with pre-warmed complete medium with 2 % FBS concentration. 
2.6.2 – Plaque assays 
LMH cells were seeded out at a density of 1x106 per well in a six-well dish.  Cells were then 
placed in the incubator and allowed to adhere prior to virus infection.  Virus was recovered 
from LN2 and thawed quickly in a 37 °C water bath.  A 10 fold dilution series of virus in 
appropriate medium was made, media was removed from cell monolayers and 1 ml of virus 
solution was added per well.  Plates were placed back into the incubator and rocked every 15 
minutes for 1 hour.  A 0.5 % avicell solution (FMC Biopolymer, Girvan, Scotland, UK) was 
made up using stock 2.4 % avicell solution and 2 % virus media with appropriate 
supplementary reagents (section 2.1.1 for media recipes).  This was kept warm at 37 °C until 
needed.  After the initial one hour incubation the inoculum was removed from cells.  2 ml of 
avicell overlay was added per well and plates were put back in a 37 °C incubator at 5 % CO2.  
After 48 hours, plates were fixed by adding 2 ml of 10 % buffered formalin per well and 
placed in a fume cupboard overnight.  Fixed plates had both formalin and avicell overlay 
removed and they were subsequently stained with 2 ml of 0.1 % toluidine blue. Plates were 
left for approximately 4 hours before the toluidine blue solution was removed.  Plates were 
then washed using H2O and allowed to dry.  
2.6.3 – Luciferase assays 
Luciferase assays were carried out using the Dual Luciferase Reporter Assay System 
(Promega).  Cells were transfected as in section 2.1.6 and harvested using the 5x passive 
lysis buffer contained within the kit diluted to 1 x concentration.  Lysed cells were left to 
rock for 30 minutes.  After 30 minutes, cell lysates were transferred to a clean 1.5 ml 
eppendorf tube and centrifuged at 1800 RPM for 5 minutes.  20 l of the sample supernatant 
was then added in triplicate to a white, opaque 96-well plate.  Luciferase Assay Reagent 
(LAR II) and Stop & Glo reagent were then prepared according to the manufacturers 
protocol but they were used at a dilution of 1:10.  A GloMax 96 luminometer (Promega) was 
used to measure the luminescence readings of both the Renilla and firefly luciferase.  
Measurements of luciferase used 50 l of each reagent instead of the suggested 100 l in the 
manufacturer’s protocol. 
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2.6.4 – RNA Synthesis 
Synthesis of RNA was carried out using the HiScribe™ T7 Quick High Yield RNA 
Synthesis Kit (New England Biolabs) according to the manufacturer’s protocol.  RNA 
Synthesis used 100 ng of template DNA and reactions were incubated for 24 hours.  
Synthesised RNA was then extracted and stored at – 80 °C.   
2.6.5 – In Vitro digestion of DNA using Cas9 protein and sgRNAs 
To synthesise both the template DNA and sgRNA DNA templates, conventional PCR was 
used as laid out in section 2.2.7.  Both sgRNA DNA and template DNA was then purify 
using a PCR purification kit as per the manufacturer’s instructions (Qiagen) (section 2.3.14).  
The DNA was then stored at – 20 °C until reactions were assembled.  
sgRNA template DNA was used for RNA synthesis as per the manufacturer’s protocol.  
Synthesised RNA was purified using an RNeasy mini kit (Qiagen).  Extracted RNA 
concentrations were determined using a NanoDrop ND-100 Spectrophotometer (Thermo 
Scientific) and samples stored at – 80 °C. 
Reactions were set up following the NEB protocol (M0386).  Molar ratios of 10:10:1 were 
set up (sgRNA: Cas9 protein: Template DNA) in a final volume of 30 µl using nuclease free 
water.  Samples were left for either 1 hour or 24 hours in a 37 °C incubator.  Following 
incubation, samples were treated with RNase A and proteinase K to denature both the cas9 
protein and sgRNA.  Samples were then analysed on a 3 % agarose gel.   
2.6.6 – CRISPR-Cas9 transfection and infections 
LMH cells were seeded in 6-well plates at a density of 1x105 cells per well and left for 24 
hours to adhere in a 37 °C, 5 % CO2 incubator.  Cells were then transfected using Xfect 
polymer (Takara) according to the manufacturer’s instructions.  5 µg of sgRNA (or if two 
were used 2.5 µg of each) was transfected alongside 5 µg of homology repair cassette 
totalling 10 µg per well.  Transfection reactions were placed back in a 37 °C, 5 % CO2 
incubator and left for 12 hours.   
After 12 hours incubation, cells were infected with wild type ILTV at an MOI of 0.001 as 
per section 2.6.1.  Following incubation with virus, cells were washed with PBS and 
complete media was added to the cells (described in section 2.1.1) except with 2 % FBS.  
Phosphonoacetic acid (PAA) was added to the media at a concentration of 100 µg/ml.  Cells 
were then placed back in 37 °C, 5 % CO2 incubator for a further 12 hours.   
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Media was replaced again with complete media with 2 % FBS concentration and cells were 
placed in a 37 °C, 5 % CO2 incubator for 48-72 hours and monitored for cell death and 
fluorescence using a fluorescent microscope. 
Samples were harvested by scraping wells with a sterile scraper and well contents transferred 
to a clean 1.5 ml cryovial tube.  Samples were then stored at – 80 °C.  
2.6.7 – Statistical analysis of data 
Statistical analysis was carried out using Minitab 17 software.  Graphs were made using 
Graphpad Prism 6 software.  All errors bars on figures represent the standard error of the 
mean unless otherwise stated.  Specific statistical analysis for individual experiments is as 
stated in each corresponding section of this thesis.    
Commonly Used Solutions 
PBS 
50 x TAE buffer 
LB medium 
LB/Agar 
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3.1 – Introduction 
There have been several different types of experimental procedures developed to look at the 
interaction of miRNAs with their targets; each advancing on its predecessor (reviewed in 
section 1.6.4).  Cross Linking and Sequencing of Hybrids (CLASH) is the latest of these 
biochemical techniques allowing for direct miRNA:mRNA interactions to be identified by 
ligating the two pieces of RNA (Helwak and Tollervey, 2014). The procedure is reviewed in 
section 1.6.4 and an outline of the procedure is shown in Figure 3.1.  With the use of these 
techniques, targets of virus-encoded miRNAs can be elucidated.   
The role of virus-encoded miRNAs in the pathogenesis of disease is well documented in the 
literature; especially in the case of herpesviruses (reviewed in section 1.7).  Marek’s Disease 
Virus (MDV) encodes for the miRNA MDV1-miR-M4 which is a functional homologue of 
the cellular miRNA miR-155.  Abolition of the miRNA from the virus abrogates the 
formation of lymphomas during lytic infection (Zhao et al., 2011).  Similarly, Kaposi’s 
sarcoma associated Herpesvirus (KSHV) has been shown to encode a miR-155 homologue 
that is implicated in the induction of B cell tumours (Gottwein et al., 2007).  Human 
Cytomegalovirus (HCMV) encodes the HCMV-miR-US25.1 that has been shown to target 
the cellular gene ATP6V0C, a gene essential for viral replication.  This targeting of a gene 
reducing pathogenesis is different to what is seen in other viruses but it suggests that 
ATP6V0C regulation may be important for immune invasion or maintenance of latency 
(Pavelin et al., 2013).  Epstein-Barr virus (EBV) is known to encode for 44 mature miRNAs 
found in three distinct clusters in the genome.  One virus-encoded miRNA, EBV-miR-
BART6-5p has been shown to target Dicer, an essential component in the biogenesis of 
miRNAs.  It also has the negative consequence that it down-regulates the effect of EBV-
encoded miRNAs so may play a critical role in regulating the expression of miRNAs (Lizasa 
et al., 2010).   
ILTV has been shown to encode for 10 miRNAs (Rachamadugu et al., 2009, Waidner et al., 
2009).  One of these, ILTV-miR-I6 was found to target ICP4.  A second miRNA, ILTV-
miR-I5 was also suggested to target ICP4 but this was not statistically significant (Waidner 
et al., 2011).  As there is little information on the remaining miRNAs and no information on 
possible cellular targets of ILTV-encoded miRNAs, the use of biochemical techniques to 
identify targets of ILTV-encoded miRNAs would advance the understanding of pathogenesis 
for this virus. It is important to elucidate these targets as a deeper understanding of 
pathobiology of the virus will inform vaccine strategy and/or breeding of birds for resistance 
to ILTV. 
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As well as using biochemical approaches to identify targets for virus-encoded miRNAs, the 
use of alignment software can be employed to assess homology between ILTV-miRNAs and 
any cellular miRNAs.  This approach was previously used by the Dalziel group whereby the 
OvHV-2-encoded miRNA OvHV2-miR-73.1 was found to be homologous to the cellular 
miRNA miR-216a (Levy, 2011).   
Finally, as discussed in chapters 4 and 5, bioinformatical approaches can be used to identify 
targets of both viral and cellular encoded miRNAs which can be then tested using more 
traditional laboratory techniques.   
3.2 – Aims 
The aims of this part of the project were to create a cell line that stably expressed a tagged 
Argonaute 2 transgene for subsequent use in CLASH experiments.  In addition to this, 
infection studies with LMH cells were carried out to elucidate an optimal time point for 
when to harvest infected cells for CLASH by assessing the expression of both viral genes 
and viral miRNAs across a time course of infection.  Other avian cell lines were also 
screened for their permissiveness to infection by ILTV.   
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Figure 3.1 - An Overview of the CLASH Technique 
A – Schematic diagram showing the His6x, Tobacco Etch Virus (TEV) and Protein A (HTP) fused to Argonaute 
2 (Ago2) protein which is used for immunoprecipitation of the Ago2. 
B – Brief outline of steps carried out during the CLASH experimental protocol 
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3.3 – Detection of viral gene expression by Reverse –Transcriptase PCR  
Viral gene expression was determined as part of the optimisation for the CLASH 
experiment, essentially to assist in picking an optimal time to harvest samples for the 
CLASH protocol.  LMH cells were either infected or mock-infected as described in section 
2.6.1.  Cells were harvested and RNA extracted.  RNA was DNase treated and was 
subsequently used for cDNA synthesis as described in section 2.2.5.  Conventional PCR (see 
section 2.2.7 for details) was then used to amplify specific viral genes and PCR products 
analysed by gel electrophoresis (as per section 2.2.12).  PCR products that were detected in 
the infected cDNA samples and not the mock infected or –RTs were taken as a positive 
result.  Genes could be detected from across the temporal gene expression profile.  One 
immediate-early designated gene, ICP4 was detected in a time dependent manner (Figure – 
3.2A).  Two early genes, Protein kinase (PK) and Thymidine Kinase (TK) were detected also 
(Figure – 3.2B & C).  Furthermore, one early/late gene, UL41 was detected (Figure – 3.2D).  























Figure – 3.2.  Detection of expression of viral genes in a time dependent manner using RT-PCR 
LMH Cells were infected with ILTV at an MOI of 0.1.  Samples were harvested at 1, 3, 6, 9, 12 and 24 
hours post infection (HPI).  RNA was extracted and DNase treated.  cDNA was synthesised and used 
for detection for the detection of viral genes.  A gDNA positive control was used as well as minus 
reverse transcriptase (-RT) controls.  Top panel in each case displays cDNA results alongside a gDNA 
control whilst lower panel shows –RT controls and a NTC.  A – ICP4, an immediate-early gene  B – 
Thymidine Kinase (TK), an early gene C – Protein Kinase (US3/PK), an early gene  D – UL41, a 
delayed-early gene  E – Glycoprotein E (gE), a late gene  
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A ICP4 
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3.4 – Detection of viral miRNAs  
The expression of virus-encoded miRNAs was also investigated using the same RNA used 
for the detection of viral genes.  This was again done as an optimisation step in preparation 
for the CLASH protocol to maximise the number of miRNAs expressed thus garnering the 
maximum amount of data possible for one time point.  RNA was DNase treated and the 
MiScript II kit was used to amplify mature miRNAs.  The SYBR green real-time PCR kit 
(Qiagen) was then used for mature miRNA detection along with a forward primer specific to 
each ILTV-encoded miRNA (as shown in Figure 3.3).  Samples were then analysed by 
agarose gel electrophoresis.  Bands detected were then cloned and sequenced.  Due to the 
process of cDNA synthesis with the MiScript II kit, primarily the polyadenylation step and 
use of an oligo-DT prime with a 3’ universal tag, genomic DNA is not detected during PCR 
and so –RTs are not applicable.  Therefore an uninfected sample was used as a control for 
each time point for each miRNA in addition to the detection of a cellular miRNA.  
According to the MiScript PCR handbook, mature miRNA PCR products are 85-87 nts in 
length.  
 In total, 7 of the 10 virally encoded miRNAs could be detected with this method (Figure 
3.4).  ILTV-miR-I1-3p could be detected at 6, 9, 12 and 24 HPI but not before whilst it’s 
complimentary strand, ILTV-miR-I1-5p could be found at 1, 6, 9, 12 and 24 HPI.  Only at 
one time point could ILTV-miR-I4 be detected which was 1 HPI.  ILTV-miR-I5-3p has the 
same expression profile as ILTV-miR-I1-5p, detected at all times except 3 HPI.  Finally, 
three miRNAs could be detected at all time points and they were ILTV-miR-I5-5p, ILTV-
miR-I6-3p and ILTV-miR-I6-5p.  In addition, gga-miR92a-3p could be found at all time 
points including the mock controls.  Some other bands were detected at around 50 bp. These 
are most likely off target effects of the primers which are constrained due to the length of 
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Figure – 3.3. Reverse Transcription and amplification of miRNAs 
For detection of miRNAs, cDNA was synthesised using the miScript II RT Kit 
(Qiagen).  This was used in conjunction with the miScript SYBR® Green PCR Kit 
(also Qiagen) to detect specific miRNAs using a specific sense primer lacking the 
last 6 nts.  Sequencing was then used to confirm the miRNA sequence.   





Figure – 3.4.  Time course of Expression for Viral miRNAs 
LMH cells were seeded out at 1x104 per well in a 24-well plate and left to adhere overnight.  
Cells were then infected with an MOI of 0.1 and subsequently harvested at 1, 3, 6, 9, 12 and 
24 hours post infection (HPI) by removing the media, scrapping the cells and suspending 
them in 350 µl of RLT buffer.  From this, RNA was extracted and DNase treated.  cDNA 
was synthesised using the MiScript II kit and subsequently used in a Real-time PCR for 
detection of miRNAs with the MiScript SYBR Green PCR Kit (Both Qiagen).  7/10 
miRNAs have so far been detected using this method as well as the cellular miRNA gga-
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3.5 – Transduction of LMH cells with lentivirus particles 
For the CLASH experiment (shown in Fig – 3.1.), purification of RISC complexes is 
required.  To do this, a tagged Ago2 transgene is used.  For delivery of the tagged transgene, 
lentiviruses are used which harbour the desired transgene and can intergrate with the host 
genome allowing for the creation of a stably transduced cell line.  To help create a pure 
population of transduced cells, a selection marker is used to remove any untransduced cells 
from the population.  
3.5.1 – LMH susceptibility to the drug Puromycin  
To help create a clonal population of transduced cells expressing a transgene, a selection 
marker, in this case, Puromycin was used to kill any untransduced cells following 
transduction.  To determine the death rate of LMH cells in the presence of the  drug 
Puromycin, cells were seeded out at a density of 1x104 cells per well in a 24-well plate.  In 
total, 3 wells were seeded per drug concentration and the average cell death was calculated 
for each condition.  After 24 hours, cells were placed under antibiotic selection pressure at 
differing concentrations to find an optimum concentration where complete cell death was 
observed in 3-5 days.  Cell death was assessed by trypan blue staining and estimating the 
percentage of dead cells.  Experiment one used a broad range of antibiotic concentrations (0 
– 10 µg/ml) and found an optimal range somewhere between 0.5 and 1 µg/ml (Figure – 
3.5A).  Subsequently, a second experiment was set up with a concentration range between 0 
and 1 µg/Ml.  The result of this second experiment found that 0.5 µg/ml Puromycin was 
optimal for complete LMH cell death within the 3 – 5 day range (Figure – 3.5B).   
 
  





Figure – 3.5.  LMH cell viability whilst under selection pressure using Puromycin 
LMH cells were seeded out in 24 wells plates and left to adhere.  Cells were then placed under drug 
selection pressure with Puromycin.  Dead cells were counted using trypan blue staining which gave 
an estimated percentage of dead cells (%).  A – A large concentration range of Puromycin (0 – 10 
µg/ml) used.  B – A narrow drug concentration range (0 – 1 µg/ml) 
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3.5.2 – Transduction of LMH cells with lentivirus particles 
Lentivirus particles were produced (diagrammatic flowchart in Figure – 3.6) via transfection 
of three plasmids into HEK293FT cells (A gift from Dr. N Smith, The Roslin Institute) and 
harvested as per section 2.5.2.  Lentivirus plasmids (A gift from Dr. F Grey, The Roslin 
Institute) were part of the 3rd generation of lentivirus generation plasmids.  A transfer 
plasmid containing a tagged Ago2 fusion gene was used in conjunction with the packaging 
plasmid psPAX2 and envelop plasmid pMD2.G.  Following transfection of cells, the 
supernatant was subsequently concentrated by ultracentrifugation before the virus pellet was 
resuspended in 200 µl PBS.  The resulting concentrated viral supernatant was spun on to 
cells (See section 2.5.4).  After approximately 18 hours, transduced LMH cells were placed 
under antibiotic selection pressure with Puromycin as determined in 3.5.1 and cells were 
allowed to proliferate.  After three passages under selection pressure, a portion of the cells 
were harvested for testing by chemiluminescence to detect the transgene (tagged Ago2 
protein).  Results from this were inconclusive.  Initial chemiluminescent blots showed faint 
banding at the correct predicted size for the tagged transgene (~100 kDa) as indicated by the 
red asterisks (Figure – 3.7A).   Upon successive passage of cells and re-testing of the cells 
for the transgene, no band could be detected at the correct size despite them still been under 
antibiotic selection pressure (Figure – 3.7B & C).  
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Concentration of virus 
by ultracentrifugation 
Figure – 3.6 The production of Lentivirus particles for delivery of an Ago 2 Transgene 
PLVX-tight-puro lenti vector (pLVX-puro) which contained HTP tagged human Ago2 (a gift from Dr 
F. Grey, The Roslin Institute) was transfected into HEK293FT cells (a gift from Dr. N Smith, The 
Roslin Institute).  Resulting Ago2 lentivirus was harvested and concentrated by ultracentrifugation 
(19500 rpm for 2 hours at 16 °C in a Beckman SW40 rotor).  Virus pellets were resuspended in an 
appropriate amount of PBS.  LMH cells were then transduced via spinning virus onto cells are per 
section 2.5.4.  After 24 hours, cells were put under selection pressure to obtain cells carrying the 
transgene.  































































































Figure – 3.7. Detection of tagged Ago2 protein in transduced LMH cells 
LMH cells were transduced with concentrated lentivirus particles carrying a tagged Ago2 
transgene.  After transduction, cells were placed under antibiotic selection pressure with 
Puromycin.  After 3 days, cells were tested for detection of the Ago2 protein by 
chemiluminescence.  A – Cells tested 3 days after antibiotic selection pressure.  B – Cells 
passaged and kept under selection pressure.  C – A second passage of cells still under selection 
pressure.  Red asterisks – Possible detection of expression of tagged Ago2.  
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3.6 – Assessment of other avian cells lines for susceptibility to ILTV 
Whilst LMHs are able to support virus replication and cytopathic effect can be observed 
(CPE), there was interest in looking at other avian cell lines as LMHs are difficult to work 
with (discussed in section 3.7).  Chicken cell lines were chosen as ILTV is predominatly a 
chicken virus however it does infect other species.  A more suitable chicken cell line was 
sought and the panel test below have previously been used for other virsues.  In total, four 
immortal chicken cell lines (LMH, DF1, HD11 and CLEC213 cells) and two primary 
chicken cell lines (chicken kidney cells and primordial chicken germ cells) were tested for 
their permissiveness to infection with ILTV, two immortalised quail cell lines (QT-35 and 
QM7 cells) were also used.  Initial infections were set up as described in 2.6.1 with an MOI 
of 0.1 and cells were harvested for DNA at 1, 6, 24, 48 & 72 hours post infection.  Samples 
were then used for real-time quantitative PCR with primers designed against ILTV genomic 
DNA as previously published (Mahmoudian et al., 2012).  To calculate the fold change, the 
expression of ILT gDNA was normalised to the cellular gene cyclophilin (CyP) using the 
2ΔΔCT protocol (Livak and Schmittgen, 2001b).  All samples were carried out in biological 
triplicate (n = 3).  One-way ANOVA was used to compare fold change over time.  Tukey’s 
comparison test was then used to determine if the means of each time point were 
significantly different from one and other.  Means that are significantly different from one 
and other have different letters.   
3.6.1 – Chicken cell lines 
LMH cells were found to have an increasing viral burden as time progressed with a peak fold 
change of ~6,400 compared to CyP at 72 hours post infection (HPI).  However this was not 
statistically significant from the input virus or at any other time point during the experiment 
(p =>0.05) (Figure – 3.8A).  Similar to published work, CPE was observed when infected 
cells were assessed using a light microscope.  
Primary chicken kidney cells displayed a slight dip in viral burden 6 HPI (fold change = 752) 
compared with the input virus (fold change = 1087) however this was not statistically 
significant (p =>0.05).  At 24 HPI viral burden peaked (fold change = 7987) before 
decreasing once again at 48 HPI (fold change = 3960).  There was no statistical significance 
between the final two time points (p =>0.05) though there was between 24 HPI and the 
earlier two time points (p =<0.01) (Figure – 3.8B).  CPE was seen when cells were assessed 
visually before harvesting.   
DF1 cells showed a decrease in viral burden over time with input virus at 1 HPI having the 
highest fold change of 191.39 compared with 13.84 at 48 HPI  Statistically, each time point 
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was significant from the other when using the Tukey’s comparison test (P =<0.05) (Figure – 
3.8C).  No CPE could be seen cells were visually checked prior to harvest at each time point.  
CLEC213 cells (A gift from Dr. Pascale Quéré, INRA, France) also showed a decrease in 
viral load over time.  No significant difference was found between 1 and 6 HPI (p =>0.05) 
but both time points were significantly different from the remaining three time points (p 
=<0.01) (Figure -3.7D).  No CPE could be seen when cells were assessed using a light 
microscope. 
The final chicken cell line, HD11 cells also showed a decrease in viral burden.  At 1 HPI the 
highest fold change was observed (fold change = 383.8) which was statistically significant 
from both 24 and 72 HPI which had fold changes of 101.9 and 117.5 respectively.  From 6 
HPI onwards however, there was no significant difference observed between the time points 
(p =>0.05) (Figure – 3.8E).  No CPE was seen when cells were observed using a light 
microscope prior to harvesting.    

















































































Figure – 3.8.  Relative ILTV genomic DNA (gDNA) levels in different Chicken cell lines 
Cells were seeded out as per their individual requirements in a 24 well plates.  They were left to 
adhere overnight before infection with ILTV at an MOI = 0.1.  Samples were then taken at 1, 6, 
24, 48 and 72 hours post infection (HPI).  DNA was extracted and subsequently used for qPCR to 
determine the relative viral load.  Data was analysed using the 2ΔΔCT method and normalised to 
Chicken CyP (chCyP).  Data displayed shows the relative fold change of gDNA compared to 
Chicken Cyp.  Error bars represent the standard error of the mean.  A – LMH Cells B – Primary 
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3.6.2 – Quail cell lines 
In addition to 5 chicken cell lines, 2 quail cell lines were also tested for their ability to 
support ILTV productive infection.  Infection studies were set as previously described in 
section 3.6.   
QT-35 cells showed a decrease in viral burden over time with the highest fold change seen at 
1 HPI (fold change = 218.1) which was significantly different from every other time point (p 
=<0.01).  At 6, 24 and 48 HPI there was no significant difference in fold change even though 
a decrease was observed (p =>0.05).  Similarly, there was no significant difference between 
24, 48 and 72 HPI (p =>0.05) but there was significance between 6 and 72 HPI (p =<0.05) 
(Figure – 3.9A).  No CPE was observed when cells were assessed prior to harvesting.   
The second quail cell line, QM7s also displayed a decrease in ILTV viral load over time.  
Statistical analysis revealed no significant difference between 1 and 6 HPI (p =>0.05).  
Likewise, there was no significant difference seen between 24, 48 and 72 HPI (p =>0.05).  
There was however a significant difference between the two Tukey’s test groupings (p 
=<0.01) (Figure - 3.9B).  Similar to QT-35’s, no CPE was seen when cells were assessed 
using a light microscope.          
  





Figure – 3.9.  Relative ILTV genomic DNA (gDNA) levels in two Quail cell lines 
Quail cell lines were seeded out as per their requirements.  After 24 hours incubation, cells were 
infected with ILTV at an MOI = 0.1.  Samples were then taken at 1, 6, 24, 48 and 72 hours post 
infection (HPI).  DNA was extracted and used for qPCR to assess viral burden in the cells.  Data was 
analysed using the 2ΔΔCT method against the endogenous gene Chicken CyP.  Figures display the 
average relative fold change of ILTV gDNA.  Error bars represent the standard error of the mean.   
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3.6.3 – Primordial Germ Cells (PGCs) viral burden 
Primordial germ cells (a gift from Dr. Mike McGrew, The Roslin Institute) were also 
assessed for their susceptibility to ILTV infection.  Experiments were set up as described in 
section 6.7 except virus was spun onto cells via centrifugation as described in section 2.6.1.  
Viral burden was seen to fluctuate with an initial decrease from 1 to 24 HPI which was 
statistically significant (p =<0.01).  There was no significant difference between 1 and 6 HPI 
as well as between 6 and 24 HPI (p =>0.05).  However, at 48 HPI an increase in viral load 
was observed compared to 24 HPI which was statistically significant (p =<0.01).  At the 
final time point (96 HPI), a modest increase in fold change was seen compared to 48 HPI 
(fold change = 2488.6 compared to fold change = 2067) but this was not significant (p 
=>0.05) (Figure – 3.10).  As PGCs are a suspension cell line, CPE observations were not 
apparent. 
  






















Figure – 3.10. Relative ILTV genomic DNA (gDNA) levels in chicken Primordial Germ 
Cells (PGCs) 
Primordial Germ Cells (PGCs) (A gift from Dr. Mike McGrew, The Roslin Institute), were counted 
and seeded into 24 well plates with appropriate media.  Cells were then spinoculated with ILTV 
virus at an MOI = 0.1 (details on spinoculation can be found in section 2.6.1 of this thesis).  Samples 
were then harvested at 1, 6, 24, 48, 72 and 96 hours post infection (HPI).  DNA was extracted and 
used for qPCR.  Relative gDNA levels of ILTV were calculated using the 2ΔΔCT method of 
analysis with Chicken CyP gene to compare against.  Figure displays the average relative fold 
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3.6.4 – Viral gene expression in primordial germ cells (PGCs) 
In addition to assessing the susceptibility of PGCs to ILTV, viral gene expression was also 
assessed.  Cells were infected as previously described (See Section 2.6.1) and at set time 
points, RNA was harvested.  Following RNA extraction and DNase treatment, cDNA was 
prepared and used in a conventional PCR (See sections 2.2.5 & 2.2.7 for protocols).  Bands 
detected in the cDNA ‘infected’ samples and not the mock cDNA or –RT samples were 
taken as positives.  Three classes of temporal gene expression were looked at.  Firstly, ICP4, 
representing an immediate-early gene was detected as early as 1 HPI and through until 96 
HPI but the bands were not as strong as earlier time points (Figure - 3.11A).  Protein Kinase 
(US3/PK), an early gene was also detected at every time point (Figure – 3.11B).  Finally, 
glycoprotein E (gE), a late gene was also found to be expressed in PGCs (Figure – 3.11C).   
 
  






Figure – 3.11.  Viral gene expression of ILTV in primordial germ cells (PGCs)  
PGCs (A gift from Dr. Mike McGrew, The Roslin Institute) were infected with ILTV at an MOI of  
0.1 as well as a parallel set of mock controls.  At set time points (1, 6, 24, 48, 72 & 96 HPI), cell 
lysate was harvested for RNA.  RNA was extracted using a RNeasy kit (Qiagen) and subsequently 
DNase treated.  RNA was used to synthesise cDNA with RNA primed using an Oligo DT primer.   
PCR reactions were carried out on the resulting cDNA.  Reactions included a gDNA loading control 
alongside –RT samples a NTC.  PCR products were then visualised on a 2.5 % agarose gel.  Bands 
detected in the infected samples and not in the mock controls or –RT samples were taken as positive 
results.  In total, three genes across the temporal gene expression cascade were tested for and they 
were; ICP4 (A), protein kinase (B) and glycoprotein E (C).    
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3.7 – Discussion  
The original aims of this part of the project were to use CLASH (as reviewed in Chapter one) 
to identify targets of miRNAs encoded by ILTV.  However, due to unforeseen 
circumstances, this project was shelved and reasons for this are outlined in this section.  
Work leading up to CLASH showed the expression of five viral genes that spanned the 
temporal cascade of gene expression across a range of time points.  As well as identifying 
viral genes, seven out of a possible ten virally-encoded miRNAs were identified.  Moreover, 
attempts were made to engineer a stably expressing cell line using a lentiviral delivery 
system.  Infection work in another 7 cell lines in addition to LMH cells was also carried out 
to identify a cell line that supported lytic infection that would be suitable for the CLASH 
experiment. 
CLASH is a technically difficult but extremely powerful biochemical approach to identifying 
miRNA-mRNA interactions in the cell.  It builds upon previous forms of identifying miRNA 
interactions within a cell such as cross-linking and immunoprecipitation (CLIP) and also 
cross-linking and analysis of cDNAs (CRAC) (Kudla et al., 2011).  The exploitation of the 
technique could have potentially yielded a large quantity of data from which downstream 
validation work could have been carried out.  Due to technical challenges in the optimisation 
of this experiment, it was however deemed to be not viable in the time frame allotted as well 
as the hurdles imposed by the lack of both reagents and suitable cells lines available.  The 
lack of a cell line that was both permissive to ILTV infection as well as expressing a tagged 
transgene was the main stumbling block in this project.  Whilst there was most likely 
detection of tagged Ago2 within transduced LMHs during early passages (Figure – 3.6), the 
banding at the predicted molecular weight was not detected in subsequent passages of the 
cells whilst still under selection marker pressure.  This suggested that the cells were 
expressing Puromycin resistance genes as they were actively dividing and multiplying 
however the likelihood is that the cells had switched off the expression of the tagged Ago2.  
Whilst not directly comparable due to the difference in species, the switching off of lentiviral 
delivered transgenes has been reported in murine embryonic carcinoma cell lines (He et al., 
2005).  Another approach was suggested, by way of using a commercially available Ago2 
antibody and carrying out immunoprecipitation against this under the experimental term 
HITS-CLASH.  This is a blend of CLASH and its predecessor HITS-CLIP.  This approach 
has been successfully used in the Grey lab (personal communication) however this does not 
guarantee success in chickens.  Firstly, the issue of a workable cell line still exists and then 
there is the issue of finding suitable antibodies that react in the chicken.  Given the time 
constraints of a PhD project it was deemed to be too much of a risk to try and get this project 
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off the ground and so therefore work was postponed until more reagents became available to 
make the project viable.    
In parallel with this work, the time course of expression of viral genes and viral miRNAs 
was investigated in LMH cells.  This was in the first instance to look at the most optimal 
time of when to harvest samples for CLASH.  In an ideal situation, one would want the 
maximum number of virally-encoded miRNAs to be expressed.  As well as this, detection of 
viral genes was necessary to ensure that the full temporal cascade of gene expression was 
occurring in the LMH cell line.  In total, five viral genes were detected spanning the full 
temporal genome (Figure – 3.2).  From this data, it was decided that 24 HPI would be the 
optimal time for harvesting samples as viral genes from all classes of expression kinetics 
were detected.   
Coupled with this was the investigation of the expression of miRNAs.  In total seven of the 
described ten miRNAs were detected in this project (Figure – 3.4).  MicroRNAs are highly 
tissue specific and so the remaining three miRNAs not detected may only be expressed in 
certain tissues or their expression may be tightly regulated (Guo et al., 2014).  Moreover, 
similar issues of detection have been seen with the previous studies looking at ILTV-
encoded miRNAs.  The initial publication showing ILTV encoded for miRNAs found a total 
of eight miRNAs and in a second study by an independent lab group, a further two were 
identified.  However, in the latter study, some of the miRNAs identified in the first study 
could not be detected (Rachamadugu et al., 2009, Waidner et al., 2009).  Furthermore, one 
miRNA, ILTV-miR-I7 only had 3 reads detected from a total of ~9100 unique small RNA 
reads.  This was one of the miRNAs not detected in this study and it is possible that it was 
not detected due to sensitivity issues caused by the low number of copies of this particular 
miRNA.  Similar to the detection of viral genes, the conclusions from the detection of viral-
miRNAs was to use a time point of 24 HPI where six of the ten miRNAs were detected.  As 
mentioned above, using CLASH may have identified more of the miRNAs as it uses 
sequencing whereas the methods used for this experiment were not as sensitive.   
As it became increasingly clear that the LMH cell line, whilst permissive to ILTV, was not 
the most suitable cell line for in vitro studies, a number of other avian cell lines of differing 
origins were investigated to see if they were permissive to ILTV infection.  One may 
question why only lytic replication was considered for the experiement considering the 
majority of herpesvirus miRNAs are expressed during latency (Grey, 2015).  The ideal 
scenario would be to carry out CLASH in a latent model of infection however this is very 
difficult to achieve even for the most studied of herpesviruses such as HSV-1.  Latency is a 
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very complex process and difficult to compact into a 2D culture model system without the 
use of pharmacueticals and/or replication defective viruses to help achieve a ‘latent’ state 
(Thellman and Triezenberg, 2017).  Whilst not ideal, lytic infection has been used previously 
for CLASH and data generated has proved significant in previous studies.  Other cells lines 
that were chosen to be tested were picked as they have been shown to permissive to infection 
with other viruses, including other herpesviruses such as MDV-1.  The cell lines that were 
tested were primary chicken kidney cells (CKCs), CLEC213 cells, DF-1 cells, HD-11 cells 
and primordial germ cells.  The former of these were very much permissive to ILTV 
infection and in agreement with numerous previous studies (Chang et al., 1960, Meulemans 
and Halen, 1978, Hughes and Jones, 1988).  Primary CKCs were not chosen for the 
experimental work however due to several reasons.  Firstly, fresh cells have to be made from 
kidneys each time an experiment needs to be carried out and so this becomes problematic in 
large scale experiments.  Secondly, primary cells cannot be passaged indefinitely unlike an 
immortalised cell line and as the introduction of a tagged transgene via lentiviral delivery 
followed by extended passage as required for CLASH such cells would not be useful.  
Finally, one may question the moral implication of sacrificing birds purely for their kidneys, 
something that does not help the 3 R’s of animal experimentation.  Similarly, chicken 
embryo fibroblasts (CEFs) were not used as whilst they are permissive to infection, they 
cannot be passaged indefinitely and so introducing a tagged transgene would face the same 
hurdles as primary CKCs.   
CLEC213 cells (A gift from Dr. Pascale Quéré, INRA, France) are a spontaneously 
immortalised cell line derived from chicken lung epithelial cells and are somewhat 
biologically relevant to ILTV pathogenesis and its invasion of the respiratory tract.  Previous 
work using CLEC213 cells had shown they were permissive to Avian Influenza virus 
infection (Esnault et al., 2011).  In stark contrast though, the cells were not permissive to 
ILTV infection with the Illinois strain and so no follow up work was carried out regarding 
these cells.  A different result may have been observed using the CSW-1 strain which is 
more virulent however by the time this strain was available, this work had been halted.  A 
cell line of this nature that is permissive to infection would be a useful tool however as it 
would be more biologically relevant than the permissive cell lines currently available.    
DF-1 cells are derived from CEFs through infection with avian leucosis virus (ALV) (Himly 
et al., 1998).  But when tested, viral load was found to decrease over time suggesting they 
were not permissive.  Whilst studies were not carried out to find out the source of the 
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replication defect, it maybe of future interest as it may identify candidate genes involved in 
ILTV replication when compared to CEFs. 
HD-11 cells are a macrophage like cell line derived by the transformation of haematopoietic 
cells by ALV (Beug et al., 1979).  Macrophages have previously reported to be permissive to 
infection and support viral replication and therefore HD-11s were looked at as a possible 
alternative (Von Buelow and Klasen, 1983, Loudovaris et al., 1991a).  The results were not 
as observed in the literature however with a decrease in viral load seen over the time course 
of the experiment (Figure – 3.7E).  Whilst there was an increase in viral burden at 48 HPI, 
the general trend was still a decrease.  There is room for some investigation in to this area of 
research however as the original experiments suggesting that macrophages were susceptible 
to ILTV infection were carried out some 25+ years ago.  This was based upon the MHC 
class of the animals with some been resistant to infection whilst others were susceptible 
(Loudovaris et al., 1991a).  It could be quite simply that the birds HD-11 cells were derived 
from were of a line of birds known to be resistant to ILTV infection.            
In addition to investigating chicken cell lines, two quail cell lines were also look at for their 
permissiveness to ILTV infection.  Firstly, QT-35s were investigated.  The results showed a 
decrease in viral load over time (Figure – 3.9A).  This is in contrast to the literature that 
suggests that they are permissive to infection with ILT however this previous experiment 
involved serial passage of infected cells with uninfected monolayers (Schnitzlein and 
Tripathy, 1995).  Serial passage of viruses is known to cause point mutations within the virus 
and thus may have interfered with any downstream experiments (Hildebrandt et al., 2014).  
This would therefore not be useful in the long term as any data generated would not be truly 
representative of the wild type virus.  In addition to QT-35 cells been investigated, QM-7 
cells, another quail cell line, were used.  The cell line supports replication of both MDV-1 
and HVT but no information was available regarding ILTV (Rong et al., 2014).  Upon 
analysis, it was found that QM-7 cells do not support ILTV replication with a decrease in 
viral load over time (Figure – 3.9B).  Whilst the investigation as to whether quail cell lines 
are permissive to infection, quail are not known to be affected by the disease and so it may 
not be a representative model for infection.  Furthermore, if any in vivo experiments are 
carried out, the main host of the virus, the chicken can be used, as it is a well-defined model 
in biomedical science.  
The final cell line to be investigated was primordial germ cells (PGCs).  Isolated from early 
chicken embryos, they are the progenitors to the germ cells found within adult birds.  It was 
conveyed that they support replication of influenza virus however any data surrounding this 
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is yet to be published (Personal communication, Dr. Nikki Smith, The Roslin Institute).  
Data presented in this study suggests that PGCs are supportive of ILTV replication with a 
modest increase in viral burden at latter time points in the experiment.  Furthermore, due to 
the nature of the cells and the potential they have for differentiation, investigations into viral 
gene expression were carried out similar to LMH cells.  Three genes were analysed spanning 
the temporal cascade of gene expression and they were ICP4, PK and gE.  All three gene 
transcripts could be detected using cDNA at all time points in the experiment (Figure – 
3.11A, B & C).  Even with these findings, it was decided not to use the cell lines for further 
downstream experiments as they are a suspension cell line and so some common 
experiments such as conventional plaque assays would become problematic.  More recently 
however, the development of an adherent PGC cell line may open up the possibility of using 
this cell line in future (Personal communication, Dr. Mike McGrew, The Roslin Institute). 
There is also the possibility of differentiating these cells into a specific cell line lineage.  By 
doing this, one can produce a number of cell lines of differing linages.  This may include 
epithelial cells to mimic the upper respiratory tract of the bird to model a site of lytic 
replication however on the other hand one could produce a neuronal cell line capable of 
mimicking a latent infection.  Whilst both would be advantageous to studies investigating the 
virus biology, the latter maybe of more use when looking at the role of miRNAs considering 
the majority of herpesviral miRNAs are involved with latency in some capacity (Grey, 
2015). 
To conclude, efforts were made to try and use CLASH to identify miRNA targets during 
ILTV infection however experiments necessary for the success of this biochemical approach 
suggested that it was not possible due to a number of reasons; primarily the lack of a 
workable cell line that allows for the expression of a stable transgene.  Whilst other 
approaches such as a combination of CLASH and HITs-CLIP could be used (HITS-
CLASH), this was deemed to be unsuitable as there was still no guarantee that this approach 
would work and yield meaningful results.  On the other however, several other 
advancements were identified such as the potential use of PGCs for use in studies, especially 
considering they have the potential to be differentiated into a number of cell linages.  Whilst 
no conclusive proof of replication can be shown in this study, the detection of all temporal 
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4.1 – Introduction 
A number of different cellular pathways can have a profound effect upon the viral lifecycle.  
Included in these is the RNA interference (RNAi) pathway, which can be manipulated by the 
invading pathogen to help facilitate completion of the viral lifecycle.  MicroRNAs have been 
known to be encoded by viruses for over a decade now and since their first identification, 
novel as well as homologous, miRNAs have been identified in a large range of differing 
virus families (Grey, 2015).  Their discovery has opened up a new field under the broader 
umbrella of virus-host interactions.  
Virus encoded miRNAs have the ability to silence gene expression in a similar fashion to 
endogenous miRNAs using the same host cell machinery (outlined in Section – 1.6.1).  This 
allows them to target both viral and cellular transcripts thus manipulating the host 
environment to their own advantage.  To date, a large proportion of the identified viral 
miRNAs are encoded for by herpesviruses with adenoviruses, polyomaviruses and 
retroviruses also having been shown to encode for them (Grey, 2015).  As they are non-
immunogenic and can have multiple targets, they are particularly useful for viruses to 
manipulate the host cell environment (Goodrum et al., 2012).  Furthermore, they take up 
very little space in viral genomes which are already compact.   
Herpes simplex virus 1 (HSV-1) encodes for 27 mature viral miRNAs, with a number of 
these miRNAs implicated in maintaining and promoting latency.  Four miRNAs have been 
shown to target viral transcripts that are necessary for reactivation of HSV-1 from latency 
(Bernier and Sagan, 2018). HSV1-miR-H6 has been shown to target the major immediate-
early protein ICP4 whilst HSV1-miR-H2-3p is able to reduce the expression of ICP0, 
another immediate-early protein (Duan et al., 2012, Umbach et al., 2008a).  The final two 
miRNAs, HSV-miR-H3 and HSV-miR-H4 respectively are encoded antisense to the 
neurovirulence factor ICP34.5 with experimental data in HSV-2 showing that these miRNAs 
are able to downregulate the expression of this protein (Tang et al., 2008).   
Similar occurrences of virally-encoded miRNAs regulating viral transcripts are present 
across the herpesvirus subfamilies. Viral miRNAs of KSHV are expressed during latent 
infection and are positioned alongside latency associated genes in the viral genome.  Of these 
expressed viral miRNAs, KSHV-miR-K12-7 and KSHV-miR-K12-9 both directly target 
RTA (ORF50), a protein essential for the induction of lytic replication (Qin et al., 2017).  In 
addition to directly targeting RTA, KSHV encoded miRNAs can also indirectly cause a 
reduction in the expression of RTA.  Targeting of Nuclear Factor I/B (NFIB) by KSHV-
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miR-K12-3 also causes a reduction in RTA expression as the former can activate the RTA 
promoter (Lu et al., 2010).  
Taken together, the majority of herpesvirus encoded miRNAs so far investigated play 
integral roles in the maintenance of latency and whilst targets of herpesvirus encoded 
miRNAs are still being elucidated, it is clear from the targets already validated that these 
viral miRNAs can and do play a major role in manipulating both the host and virus gene 
expression profile to ensure persistence.  This is perhaps reflective of the long evolutionary 
history between herpesviruses and their natural hosts.   
As more viral miRNAs are identified and characterised using new, more sensitive, laboratory 
techniques complimented by the ever-decreasing cost of next-generation sequencing and 
bioinformatical approaches, the diverse mechanisms and interactions between virally-
encoded miRNAs and their targets will only improve.  These continuing advancements will 
no doubt aid in the understanding of virus-host interactions at the small RNA level.          
4.2 – Aims 
The aims for this part of the project were to employ bio-informatics to predict viral targets of 
virus-encoded miRNAs.  To carry this out, viral gene transcripts needed to be mined from 
the genome and coupled with the miRNA sequences.  Following target predictions, top hits 
were to be investigated in a reporter based screen.  Any targets showing knockdown were 
then investigated further.    
4.3 – RNA Hybrid 
4.3.1 – Creation of Viral transcripts for Bioinformatic Use 
Every predicted viral transcript was screened for potential viral miRNA target sites.  To 
create this list, a set of parameters was laid out.  As the ILTV genome is not extensively 
annotated, an arbitrary 1000 bp upstream of the ATG start codon was included to ensure full 
coverage of the 5’UTR region of transcripts.  Likewise, a minimum of 50 bp downstream of 
the designated polyA site was used to ensure full coverage of the predicted mRNA transcript.  
For genes encoded in a right to left orientation, the sequences were then reverse 
complemented to put all genes in a left to right orientation.  In total, 79 ORFs were included 
in the data covering every predicted gene of ILTV.  All sequences used in the predictions 
were taken from the ILTV genome (NCBI reference sequence: NC_006623.1).   
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4.3.2 – ILTV miRNA sequences 
Sequences for the 10 mature miRNAs were taken from MiRBase (release 21, 
[http://www.mirbase.org/]).  These were then appropriately named and added to a separate 
file and this was then used in conjunction with the viral transcripts files created in 4.3.1. 
4.3.3 – RNA Hybrid Parameters  
RNA Hybrid was used for target prediction (https://bibiserv2.cebitec.uni-
bielefeld.de/rnahybrid) (Rehmsmeier et al., 2004).  To ensure consistency throughout the 
prediction process, a general set of rules were employed.  Firstly, to ensure the seed 
sequence was the core binding site, helix constraints were set from nt 2 to nt 8.  No 
minimum free energy (MFE) threshold was used and no G:U base pairing was allowed for 
the seed sequence.  Finally, the number of hits per target was set to 10 and no approximate p-
values were calculated.  These parameters were used for the entirety of the following project 
laid out in this chapter. 
4.3.3 – Filtering of RNA Hybrid predictions  
Once the initial screen was carried out, results were then filtered and sorted.  In the first 
instance, targets were sorted on two main criteria, 1) the MFE had to be greater than or equal 
to -15 kcal/mol and 2), results were filtered to only include viral genes that were designated 
to be an immediate-early or early gene class in reference to the temporal regulation of gene 
expression (reviewed in section 1.3.2).  The former was chosen as a cut off as the Dalziel lab 
group has previously identified and validated targets with this MFE (Riaz, 2014 ).  With 
respect to the second criterium, this was done as any effects upon IE or E genes would have 
more of an effect upon the virus and they were also likely to have more interactions with the 
host.  This left a total of 227 predictions in the data set.  Further filtering on this dataset look 
at the prescribed functions of the genes by reviewing the literature on homologues, primarily 
in HSV-1, but also in other Alphaherpesviruses.  When these filters were applied a total of 
28 candidates were taken forward for experimental testing with one previously validated 
target site within ICP4 (miR-I6-5p) also taken forward to act as a control for the initial phase 
of laboratory experiments (Waidner et al., 2011).  Table 4.1 details the targets taken forward 
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miRNA Target Site Region? MFE (Kcal/mol) Gene Function? 
ICP4 1 I6-5p 4521 CDS -50.6 Absolutely required for viral growth and initiation of lytic replication 
UL54 1 I6-3p 1543 CDS -33.7 ICP27 – several roles in virus life cycle and highly conserved 
UL48 1 I5-3p 3376 3’UTR -18.4 VP16 – forms a complex with Oct1 & HCF to transcriptionally activate 
IE-genes 2 I6-5p 3716 3’UTR -21.5 
UL46 1 I5-3p 2126 CDS -18.4 VP11/12 – Interacts with UL48 and modulates its activity 
2 I6-5p 2466 CDS -21.5 
UL30 1 I6-5p 645 5’UTR -25.8 Encodes for DNA polymerase and is responsible for viral DNA 
replication 2 I5-3p 2162 CDS -25.2 
3 I3 3747 CDS -29.7 
UL28 1 I5-5p 5696 3’UTR -29.3 ICP18.5 – Responsible for processing and packaging of viral DNA 
2 I5-5p 2389 CDS -30.5 
3 I2 57 5’UTR -30.3 
UL24 1 I6-5p 2162 3’UTR -27.7 Conserved across the herpesviridae family but function is not fully 
established 2 I1-5p 3665 3’UTR -22.9 
UL9 1 I6-3p 972 5’UTR -24.0 
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2 I6-3p 1068 CDS -26.3 Facilitates the docking of viral replication machinery to viral DNA 
origins 
UL2 1 I2 1423 CDS -24.5 Uracil DNA Glycosylase which is responsible for removing of uracil 
effectively proof-reading synthesised genomes 2 I6-5p 747 5’UTR -23.9 
3 I2 164 5’UTR -31.7 
UL-1 1 I3 2539 CDS -30.1 I/E protein with unknown function but it is absolutely required in vitro 
2 I5-5p 2290 CDS -33.9 
3 I6-5p 2284 CDS -29.6 
UL47 
(sORF1) 
1 I5-5p 74 5’UTR -20.4 VP13/14 – an I/E protein which interacts with VP16 and VHS 
US3 1 I2 773 5’UTR -28.5 Conserved amongst Alphaherpesviruses.  Multifunction protein kinase 
involved with optimal virus replication 2 I4 1108 CDS -29.5 
3 I6-5p 1489 CDS -27.5 
ORF F 1 I6-5p 601 5’UTR -30.3 Unknown protein/function but contains 6xCTD domains which are 
normally found in RNA polymerase II.  Possible polymerase activity 2 I6-3p 677 5’UTR -33.0 
3 I6-3p 2458 CDS -33.3 
Target site refers to the first nucleotide position where the miRNA binds to the mRNA.   
Region refers to where in the mRNA transcript the miRNA binds.  5’UTR = 5’End, CDS = Protein coding region and 3’UTR = 3’ End   
Gene function is taken from existing data in the literature or inferred from HSV-1 homologues 
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4.4 – Screening of RNA Hybrid Predictions by Luciferase Assay 
The 29 targets taken forward for testing were all cloned into the dual luciferase reporter 
plasmid Psi-Check 2 (Appendix 1).  To clone the targets, sense and antisense long 
oligonucleotides ~110 bp were designed spanning the target site region.  These were 
annealed and cloned into the vector using restriction endonucleases.  To confirm positive 
clones, colony PCR was used with primers spanning the multiple cloning site.  From this, 
positive clones were picked, amplified and sent for sequencing to ensure the target sites were 
intact with no mutations.  
To test the constructs in vitro, Psi-Check 2 plasmids with and without the cloned target site 
were transfected into HEK293T cells alongside a mature miRNA mimic or a scrambled 
siRNA control.  Samples were harvested after 48 hours incubation and used for luciferase 
assays as described in 2.6.3.   
4.4.1 – Testing the system using a known target 
To ensure the system was working, a validated target of ILTV-miR-I6-5p in ICP4, (termed 
ICP4 T1 in this project (Table 4.1)) (Waidner et al., 2011) was tested first.  RNA Hybrid 
predictions carried out as part of this study showed perfect Watson-crick binding between 
the miRNA and target along the full length of the miRNA that was reflected in the MFE 
result of -50.6 kcal/mol (Figure – 4.1A).  When the luciferase vector containing ICP4 T1 was 
co-transfected with a miR-16-5p mimic a 35 % reduction in luciferase expression was 
observed (Figure - 4.1B).  Upon statistical analysis, this was found to be significant from the 
scrambled siRNA (p =<0.001) with n = 8 biological replicates (n = 24 technical repeats).  
To confirm this reduction was due to the action of the miRNA, the seed sequence was 
mutated.  This was carried out by redesigning the long oligonucleotides with changes to the 
seed sequence only and repeating the cloning process followed by sequencing of the cloned 
product.  When the mutated target site was tested (termed Mut-ICP4 T1), the effects of 
ILTV-miR-I6-5p were abrogated with a reduction of luciferase expression of only 10 % 
(Figure – 4.1B).  This was not significantly different from the scrambled siRNA control but 
was statistically different from the wild type (p =<0.001).   
 
  




Figure – 4.1. Relative luciferase expression levels of ICP4-T1 and Mut-ICP4-T1 sequences in Psi-
check 2 with ILTV-miR-I6-5p compared to a scrambled siRNA control 
RNA Hybrid was used to predict viral targets of virally encoded miRNAs (A).  HEK293T cells 
were transfected with a Psi-Check 2 reporter plasmid harbouring a 110 bp sequence containing an 
ILTV-miR-I6-5p sequence or a mutated sequence.  Wild type and mutated seed sequence of the mRNA 
in bold and underlined (B).  ILTV-miR-I6-5p or a scrambled siRNA were also transfected into cells.  
After 48 hours incubation, Renilla luciferase levels were measured and normalised to firefly luciferase 
levels with expression levels compared between control and test miRNA conditions (C). N = 8 
biological replicates with n = 24 technical repeats.  Error bars display Standard error of the mean 
(SEM)  





mfe: -50.6 kcal/mol 
Position:  4521 
Target 5' A                      A 3' 
           CGACGAUGAGGGUACAGGAGAC     
           GCUGCUACUCCCAUGUCCUCUG     
MiRNA  3'                          5' 
A 
B 
Wild Type - CGACGATGAGGGTACAGGAGACA  
Mutant    - CGACGATGAGGGTCCCAACAACA 
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4.5 – Testing of targets using a Luciferase based system 
4.5.1 – Screening of predicted targets  
In total, 28 novel miRNA targets were tested in this screen.  A summary of the results can be 
found below in Table 4.2.  From the constructs tested (excluding the positive control ICP4 
target), three targets showed decreases in luciferase expression however upon statistical 
analysis, only two of these were found to be statistically significant.  Experiments listed 
below were carried out in duplicate with n = 4 biological replicates and n = 12 technical 
replicates per experiment totalling n = 8 biological and n = 24 technical repeats.   
4.5.2 – Targeting of UL46 & UL48 by ILTV-miR-I6-5p 
Using RNA Hybrid, a target for ILTV-miR-I6-5p contained within the 3’UTR of UL48 by 
was identified (Detailed in Figure - 4.2A).  The target site is approximately 1520 nt 
downstream of the stop codon for UL48 and around 200 nt upstream of the predicted PolyA 
site.  Due to its location in the genome, this same target was also found within the coding 
region of UL46 by RNA Hybrid (diagrammatic representation shown in Figure – 4.6A).  
Within UL46, the predicted site lies around 150 nt upstream of the stop codon of UL46 and 
200 nt upstream of the same PolyA site (Figure - 4.2B).  The target sequence for ILTV-miR-
I6-5p was cloned into Psi-Check 2 and tested using a mature miRNA mimic.  Upon analysis, 
luciferase expression was reduced by 20 % compared to the scrambled siRNA (p =<0.001) 
(Figure - 4.2C).  Mutation of the seed sequence abrogated this effect with no significant 
difference between the mutant construct and empty construct plus mimic.  There was a 
statistically significant difference between the wild type sequence and the mutant sequence 
(p =<0.001).  Further validation work was carried out and detailed in section 4.7. 
4.5.3 – Targeting of UL29 by ILTV-miR-I2 
RNA Hybrid analysis predicted a potential target site for ILTV-miR-I2 in the 5’UTR of 
UL28 (Target 1, Table 4.2) however this was around 940 nt upstream of the ATG start site.  
This same site was also situated in the coding region of UL29 with the same mean free 
energy of -30.3 kcal/mol (Figures 4.3A&B).  When cloned and tested in the reporter 
construct, a reduction of 15 % was observed when compared to the scramble siRNA control 
(Figure – 4.3C).  Upon statistical analysis, this was found to be significantly different (p 
=0.004).  Upon mutation of the seed sequence, the effects of the miRNA mimic were 
abrogated and this was statistically different from the wild type sequence (p =<0.001).  In 
addition to this, there was no significant difference found between the mutant sequence and 
empty vector control plus mature miRNA mimic (Figure – 4.3C).  Further validation work is 
laid out in section 4.6.         
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4.5.4 – Targeting of UL24 by ILTV-miR-I6-5p 
UL24 was predicted to be targeted by ILTV-miR-I6-5p in the 3’UTR approximately 300 nt 
downstream of the stop codon.  The predicted PolyA site is around 1500 nt further 
downstream.  RNA Hybrid gave a mean free energy prediction of -27.7 kcal/mol (Figure – 
4.4A).  The target site was cloned as previously described into Psi-Check 2 and tested using 
a mature miRNA mimic in conjunction with a siRNA scramble control.  Upon analysis, 
luciferase expression was reduced by 5 % when compared to the siRNA scramble.  
Statistical analysis revealed that this interaction was not significant (Figure – 4.4B).  For this 
reason, no mutant construct was tested and this target was not taken further.  
  
























Error of the 
Mean  
(%) 
ICP4 1 I6-5p -50.6 Yes Yes 65.22 % 4.63 % 
UL54 1 I6-3p -33.7 No No 109.64 % 2.31 % 
UL48 1 I5-3p -18.4 No No 136.33 % 1.87 % 
2 I6-5p -21.5 Yes Yes 79.78 % 4.01 % 
UL46 1 I5-3p -18.4 No No 136.33 % 1.87 % 
2 I6-5p -21.5 Yes Yes 79.78 % 4.01 % 
UL30 1 I6-5p -25.8 No No 107.34 % 1.78 % 
2 I5-3p -25.2 No No 105.87 % 2.32 % 
3 I3 -29.7 No No 99.64 % 2.46 % 
UL28* 1 I5-5p -29.3 No No 109.38 % 3.62 % 
2 I5-5p -30.5 No No 108.57 % 5.30 % 
3* I2 -30.3 Yes Yes 85.87 % 11.96 % 
UL24 1 I6-5p -27.7 Yes No 94.64 % 1.48 % 
2 I1-5p -22.9 No No 102.18 % 3.34 % 
UL9 1 I6-3p -24.0 No No 124.34 % 2.74 % 
2 I6-3p -26.3 No No 106.34 % 2.33 % 
UL2 1 I2 -24.5 No No 134.32 % 2.72 % 
2 I6-5p -23.9 No No 111.39 % 0.56 % 
3 I2 -31.7 No No 138.04 % 1.79 % 
UL-1 1 I3 -30.1 No No 127.46 % 2.73 % 
2 I5-5p -33.9 No No 113.13 % 1.30 % 
3 I6-5p -29.6 No No 117.84 % 1.64 % 
UL47 
(sORF1) 
1 I5-5p -20.4 No No 119.64 % 1.64 % 
US3 1 I2 -28.5 No No 142.44 % 1.40 % 
2 I4 -29.5 No No 113.96 % 2.23 % 
3 I6-5p -27.5 No No 125.12 % 3.64 % 
ORF F 1 I6-5p -30.3 No No 112.34 % 1.84 % 
2 I6-3p -33.0 No No 117.93 % 2.21 % 
3 I6-3p -33.3 No No 105.24 % 2.37 % 
* = Refers to UL29 once subsequent investigations were carried out regarding the location of the 
target site.  







mfe: -21.5 kcal/mol 
Position 3716 
Target 5'             A         G 3' 
                       ACAGGAGAC     
                       UGUCCUCUG     






mfe: -21.5 kcal/mol 
Position 2466 
Target 5'             A         G 3' 
                       ACAGGAGAC     
                       UGUCCUCUG     
MiRNA  3' GCUGCUACUCCCA           5' 
B 
C 
Figure – 4.2.  Predicted targets of ILTV-miR-I6-5p and relative luciferase expression levels 
of UL48/46-T2 and Mut-UL48/46-T2 sequences in Psi-check 2 with ILTV-miR-I6-5p 
compared to a scrambled siRNA control 
RNA Hybrid was used to predict viral targets of virally encoded miRNAs (A&B).  HEK293T 
cells were transfected with a dual-luciferase reporter plasmid containing either a wild-type or a 
mutated sequence containing a predicted miRNA target.  A mature miRNA mimic or a scrambled 
siRNA control were co-transfected with the reporter plasmid and after 48 hours incubation, cells 
were harvested.  Renilla luciferase levels were measured and normalised to firefly luciferase 
levels with expression then compared between control and test miRNA conditions (C). Error bars 
display Standard error of the mean (SEM) 
P-values - * = <0.05, ** = <0.01, *** = <0.001, ns = Not significant  





MiRNA : ILTV-miR-I2 
Length: 24 
mfe: -30.3 kcal/mol 
Position  3134 
Target 5' C         AGAU         A 3' 
           CGGC CCUA     CAGCCUUU     
           GCCG GGAU     GUCGGAAG     
MiRNA  3' A    A    AGCGU        G 5' 
B 
Target: UL28 
MiRNA : ILTV-miR-I2 
Length: 24 
mfe: -30.3 kcal/mol 
Position  57 
Target 5' C         AGAU         A 3' 
           CGGC CCUA     CAGCCUUU     
           GCCG GGAU     GUCGGAAG     
MiRNA  3' A    A    AGCGU        G 5' 
A 
C 
Figure – 4.3. Relative luciferase expression levels of Psi-check 2 plasmid containing either a wild 
type UL29-T1 sequence or mutant UL29-T1 co-transfected with ILTV-miR-I2 compared to a 
scrambled siRNA control 
RNA Hybrid was used to predict viral targets of virally encoded miRNAs and ILTV-miR-I2 was 
predicted to target the same sequence in both UL28 and UL29 (A&B).  HEK293T cells were 
transfected with a Psi-Check 2 reporter plasmid harbouring a 110 bp sequence predicted to be target by 
the viral miRNA ILTV-miR-I2.  ILTV-miR-I2 or a scrambled siRNA were also transfected into cells.  
After 48 hours incubation, Renilla luciferase levels were measured and normalised to firefly luciferase 
levels with expression levels compared between control and test miRNA conditions (C). Error bars 
display Standard error of the mean (SEM) 
P-values - * = <0.05, ** = <0.01, *** = <0.001, ns = Not significant 







MiRNA : ILTV-miR-I6-5p 
Length: 22 
mfe: -27.7 kcal/mol 
Position  2162 
Target 5' G      UUAGCCCAGC   CC          A 3' 
           GAUGAU          GGG  GUGCAGGAGA     
           CUGCUA          CUC  CAUGUCCUCU     
MiRNA  3' G                   C           G 5' 
A 
Figure – 4.4. Relative luciferase expression levels of Psi-check 2 plasmid containing UL24-T1 
sequence co-transfected with ILTV-miR-I6-5p compared to a scrambled siRNA control 
RNA Hybrid was used to predict viral targets of virally encoded miRNAs (A).  HEK293T cells 
were transfected with a Psi-Check 2 reporter plasmid harbouring a 110 bp sequence predicted to be 
target by the viral miRNA ILTV-miR-I6-5p.  ILTV-miR-I6-5p or a scrambled siRNA were also 
transfected into cells.  After 48 hours incubation, Renilla luciferase levels were measured and 
normalised to firefly luciferase levels with expression levels compared between control and test 
miRNA conditions (B).  Error bars display Standard error of the mean (SEM) 
P-values - * = <0.05, ** = <0.01, *** = <0.001, ns = Not significant 
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4.6 – Investigating UL29 as a target of ILTV-miR-I2  
4.6.1 – Introduction 
UL29, sometimes referred to as ICP8, encodes for an early gene product (Mahmoudian et al., 
2012).  The protein produced is commonly referred to as the major DNA-binding protein and 
plays several key roles during virus infection to such an extent that a homologue is encoded 
for by all known herpesviruses (Weller and Coen, 2012).  It is believed to play central roles 
in viral DNA synthesis, control of viral gene expression and the formation of both pre-
replicative and replication compartments (Weller and Coen, 2012).   
More recent work has shown the importance of UL29 in the formation of filaments that are 
essential for the assembly of replication compartments.  These filaments are proposed to 
form a scaffold to which other proteins are recruited to aide in the replication of viral DNA 
(Darwish et al., 2016).  Taken together, these interactions suggest a key role for UL29 
(ICP8) in the herpesvirus replication cycle making it a prime target for suppression by both 
the virus and cellular response pathways.      
4.6.2 – Cloning of a 6xHis-UL29 construct 
Attempts to validate the findings of the luciferase based reporter screen were carried out 
using a plasmid expressing UL29 tagged with 6xHis to allow for detection using 
conventional antibodies.  To carry this out, primers were designed to amplify the full coding 
region of UL29 and included a 6xHis tag on the sense primer (forward) downstream of the 
ATG start site to ensure the tag was incorporated into the expressed protein.   
PCR was used to amplify up the DNA region of interest and PCR products visualised on an 
agarose gel.  Bands of the approximate molecular weight were excised, DNA was extracted, 
cloned into the TOPO4 vector and E. coli transformed as outlined in 2.3.4.  Colonies were 
picked and amplified in liquid LB broth overnight.  DNA was extracted and sent for 
sequencing to confirm the success of the PCR (Data Not Shown).  Restriction endonuclease 
digestion was then used to insert the PCR product into the expression plasmid PcDNA3.1+.  
Using Kpn1 and Not1, the verified UL29 fragment was excised from TOPO4 and inserted 
into pcDNA3.1+ digested with the same restriction endonucleases.  Following ligation and 
transformation, small cultures were prepared and DNA prepped for a diagnostic digest.   
Digestion with Kpn1 and Not1 confirmed the presence of 6xHis-UL29 in pcDNA3.1+ using 
the sequenced TOPO 4 plasmid as a control (Data Not Shown).     
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4.6.3 – Mutagenesis of UL29-6xHis using mutagenesis PCR 
Once UL29-6xHis was cloned, this construct was used to make a mutant plasmid whereby 
the miRNA target seed sequence was mutated.  This was done using mutagenesis primers 
designed using the Agilent QuikChange Primer Design 
(https://www.genomics.agilent.com/primerDesignProgram.jsp).  These primers were then 
used for mutagenesis PCR as per laid out in Section 2.2.9 of this thesis (Data Not Shown).  
The plasmid made through mutagenesis PCR was named mut-UL29-6xHis. 
4.6.4 – Validation attempts by Western Blot of ILTV-miR-I2 knockdown of UL29-
6xHis   
Using both the wild-type and mutant UL29 plasmid, validation of the miRNA interaction 
was carried out.   HEK293T cells were seeded at an appropriate density in 12-well plates and 
transfected with either the wild-type or mutant UL29-6xHis construct on its own, with the 
mature miRNA mimic or a siRNA scramble control.  Cells were left for 48 hours and then 
harvested for protein quantification using Laemmli buffer.  20 µl of sample were loaded per 
lane in a SDS—PAGE gel (Bio-Rad Industries) and gels were run for 100 minutes at 80 v.  
Following transfer of the proteins onto nitrocellulose membrane (Bio-Rad) using the 
TransBlot Turbo system (Bio-Rad) the membrane was probed with antibodies against 6His 
and Alpha-tubulin at appropriate dilutions laid out in Table 2.1 of section 2.4.6.  Appropriate 
secondary Li-Cor antibodies were then used (also laid out in Table 2.1 of section 2.4.6) and 
membranes were imaged using the Li-Cor system. 
Alpha tubulin bands were detected at approximately 50 kDa and are shown in green on 
Figure – 4.6.  No banding for 6His (UL29) could be detected at the estimated molecular 
weight of 110 kDa (marked with white asterisks on Figure – 4.6).  Multiple biological 
repeats (n=3) failed to detect either the wild-type or mutant UL29-6xHis proteins on an 
immunoblot whilst alpha-tubulin could readily be detected on all.  
Due to this lack of detection, validation of the interaction between UL29 and ILTV-miR-I2 
could not be achieved.  Time restrictions and resources meant that other methods of 
validation were not attempted for this particular interaction.   
 
  





Figure – 4.5. UL29-6xHis Western blot validation attempt 
UL29 was cloned into pcDNA3.1+ with a 6xHis tag to allow for detection.  Once cloned, a mutant 
UL29-6xHis with an altered miRNA seed sequence was created using mutagenesis primers as laid 
out in Sectio2.2.9 of this thesis.  These constructs were transfected into HEK293T cells either on 
their own (1), with the mature miRNA mimic (2) or with a scramble siRNA control (3).  Cells were 
then harvested and lysates prepared for protein quantification using Laemmli buffer.  Lysates were 
used in a western blot as described (section 2.4) and probed with appropriate antibodies. Green 
banding shows alpha tubulin.  White asterisks indicate the size of the band where UL29-6xHis and 
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4.7 – Further Investigation into UL48 or UL46 as a target of ILTV-miR-I6-
5p  
4.7.1 – Introduction 
Most of the information regarding the interactions between UL46, UL48 and ICP4 promoter 
(ICP4p) is based upon research from other Alphaherpesviruses, particularly HSV-1 and 
HSV-2 (Kato et al., 2000).  UL46, also referred to as VP11/12 is an ILTV early/late 
(Mahmoudian et al., 2012).  It encodes a tegument protein that is unique to the 
Alphaherpesvirus family and has several roles in both virion assembly as well as interactions 
with UL48, the major trans inducing factor (α-TIF) (Kato et al., 2000).   
During virion assembly, UL46 is thought to play a role alongside UL47, UL48 and UL49 in 
organising the tegument by forming interactions with both the inner and outer tegument 
proteins as well as viral glycoproteins (Owen et al., 2015).  The gene is however dispensable 
for virus replication in vitro with only a decrease in plaque size observed (Kopp et al., 2002).   
Moreover, UL46 known as the major trans inducing factor (α-TIF) has been shown to 
interact with UL48.  Infection studies have shown that it co-localises with UL48 in infected 
cells and in reporter based assays can increase the expression from the ICP4 promoter when 
co-expressed with UL48.  In stark contrast however, it inhibits ICP4 promoter driven gene 
expression when expressed on its own (Kato et al., 2000). 
UL48 (VP16) is a key activator of lytic replication and interacts with the cellular proteins 
HCF and OCT-1, forming a transcriptional regulatory VP16-induced complex in HSV-1 that 
binds to the sequence ‘TAATGARAT’ (Thomas et al., 1998).  This induces the expression of 
all sequences with this sequence and includes the major immediate-early gene ICP4.  In 
addition to this, UL48 also plays roles in tegument formation and virion maturation.   
Work carried out using pseudorabies virus (SuHV-1) UL48 null viruses demonstrated that 
virus replication kinetics were greatly delayed and these viruses have significantly reduced 
viral titres and plaque sizes (Fuchs et al., 2003).  This group also demonstrated that UL48 
was necessary to link the capsid to future envelope-associated tegument proteins during 
virion formation (Fuchs et al., 2002a) suggesting that UL48 has two important roles in the 
virus life cycle at different stages.      
4.7.2 – Investigating whether UL46 or UL48 is the primary target of ILTV-miR-I6-5p 
Findings from the luciferase based screen (section 4.5.1 of this chapter) showed knockdown 
of either UL46 or UL48 in the presence of a ILTV-miR-I6-5p mimic however it was not 
known which viral transcript(s) was targeted by the miRNA.  To investigate this, a series of 
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RT-PCRs were carried out to determine if UL46 or UL48 or both transcripts contained the 
predicted miRNA target sequence.  The rationale behind this experiment was to try and 
elucidate which transcript is targeted as there is a lack of information regarding 
transcriptional start and termination sites for ILTV.  It was thought that by using cDNA, it 
would help distinguish somewhat if the site is situated     
Primers were designed using a sense (forward) primer situated upstream of the UL48 stop 
codon and then two anti-sense (reverse) primers.  The first of these was situated down steam 
of the UL48 stop codon but crucially upstream of the UL46 start codon whilst the second 
primer was situated downstream of miRNA target site (displayed in Figure – 4.6A). 
A second set of primers were designed to target the UL46 coding region with a sense primer 
downstream of the UL46 AUG start codon and the same reverse primer downstream of the 
miRNA target site.  
RT-PCRs were then carried out on DNase treated RNA with cDNA synthesised from either 
randomly primed RNA or Oligo (DT) primed RNA from both infected and mock infected 
samples.  In addition to this, appropriate minus reverse transcriptase (-RT) and DNA positive 
controls were included.  PCR products were then visualised using agarose gel electrophoresis 
and imaged. 
Primer set one for UL48 showed bands produced in both randomly primed and oligo (DT) 
primed infected cDNA at the same size as the DNA positive control (Figure – 4.6B).  No 
bands could be detected using primer set 2 apart from the DNA positive control (Figure – 
4.6C).   
In contrast, primer set 3 which targeted the UL46 coding region showed strong banding for 
both randomly primed and oligo (DT) primed infected cDNA alongside the DNA positive 
control (Figure – 4.6D).  These results show the miRNA target site to be in the UL46 coding 
region and not in the UL48 3’UTR.   
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Figure – 4.6. RT-PCR investigations into which ILTV transcript is targeted by ILTV-miR-I6-5p  
RNA Hybrid predicted ILTV-miR-I6-5p to target both the 3’UTR of UL48 and the coding region of UL46. 
Schematic diagram of the genome arrangement surrounding UL48 and UL46 (A). RT-PCR analysis was carried 
out using a forward primer upstream of the UL48 stop codon along with a reverse primer upstream of UL46 
(primer set 1, B) or downstream of the predicted miRNA target site (primer set 2, C).  Finally, a primer situated 
downstream of the UL46 start codon was used in conjunction with the reverse primer downstream of the miRNA 
target site (primer set 3, D).  Arrows depict primer direction and numbers refer to primer set.  Boxes in (A) 
represent the coding region of ORFs whilst solid black line represents the 3’UTR of the respected ORFs.  
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4.7.3 – Cloning of a UL46-HA construct 
As the miRNA target was shown to be within the coding region of UL46, primers were 
designed to amplify the coding region of UL46 and included a small tag to allow for 
detection.  Initial attempts to PCR amplify up the UL46 region proved difficult (Data Not 
Shown) and so a set further set of primers termed outer UL46 primers were designed to 
amplify up a larger region than just the specific coding region.  From this, the HA-tagged 
primers were then used to amplify up the region of interest with the tag at either the N or C-
terminal.   
PCR products were visualised on an agarose gel with bands excised and purified prior to 
ligation and transformation into TOPO 4 vector.  Sequencing was then used to confirm the 
sequence as UL46 with the HA tag at either the N or C-terminal (Data Not Shown).  Tagged 
UL46 HA was then cloned into the plasmid pcDNA3.1+.  Following ligation and 
transformation, DNA was extracted from small cultures and diagnostic digests were carried 
out to look for insertion of the product.  Upon digest, it was found only C-terminal tagged 
UL46; termed UL46-HA, had been successfully cloned into pcDNA3.1+.  In the interests of 
time, the decision not to carry on with cloning an N-terminal tagged UL46 was taken, 
therefore only UL46-HA was taken forward for use in downstream experiments.   
4.7.4 – Mutagenesis of UL46-HA plasmid to ablate the miRNA seed sequence 
Upon successful cloning of UL46-HA, mutagenesis primers were designed to mutate the 
miRNA seed sequence of ILTV-miR-I6-5p using Agilent QuikChange Primer Design as 
described in Section 4.6.3 of this chapter. Mutagenesis PCRs were carried out as previous 
and products were transformed into ultra-competent cells as per the manufacturer’s 
instructions.  The mutant construct was termed mut-UL46-HA.  
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4.7.5 – Validation attempts of ILTV-miR-I6-5p targeting UL46 
Using both wild-type and mutant UL46-HA constructs, HEK293T cells were transfected 
with the plasmids either on their own, with the mature ILTV-miR-I6-5p mimic or with a 
scramble siRNA control.  Following incubation, cells were harvested for protein 
quantification with Laemmli buffer.  SDS-PAGE gels were loaded with 20 µl of sample per 
lane.  Following separation, proteins were transferred using the TransBlot Turbo system 
(Bio-Rad) and immunoblots were probed with HA and alpha-tubulin antibodies at 
appropriate dilutions (See Table 2.1 in Section 2.4.6).  Secondary Li-Cor antibodies were 
then used for visualisation (also Table 2.1 for dilution concentrations) before immunoblots 
were imaged on the Li-Cor system. 
Alpha-tubulin was detected at 50 kDa and is shown in green on Figure – 4.7A.  Both wild-
type and mutant UL46-HA could be detected with an approximate molecular weight of 63 
kDa (bands shown in red, Figure – 4.7A).  Protein levels were then quantified using Image 
Studio (Li-Cor).  Individual protein levels were calculated for alpha tubulin and UL46 for 
each lane.  UL46 levels were then normalised against the alpha-tubulin reading and this was 
carried out for both wild-type and mutant constructs across all conditions and biological 
repeats (n=4).  Normalised UL46-HA levels were then used to look at protein level changes 
by using the protein only lane as control levels.  Data analysis found no significant 
difference between the wild-type and mutant UL46-HA plasmids in the presence of the 
mature miRNA mimic.  Similarly, there was no significant difference between the protein 
only (both wild-type and mutant) and protein + miRNA mimic across the biological 
replicates.  A small, statistically significant difference was observed between the WT-UL46-
HA and mut-UL46-HA in the presence of the siRNA scramble (p = 0.039) though the mut-
UL46-HA plus scramble was not statistically significant from any other condition.  
The Western blots could not determine a statistically significant knockdown of WT-UL46-
HA in the presence of ILTV-miR-I6-5p over several biological replicates (n = 4) and 
therefore this target was also not validated. 
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Figure – 4.7.  UL46-HA Western blot validation attempts and relative expression of UL46-HA and  
mut-UL46-HA   
UL46 was cloned with a HA tag into pcDNA3.1+.  Following successful cloning a mutant UL46-HA (termed 
mut-UL46-HA) was created by mutagenesis PCR to alter the miRNA seed sequence of the ILTV-miR-I6-5p 
target site.  These constructs were transfected into HEK293T cells either on their own (1), with the mature 
miRNA mimic (2) or with a scramble siRNA control (3).  48 hours post transfection, cells were harvested for 
protein quantification using Laemmli buffer.  Lysates were boiled and used for conventional western blotting.  
Immunoblots were probed with a HA antibody (red banding) and an alpha-tubulin antibody (green banding) as a 
loading control (A).  Protein levels were quantified using Image studio software (Li-Cor).  HA levels were 
compared to alpha tubulin levels as a control and then HA levels were compared between conditions using the 
only lane as the standard to look at relative expression levels of UL46-HA (B).  
P-values, * = <0.05, ns = not significant    
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4.8 – Investigating the Interplay between UL46, UL48 and ICP4 Promoter 
4.8.1 – Cloning of ICP4 promoter and UL48-FLAG constructs 
As well as cloning the coding region of UL46 with a HA tag into pcDNA3.1+, the coding 
region of UL48 with a FLAG tag as well as the full promoter region of ICP4 was cloned into 
pcDNA3.1+ and PGL3b respectively.  The same process as used for UL46-HA was used to 
clone UL48-FLAG into pcDNA3.1+ except there was no need for an extra PCR step using 
outer primers to amplify across the UL48 region.   
To clone the ICP4 promoter, termed ICP4p, primers were designed to amplify up the 5’UTR 
of ICP4.  To ensure the full promoter was covered, a sense (forward) primer was designed 
approximately 1000 bp upstream of the AUG start codon and an anti-sense (reverse) primer 
was designed around 50 bp downstream of the AUG start codon.  PCR was then used to 
amplify the region of interest which was then visualised on an agarose gel.  Excised bands 
were purified and ligated into the TOPO 4 vector as previously described.  This was then 
sequenced which confirmed the PCR was successful (Data Not Shown).  The product of 
interest was then excised from TOPO 4 and cloned into PGL3b (Data Not Shown).  
4.8.2 – Investigating the interplay between UL46, sORF1 (UL47), UL48 and ICP4 
promoter by luciferase assay 
Work in HSV has shown that UL46 interacts with UL48 which in turn interacts with the 
promoter of ICP4 at the TAATGARAT sequence (Thomas et al., 1998, Kato et al., 2000).  
Therefore investigations into the interactions between UL46, UL48 and ICP4p in ILTV were 
carried out.  This was done using the cloned pUL46-HA, pUL48-FLAG and ICP4p 
constructs previously mentioned.  In addition, pUL47 (sORF1), another protein thought to 
mediate UL48 was also used.  This was cloned by Dr. I Dry (The Roslin Institute) and 
provided as a kind gift.  This included a 6xHis tag at the C-terminal.   
Six-well plates were seeded with CLEC213 cells and left to adhere overnight.  CLEC213 
cells are of chicken lung epithelial origin and are biologically relevant to ILTV infection.  
Cells were transfected with a total of 2.5 µg of plasmid DNA which consisted of 820 ng 
ICP4p promoter, 820 ng “protein 1” and 820 ng “protein 2” (either pUL46, pUL47 or pUL48 
with empty pcDNA3.1+ or a combination of two of the proteins) plus 40 ng of SV40 
plasmid which contains a Renilla luciferase and acts as a control.  Transfected cells were 
incubated for 48 hours before harvesting as described (Chapter 2, Section 2.6.3).  Luciferase 
assays were then performed as described and data was then analysed. 
Firstly, luciferase expression was analysed to determine if the ICP4 promoter was 
constitutively active.  Compared to an empty vector control, luciferase levels were increased 
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129-fold in the cells transfected with the plasmid containing the ICP4 promoter.  This was 
statistically significant (p =<0.0001). 
Luciferase expression in the presence of the pUL46, pUL47 or pUL48 or combinations of 
these was then analysed using the levels in the presence of only the ICP4p plasmid as 
baseline.  In total, 2.5 µg of DNA was transfected per well consisting of 820 ngs ICP4p, 820 
ngs protein 1, 820 ngs protein 2 and 40 ngs of Renilla luciferase.  Where only a single 
protein is used, control DNA (empty pcDNA 3.1+) was used to ensure a standard 2.5 µg of 
DNA was transfected per well each time.  When co-transfected with pUL46 only, promoter 
activity decreased by 50 %.  Statistical analysis confirmed this to be significant (p =<0.001).  
ICP4p in the presence of pUL47 also showed a statistically significant decrease in luciferase 
expression (p =0.047) whereas there was no significant difference of expression when co-
transfected with pUL48.  Dual transfection of both pUL46 and pUL47 with ICP4p also 
caused a statistically significant decrease in expression (p =<0.001). In contrast there was no 
difference seen between ICP4p alone and co-transfection with UL46 and UL48.  Likewise, 
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Figure – 4.8. The interplay between UL46, UL47 and UL48 in activating the ICP4 promoter in a reporter 
based system 
UL46, UL47 and UL48 were cloned into the expression plasmid pcDNA3.1+ whilst ICP4 promoter (ICP4p) was 
cloned into PGL3b.  CLEC213 cells were transfected with 2.5 µg total plasmid DNA consisting of 820 ng of 
ICP4p, 820 ng protein 1, 820 ng protein 2 (where only one [or no protein] was transfected, empty plasmid 
control pcDNA3.1+ was used) and 40 ng of Renilla luciferase plasmid (B).  Activity of the promoter was tested 
against an empty PGL3b control and normalised to the empty vector control (A).  To look at promoter activity in 
the presence of viral proteins, expression levels were normalised to ICP4p (B).  Error bars represent Standard 
error of the mean.   
P-values - * = <0.05, ** = <0.01, *** = <0.001, ns = Not significant 
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4.9 – Discussion   
To date, very little work has been done looking at the role of ILTV-encoded miRNAs during 
infection and their potential targets.  The work described in this chapter investigated the role 
of virus-encoded miRNAs targeting virally derived transcripts.  Using a bio-informatics 
pipeline, potential viral targets of virally encoded miRNAs were first predicted using RNA 
Hybrid, an online programme that predicts the binding patterns between miRNAs and 
mRNA transcripts.  The data generated from this bioinformatic screen was sorted and 
filtered which left a total of 227 predictions of interactions across the viral genome.  An 
additional sort was then carried out to only include viral genes that were either essential to 
the virus (excluding capsid proteins or glycoproteins) or suppression of which may lead to a 
change in virus biology, this left a total of 28 potential viral miRNA targets that were taken 
forward to an initial reporter-based screen.  As well as the 28 novel targets, a previously 
identified ILTV target/miRNA combination  was included to ensure that the system chosen 
was working correctly.  Using ILTV-miR-I6-5p and its known target in the virus IE gene 
ICP4, the system was shown to work with reduction in luciferase levels observed which were 
then abrogated upon mutation of the seed sequence.  The 28 novel targets were subsequently 
cloned into the dual-luciferase vector Psi-Check 2 using pairs of long oligonucleotides of 
~110 bp.  Testing of the targets found three that had lower levels of luciferase activity when 
compared to the scrambled siRNA control however only two of these turned out to be 
statistically significant.   
The first miRNAs were identified in the early 1990’s in C.elegans with work some ten years 
later finding miRNAs that were encoded for by Epstein-Barr virus (EBV) and since then a 
large new field of virus-host interactions has opened up looking at the role of RNAi in virus 
infection (Lee et al., 1993, Pfeffer et al., 2004b).  These interactions are not only looked at 
from the perspective of how the virus might manipulate the cell to gain a competitive 
advantage over the immune response organisms mount against invading pathogens but also 
in terms of how viruses can use small RNAs to regulate their own expression.   
Virus encoded miRNAs have now been known about for nearly15 years and since then, 
upwards of 530 virally encoded miRNAs have been identified across 35 individual viruses 
according to the latest release of MiRBase (Release 22, March 2018) (Griffiths-Jones et al., 
2006).  This number relies upon researchers submitting their findings to the repository but 
with new viruses been discovered coupled with the tumbling cost of next-generation 
sequencing, new viral miRNAs are discovered much more frequently than they were 
previously and so this number whilst accurate to MiRBase may be different to the true 
number of actual virus-encoded miRNAs discovered to date.   
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RNA Hybrid is an online tool that works on the basis of looking for the ‘best fit’ between a 
miRNA and a possible mRNA target.  Therefore, the sequences of the 10 known miRNAs of 
ILTV were taken from MiRBase and used to predict virus targets of virally encoded 
miRNAs.  Due to the poor annotation of the viral genome, an arbitrary 1000 bp upstream of 
the AUG start site and 50 bp downstream of the designated PolyA signal were used to ensure 
that the full mRNA transcript was taken into account.  Whilst this approach should cover the 
full transcripts of every open reading frame, it also has the complication that predicted 
miRNA targets can overlap between two or more viral transcripts.  Herpesvirus genomes are 
compact and have very little space between open reading frames thus making it problematic 
when looking at binding patterns of miRNAs (Afonso et al., 2001).  This was the case for 
several of the predicted targets and also for some of the targets taken forward into the 
luciferase based screen.  Predicted target sequences in both UL29 and UL46 were also 
present in the UL28 and UL48 sequences respectively.  For the former of these, the predicted 
site in UL28 was approximately 950 bp upstream of the AUG start site but was within the 
coding region of UL29.  Because of this and the observation in the literature that 5’UTRs of 
HSV-1 vary between ~148 – 530 bp in length, the decision was taken that the site was in 
UL29 (Greco et al., 1994). 
Conversely, the predicted site of ILTV-miR-I6-5p within UL46 & UL48 was more complex 
and required RT-PCR to decipher.  Primer sets designed to amplify only from the UL48 
transcript at the 3’UTR were designed whilst a further primer was designed to amplify only 
from the UL46 coding region (Figure – 4.7).  This approach gave the result that the site was 
within the UL46 coding region as opposed to the 3’UTR of UL48.  This of course does not 
guarantee that the target site is not within the 3’UTR of UL48 but more sensitive approaches 
would need to be taken such as 3’ and 5’ Rapid Amplification of cDNA Ends (RACE) to 
map the specific RNA transcripts of the respective open reading frames.  Whilst this would 
have given a definitive answer, it was not within the aims of this project to map out gene 
transcripts.   
Filtering and sorting of the data followed strict criteria to minimise the chances of false 
predictions been taken forward.  Firstly, the decision was taken to omit any predictions that 
were above a minimum threshold of – 15 kcal/mol.  This was due to previous findings in the 
lab which validated targets with minimum free energies of – 15.4 kcal/mol (Riaz, 2014 ).  
Duplex formation between a miRNA and mRNA is stronger when the minimum free energy 
is low thus in turn making it more thermodynamically stable requiring the need for more 
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energy to disrupt the duplex formation (Huang et al., 2010).  Due to this, a large proportion 
of the predicted targets were immediately omitted and cut the number of predictions down.   
These predictions were then filtered again using an approach based on what was known 
about the potential role of genes in virus biology.   The core of this was to identify when in 
the virus life cycle the gene was expressed i.e. what temporal class of gene expression it was.  
Targets affecting immediate-early and early genes were considered arbitrarily to be likely of 
interest as opposed to late genes.  As well as this, the function of the target was also 
investigated.  As the genome of ILTV is again poorly annotated, homologues of transcripts 
were examined primarily in HSV-1 to see if they had any designated function and if they 
were classed as essential.  From this, 28 novel targets were identified out of the 227 
predictions following the initial filtering.   
In addition to the 28 novel targets, one known viral target was included to ensure the 
luciferase based reporter system was working.  ICP4, the essential major immediate-early 
protein is known to be targeted by both ILTVmiR-I6-5p and ILTV-miR-I5-5p (Waidner et 
al., 2011).  These miRNAs have perfect Watson-crick binding complementarity to ICP4 as 
they are encoded anti-sense to the open reading frame.  Only ILTV-miR-I6-5p was included 
in this study and not ILTV-miR-I5-5p.  Data presented in this project found a 35 % reduction 
in luciferase expression when compared to a scrambled siRNA control and this was 
statistically significant (p =<0.001).  This knockdown is greater than what was seen in the 
previous work that found a 23 % reduction in luciferase activity in the presence of ILTV-
miR-I6 that was not statistically significant.  Similarly, introduction of mutations to the 
miRNA seed sequence alleviated the effect of the miRNA which suggest a specific 
interaction.  As the system was working with the replication of published data, the novel 
targets were subsequently tested.  
Of the 28 novel targets tested, only three showed decreases in luciferase activity (outlined in 
Table – 4.2) and these were UL24 T1, UL28/29 T3 and UL46/48 T2.  The former of these 
showed only a minor decrease in luciferase activity of 5 % which when tested statistically 
showed no significant difference from the scramble siRNA control (Figure – 4.4B).  The 
data from these results meant that this work halted here as whilst an apparent difference was 
observed, it was not significant and a 5 % reduction is unlikely to have a large effect upon 
the virus biology.  Intriguingly, they were several predicted targets in UL24 and whilst its 
function is still not fully understood, homologues are found across the herpesvirus family 
suggesting it does have important functions for the virus.  Therefore, the significance of 
these predicted interactions may become apparent in future.   
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In comparison, the latter two predicted targets that were tested showed 15 % & 20 % 
reduction in luciferase activity respectively (Figures – 4.2C and 4.3C).  Whilst again this was 
lower than that of the positive control for the reporter based assay (Figure – 4.1B), one must 
take into account that the target in ICP4 is perfectly complimentary to the miRNA and so the 
minimum free energy is much lower.  Moreover, previous work in the lab by Dr. Riaz (The 
Roslin Institute) found knockdowns of around 20 % in a reporter based system (Riaz, 2014 ).  
The interactions were found to be specific as upon mutation of the miRNA seed sequence for 
both UL29 and UL46, an abrogation of the miRNA effect was seen with levels of the mutant 
sequence similar to that of the siRNA scramble and empty vector controls (Figures – 4.2C 
and 4.3C).  This suggests that the interaction and observed knockdown is due to the action of 
the miRNA.   
Whilst knockdown was seen in the reporter system, validation using alternative methods, 
specifically western blotting proved to be inconclusive.  Firstly, both UL29 and UL46 coding 
regions were cloned into the expression plasmid pcDNA3.1+ with a small tag to allow for 
detection using antibodies.  Cloning of these genes was successful as laid out in sections 
4.6.2 and 4.7.2 yet both had their own separate problems when it came to validating the 
interaction of these transcripts with the miRNAs. 
Firstly, UL29 was shown to be cloned successfully with a 6xHis tag (Data Not Shown).  
Transfections of the UL29-6xHis plasmid into HEK293T cells alongside the mature miRNA 
mimic ILTV-miR-I2 or a siRNA scramble control were carried out before cells were 
harvested for protein by lysing with Laemmli buffer and boiling.  These lysates were then 
used for conventional western blot as outlined in section 2.4 of this thesis.  Upon imaging, no 
banding could be detected for UL29 in any of the lysate samples, including UL29-6xHis 
only lanes across multiple biological replicates.  This could have simply been down to 
human error however across several biological repeats that is not plausible.  Furthermore, 
mammalian and insect cells have high levels of histidine residues and so the antibody could 
have simply bound with more affinity to another protein, possibly explaining the banding 
pattern found at approximately 55 kDa (Figure – 4.5) (Kimple et al., 2013).  Another 
possible cause of this lack of detection is the half-life of UL29.  In previous experiments 
looking into the function of UL29 (ICP8) of HSV-1, detection of ICP8 via western blot was 
not possible in certain cell lines (Orberg and Schaffer, 1987).  This may be the case here as 
validation work was carried out in HEK293T cells (of human origin) and the results may 
have differed if using a chicken cell line.  To date, no explanation has solved why the protein 
could be not detected by immunoblot but it is of significance to finish validating this work as 
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it would shed light on to one of the functions of ILTV-miR-I2.  As discussed in Chapter 3 of 
this thesis, biochemical approaches such as CLASH/HITS-CLIP may be able to aid in 
validating this target when the appropriate biological reagents are available.  
In contrast, UL46-HA could be detected by western blot (Figure – 4.7A) following cloning 
of the coding region into pcDNA3.1+ (Data Not Shown).  Both a wild type UL46-HA and a 
mutant MUT-UL46-HA were constructed with the latter having the same mutations made as 
the reporter assay.  Analysis of the protein levels by image studio (Li-Cor Biosciences) 
found there to be no difference in levels of the wild-type protein and the mutant protein in 
the presence of the miRNA mimic when compared to a protein only lane (Figure – 4.7B).  
This therefore did not validate the previous findings using the reporter assay and so one 
cannot categorically state that UL46 is targeted by ILTV-miR-I6-5p.  In a similar manner to 
UL29, other biochemical approaches such as CLASH would be able to validate the findings 
if the interaction is real during virus infection. 
Whilst the validation work for UL46 was ongoing, other viral genes were cloned as well as 
the ICP4 promoter region to investigate the interplay between UL46, UL48 and ICP4p.  As 
briefly introduced in section 4.7.1 of this chapter, UL46 can modulate the effects of UL48 on 
ICP4 expression in HSV-2.  Therefore, the interplay between these three proteins and ICP4p 
was investigated using a promoter assay system.  As stated previously, ICP4p was cloned 
into PGL3b to drive the expression of firefly luciferase and following transfection of a 
chicken cell line  a 129-fold increase in luciferase expression with ICP4p was observed when 
compared to the plasmid alone (Figure – 4.8A). This suggested that the promoter was active 
and could drive the expression of the reporter protein.   
Co-transfection of the reporter plasmid in conjunction with either the plasmids expressing 
pUL46, pUL47 or pUL48 on their own or in a combination of the two was then carried out 
as described.  In line with previous published data for HSV-2, transfection of pUL46 
alongside ICP4p caused a decrease in luciferase activity suggesting an inhibition of ICP4p 
activity by pUL46.  Kato et al. (2000) previously published similar findings on this 
interaction using HSV-2 gene products in a reporter based system.  Transfection of pUL48 
on its own with ICP4p showed no statistically significant difference from ICP4p on its own 
which differs from results seen in HSV-2 and other viruses (Kato et al., 2000).  Also, co-
transfection of both pUL46 and pUL48 did not result in an increase in ICP4p luciferase 
expression but in fact a decrease on ICP4p only levels however this was not statistically 
significant (Figure – 4.8B). pUL46 and pUL48 co-transfection showed an increase in ICP4p 
activity in HSV-2 in previously published reports (Kato et al., 2000).  These data would 
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suggest that pUL46 of ILTV does modulate the interaction between pUL48 and ICP4p 
however it has a negative effect in ILTV when compared to the previously published data.  
As this is the opposite of what is seen in the literature, further investigation is warranted to 
see if this interaction is indeed correct in a more biologically relevant context as opposed to 
using a reporter system.                   
In summary, the use of bioinformatics and in silico approaches are complimentary to 
traditional biochemical approaches that are used to identify small RNA interactions however 
they also have many drawbacks.  As found in this project, predicted miRNA targets that 
show protein knockdown in reporter based systems do not necessarily translate to real-world 
targets.  In conjunction, predicted targets also don’t necessarily have an effect when tested 
biochemically as found with a large proportion of the novel targets tested in the first part of 
this project following bioinformatic prediction.  The basis of this project was to use 
bioinformatic approaches to identify viral targets of virus-encoded miRNAs and validate 
them using available biochemical methods.  This was carried out as previous attempts to use 
biochemical based methods (CLASH) as outlined in chapter 3 of this thesis are technically 
very challenging with the currently available reagents.  Despite this, investigating the RNAi 
pathway in the context of ILTV infection should still be of priority due to the relative lack of 
knowledge regarding the virus encoded miRNAs of ILTV.  Follow up work investigating the 
interplay between pUL46, pUL48 and the ICP4 promoter also warrants further investigation 
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5.1 – Introduction 
MicroRNAs (miRNAs) have been shown to be effective regulators of gene expression.  
Endogenous cellular miRNAs are able to target a wide variety of cellular genes and subtly 
changing the signalling pathways.  An increasing body of evidence is beginning to show that 
they also have the ability to effectively target viral transcripts in a wide range of differing 
virus families.        
Hepatitis C Virus (HCV) infection sets off a cascade of antiviral responses through the 
interferon pathway resulting in the expression of 8 miRNAs that target the positive sense 
genome (miR-1, miR-30, miR-128, miR-196, miR-296, miR-351, miR-431 and miR-448) 
(Pedersen et al., 2007).  Introduction into cells of synthetic mimics of these miRNAs 
replicated the antiviral response seen in vitro.  Likewise, Coxsackievirus B3 (CVB3) is 
targeted by the host miRNA miR-342-5p in the 2C region leading to viral RNA degradation 
thus reducing both RNA and protein levels.  The target site was found across CVB types 1-5 
suggesting that miR-342-5p may also have an effect on other types of CVB viruses (Wang et 
al., 2012).      
Larger, double stranded DNA viruses are also targets of the host RNAi pathway.  The 
neuronal tissue specific miRNA hsa-miR-138 has been shown to target the immediate-early 
gene ICP0 of HSV-1.  Mice infected with mutant HSV-1 with the miRNA target sites 
ablated were four times more likely to die from infection compared with mice infected with 
wild type virus (Pan et al., 2014).  Likewise, the immediate-early gene UL112 of HCMV is 
targeted by the cellular encoded miRNA hsa-miR-200 family.  The viral protein is critical in 
the reactivation of HCMV from latency thus the targeting promotes maintenance of viral 
latency (O'Connor et al., 2014).  One of the other members of this miRNA family has also 
been implicated in the switch between latency and lytic replication in EBV.  Both hsa-miR-
200b and hsa-miR-429 have been shown to reduce the expression levels of ZEB1 and ZEB2 
in EBV-positive cell lines resulting in a switch to lytic replication.  This suggests both of 
these miRNAs are key regulators in the reactivation of EBV from latency (Ellis-Connell et 
al., 2010) (Lin et al., 2010).   
Effects on virus infection by RNAi are not always necessarily as a direct result of a host 
miRNA targeting a viral mRNA transcript.  Downregulation of cellular genes by host 
miRNAs can also have a significant effect upon viral infection.  Cellular miRNAs hsa-miR-
27a/b have been shown to negatively regulate the levels of SNAP25 and TXN2 which 
consequently causes an 80 % reduction in adenovirus genomic copy number in cells 
transfected with a synthetic mimic.  Closer inspection showed reduced levels of SNAP25 
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was implicated in adenovirus entry into cells.  In addition, reduced levels of TXN2 caused 
cell cycle arrest, thus blocking adenovirus replication which requires the cell cycle 
(Machitani et al., 2017).  In some cases however, the targets can be both direct and indirect.  
The chicken miRNA gga-miR-130b has been shown to target the segment A portion of the 
Infectious Bursal Disease Virus (IBDV) genome causing a direct reduction in IBDV protein 
expression but in addition to this, expression of miR-130b also caused a downregulation in 
the levels of suppressors of cytokine signalling 5 (SOCS5) thus increasing the expression 
levels of IFN-β.  Taken together, the results show a crucial role of miR-130b in host defence 
against IBDV infection (Fu et al., 2017).    
The manipulation of the host environment by RNAi can either be advantageous or 
detrimental to a virus in both a productive infection but also for viruses which possess the 
ability to establish lifelong latency within infected hosts.  These effects can be either direct 
or indirect to the virus with some highlighted cases using both pathways as a method of host 
defence.  With more powerful laboratory methods being developed continuously in addition 
to the perpetual advancements in sequencing technologies, no doubt more of these 
interactions will be identified in the future.  HITS-CLIP, PAR-CLIP and CLASH all have 
the ability to identify miRNA:mRNA interactions which includes cellular miRNAs targeting 
viral mRNAs.  Complementary to this is the use of bioinformatical approaches to identify 
potential target sites for miRNAs which can then be tested in a traditional laboratory setting.    
5.2 – Aims 
The aims for this part of the project was to take the existing data set of viral transcripts 
created in Chapter 4 of this Thesis (Appendix 3) and screen them for miRNA binding sites 
using a list of high confidence chicken miRNAs taken from MiRBase 21 (released June 
2014, [http://www.mirbase.org/]).  Any identified target sites would then be investigated 
further using different biochemical approaches. 
5.3 – The Use of RNA Hybrid to screen for candidates 
RNA Hybrid parameters were set as per Chapter 3 except the minimum free energy (mfe) 
had a minimum requirement of -25 kcal/mol or below.  All 79 ORFs were tested against a 
total of 54 mature miRNA sequences as taken from MiRBase (release 21, June, 2014).  
Similar to Chapter 3, predicted target sites were then ranked according to minimum free 
energy value.  No exclusions were made with regards to gene function or temporal 
expression profile in this instance.  This led to a final list of 103 target predictions of cellular 
miRNAs targeting viral transcripts.  A summary of the predictions can be found in Table 5.1. 
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MFE Gene Function 
UL51 128-2-5p 589 5' UTR -34.9 unknown 
UL-1 222b-5p 270 5' UTR -34.9 Unknown but essential 
UL15a 125b-5p 986 5' UTR -33.2 terminase/DNA Packaging 
UL15b 125b-5p 4453 3' UTR -33.2 terminase/DNA Packaging 
UL36 128-2-5p 2091 CDS -32.6 Major Tegument Protein 
UL24 460b-3p 702 5'UTR -32.2 unknown 
UL1 10a-5p 89 5' UTR -31.7 Glycoprotein gL 
UL0 10a-5p 1670 CDS -31.7 unknown 
UL-1 30c-1-3p 1621 CDS -30.9 unknown but essential  
ICP4 133a-3p 584 5' UTR -30.3 Gene Regulation 
UL56 499-3p 415 5' UTR -30.3 Vesicular Trafficking 
UL22 17-3p 2261 CDS -30.1 Glycoprotein gH 
UL23 17-3p 3390 3’UTR -30.1 thymidine kinase 
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US6 27b-5p 3288 3’UTR -29.9 Glycoprotein  gD 
US7 27b-5p 2048 3’UTR -29.9 Glycoprotein  gI 
US8 27b-5p 761 5' UTR -29.9 Glycoprotein  gE 
UL42 133a-3p 1929 CDS -29.8 process factor for DNA pol 
UL43 133a-3p 546 5' UTR -29.8 unknown 
ORF A  128-2-5p 317 5' UTR -29.6 unknown 
UL7 222b-5p 484 5' UTR -29.4 unknown 
UL6 222b-5p 2402 CDS -29.4 minor capsid protein 
UL-1 125b-5p 600 CDS -29.1 unknown but essential 
sORF1 222b-5p 2919 CDS -29.1 modulates UL48 
US4 222b-5p 969 5' UTR -29.1 Glycoprotein  gG 
UL44 22-3p 1091 CDS -29.1 Glycoprotein  gC 
UL36 460b-5p 4173 CDS -29 Major Tegument Protein 
UL27 128-2-5p 510 5' UTR -28.8 Glycoprotein  gB 
UL28 128-2-5p 2778 3’UTR -28.8 ICP18.5 
UL39 221-3p 1530 CDS -28.8 Large-subunit Ribonucleotide Reductase 
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UL30 140-3p 29 5' UTR -28.7 DNA POL 
UL54 33-5p 2295 5' UTR -28.6 post-transcriptional regulator of gene expression 
ICP4 133a-3p 2563 CDS -28.5 Gene Regulation 
UL24 126-3p 3322 CDS -28.3 unknown 
UL25 126-3p 2482 CDS -28.3 DNA Packaging Protein 
UL26 126-3p 592 5' UTR -28.3 Capsid Protein p40 
UL51 34b-5p 1555 CDS -28.3 unknown 
ORF C 34b-5p 1345 CDS -28.3 unknown 
UL21 460b-3p 859 5' UTR -28.3 nucleocapsid protein 
UL26 128-2-5p 1797 CDS -27.8 Capsid Protein p40 
UL26.5 128-2-5p 927 5' UTR -27.8 virion scaffold protein 
UL15b 187-5p 3132 3’UTR -27.8 terminase/DNA Packaging 
UL1 10b-5p 89 5' UTR -27.7 Glycoprotein  gL 
UL0 10b-5p 1670 CDS -27.7 unknown 
UL31 133a-3p 134 5' UTR -27.7 nuclear phosphoprotein 
UL32 133a-3p 1873 CDS -27.7 envelope glycoprotein 
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ORF C 29b-1-5p 1197 CDS -27.7 unknown 
UL22 34b-5p 3540 3’UTR -27.7 Glycoprotein  gH 
UL29 222b-5p 457 5' UTR -27.4 Major Single Strand DNA binding protein 
ICP4 181b-5p 1968 CDS -27.3 Gene Regulation 
UL15b 221-5p 1430 CDS -27.3 terminase/DNA Packaging 
UL14 460b-3p 773 5' UTR -27.3 unknown 
UL13 460b-3p 322 5' UTR -27.3 protein kinase 
UL7 128-3p 1506 CDS -27.2 unknown 
UL6 128-3p 3424 3’UTR -27.2 minor capsid protein 
UL36 460b-3p 7436 CDS -27 Major Tegument Protein 
UL5 187-3p 1533 CDS -26.9 Helicase-primase component 
ICP4 30c-2-3p 1109 CDS -26.9 Gene Regulation 
UL39 125b-5p 929 5' UTR -26.7 Large-subunit Ribonucleotide Reductase 
UL36 133a-3p 418 5' UTR -26.7 Major Tegument Protein 
UL37 133a-3p 3712 CDS -26.7 Tegument Protein 
ICP4as 181b-5p 1969 CDS -26.7 Gene Regulation 
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sORF1 30c-1-3p 1799 CDS -26.7 modulates UL48 
ORF E 34b-5p 1072 CDS -26.7 unknown 
UL23 34b-5p 4669 3’UTR -26.7 thymidine kinase 
UL36 460b-5p 8070 3' UTR -26.7 Major Tegument Protein 
UL52 128-2-5p 3032 CDS -26.6 DNA Helicase-Primase 
US5 128-2-5p 1657 CDS -26.6 Glycoprotein  gJ 
UL29 187-3p 2793 CDS -26.6 Major Single Strand DNA binding protein 
UL50 30c-1-3p 1113 CDS -26.3 Deoxyuridine triphosphate 
UL20 133a-3p 2902 CDS -26.1 membrane protein 
UL19 133a-3p 2122 CDS -26.1 major capsid protein 
UL38 30c-1-3p 2026 CDS -26.1 DNA binding/Capsid Protein 
UL39 30c-1-3p 449 5' UTR -26.1 Large-subunit Ribonucleotide Reductase 
UL41 187-3p 1350 CDS -26 VHS 
UL20 221-3p 659 5' UTR -26 membrane protein 
ICP4 30a-5p 3708 CDS -25.9 Gene Regulation 
ICP4 30c-5p 3685 CDS -25.9 unknown 
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UL15a Let-7 1425 CDS -25.9 teminase/DNA packaging 
UL15b Let-7 4893 CDS -25.9 terminase/DNA Packaging 
UL33 221-3p 596 5' UTR -25.8 DNA Packaging 
UL34 221-3p 161 5' UTR -25.8 Membrane phosphoprotein 
UL38 187-5p 1553 CDS -25.7 DNA binding/Capsid Protein 
UL14 33-3p 786 5' UTR -25.7 unknown 
UL13 33-3p 335 5' UTR -25.7 protein kinase 
UL24 22-3p 2043 CDS -25.6 unknown 
UL25 22-3p 1203 CDS -25.6 DNA Packaging Protein 
ORF C 30c-1-3p 1683 3’UTR -25.6 unknown 
UL41 499-3p 1763 CDS -25.5 VHS 
ICP4 140-3p 4923 CDS -25.4 Gene Regulation 
ICP4 126-3p 3153 CDS -25.3 Gene Regulation 
UL36 22-3p 158 5' UTR -25.2 Major Tegument Protein 
UL37 22-3p 3452 CDS -25.2 Tegument Protein 
UL3.5 10a-5p 1091 CDS -25.1 Virion Morphogenesis 
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UL3 10a-5p 1786 CDS -25.1 unknown 
UL3.5 10b-5p 1091 CDS -25.1 Virion Morphogenesis 
UL3 10b-5p 1786 CDS -25.1 unknown 
US5 222b-5p 1878 CDS -25.1 Glycoprotein  gJ 
UL44 34b-3p 569 5' UTR -25.1 Glycoprotein  gC 
UL42 34b-5p 3852 CDS -25.1 process factor for DNA pol 
UL43 34b-5p 2469 CDS -25.1 unknown 
UL17 10a-3p 207 5' UTR -25 Tegument Protein 
UL20 429-3p 1704 CDS -25 membrane protein 
UL19 429-3p 924 5' UTR -25 major capsid protein 
Target site is the first base pair where the miRNA interacts with the miRNA starting from ‘0’ 1000 bp upstream of the AUG start codon  
Predicted region = 5’UTR – 5’ Untranslated region, 3’UTR – 3’ Untranslated region, CDS – Protein coding sequence 
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5.4 – Screening of RNA Hybrid Predictions by Luciferase Assay  
From the sorted list of predicted targets, 3 were chosen that were all predicted to be targeted 
by the cellular miRNA gga-miR-133a-3p.  Two of these were contained within ICP4, a 
known essential immediate-early gene and one was within UL20, an ORF encoding for a 
membrane protein.  Some viral genes had more than one target for the same miRNA as was 
the case for ICP4.  
Long Oligonucleotide probes were ordered, annealed and cloned into the reporter plasmid 
Psi-Check-2 using restriction digest (see appendix 1 for vector maps).  Positive clones were 
screened using colony PCR as described and one positive clone was then subsequently 
picked, amplified and sequenced to confirm the presence of the cloned region containing the 
predicted miRNA target site (Data Not Shown).  Luciferase assays were then carried out as 
described in section 2.6.3.  Data shown in Figure -5.1 A, B & C show the combined results 
of two independent assays with n = 8 biological replicates and n = 24 technical replicates. 
Two targets, gga-ICP4-T2 and gga-UL20 showed no statistical difference when compared to 
an empty vector control in the presence of miR-133a-3p (Figure - 5.1 A & B).  However, 
they were statistically significant from the siRNA scramble control (p =<0.001).  In contrast, 
one target, gga-ICP4-T1 showed a statistically significant reduction in luciferase activity 
when compared to the empty vector control in the presence of gga-miR-133a-3p (p =<0.01).  
There was also a statistically significant difference (p =<0.001) between the siRNA scramble 
control and both the empty vector control and gga-ICP4-T1 plasmid.  Upon mutation of the 
seed sequence contained within the gga-ICP4-T1 plasmid, luciferase levels were restored to 
similar levels (no significant difference) as the empty vector control (Figure - 5.1 C).  
 
  





Figure - 5.1 – Relative luciferase expression levels of cloned gga-miR-133a-3p targets 
compared to a scrambled siRNA  
HEK293T cells were transfected with a Psi-Check-2 plasmid containing a ~110 bp region of 
ILTV genomic DNA harbouring the predicted gga-miR-133a-3p target sites; or with the miRNA 
site mutated.  After 48 hrs, Renilla luciferase levels were measured and normalised to firefly 
luciferase levels and expression in control and test miRNA compared.  Three constructs were 
tested; A – gga-ICP4-T2, B – gga-UL20 and C - gga-ICP4-T1. N = 8 Biological replicates and 
N = 24 technical repeats.  Error bars display standard error of the mean (SEM).   
*** = p<0.0001, ns = not significant  
C 
B A 
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5.5 – RT-PCR analysis of the 5’UTR of ICP4 
The miR-133a-3p target site starts 416 bp upstream of the predicted AUG codon and it was 
not clear if it would be incorporated into the mRNA transcript of ICP4.  Therefore a series of 
RT-PCRs (see section 2.2.7) were set up with a reverse primer positioned approximately 20 
bp downstream of the AUG codon and a panel of forward primers which were progressively 
further away from start codon.  RNA was extracted from LMH cells infected with ILTV and 
from this cDNA was synthesised using both Oligo (DT) primer and random primers as per 
section 2.2.5.  The resulting cDNA was used for amplification of the region alongside an 
uninfected control, -RTs, a viral DNA positive control and a no template control.  Initially, 
forward primers were designed to bind 1000, 450 and 100 bp upstream of the AUG start site.  
Both 1000 and 450 bp primer locations did not produce a band from cDNA synthesised with 
random primers of oligo DT primers (designated primer set 1 & 2 respectively) when 
analysed using agarose gel electrophoresis (Figure – 5.2 B & C).  However, the DNA 
positive control produced a band of the predicted size.  Conversely, primer set 3 (situated 
100 bp upstream) did produce bands in both random primed and oligo DT primed cDNA that 
were of the same size as the DNA positive control (Figure – 5.2 D).    
This prompted a closer inspection of the area surrounding the miRNA target site that 
identified a potential TATA box region upstream of the target site.  Due to this finding, a 
fourth primer was designed which was approximately 420 bp upstream of the ATG and 
encompassed some of the predicted binding site for the miRNA but crucially not the seed 
sequence. Upon analysis, a band was visualised in the random primed infected cDNA but not 
in the oligo DT primed cDNA.  The band visualised was at the same size as the DNA 
positive control (Figure – 5.2 E).   
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Figure - 5.2 – Detection of 5’UTR PCR products of ICP4 using RT-PCR 
Primers were designed at 1000, 450 and 100 bp upstream of the ATG start site with a 
universal reverse primer situated 50 bp downstream.  RNA was extracted from either ILTV 
infected cells or mock infected cells and DNase treated.  cDNA was synthesised using 
either random primers or Oligo dT.  PCRs were run in conjunction with minus reverse 
transcription (-RT) and viral DNA positive controls.  PCR products were visualised on 2 % 
agarose gel and imaged. Lightning bolt represents the predicted miR-133a target site, red 
arrows depict primer location and direction.  ‘Uni’ = universal reverse primer.    
A – Diagrammatic representation of the viral transcript showing approximate primer 
locations.  B – Primer set one.  C – Primer set two.  D – Primer set three.  E – Primer set 
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5.6 – The Effect of miR-133a on Virus Replication? 
 Virus infection studies were conducted to determine if the effects seen in the luciferase 
reporter assays translated into a more biologically relevant setting.  LMH cells were 
transfected with gga-miR-133a-3p, ILTV-miR-I6-5p or a siRNA scramble alongside a mock 
control.  After 12 hours transfection incubation, cells were infected with cell free virus 
(CSW-1) at an MOI of 0.1.  Samples were taken at 1, 4, 8, 12 and 24 hours post infection.  
Supernatant taken from wells was then used for conventional plaque assay analysis whilst 
cells were harvested and processed for RT-qPCR analysis of ICP4 transcript levels. 
5.6.1 – Levels of ICP4 mRNA transcript from virus grown in transfected cells 
Primers targeting the viral gene ICP4 were designed with the help of Dr. W Tan, The Roslin 
Institute as previously published primers for ICP4 (Mahmoudian et al., 2012) were found to 
amplify products in uninfected cells.  Extracted RNA was DNase treated and cDNA 
synthesised using random primers.  Synthesised cDNA was then analysed by qPCR to 
determine the relative levels of ICP4 transcript.  The 2ΔΔCt method of analysis [as outlined 
by (Livak and Schmittgen, 2001a)] was used to determine the relative fold change of ICP4 
transcripts compared to the house keeping gene chicken GAPDH.  In total, 3 biological 
replicates (N = 3).  Error bars display standard error of the mean (SEM).  Generally, apparent 
RNA levels of ICP4 were unaffected by the introduction of miR-133a compared to the other 
conditions across the whole experiment apart from at specific time points (data summarised 
in Table – 5.2.).  At 8 HPI, levels of ICP4 transcript were significantly higher compared to 
both siRNA scramble and ILTV-miRI6-5p (p = <0.05).  At subsequent time points, no 
significant difference could be seen between the three conditions however levels of ICP4 
mRNA at 24 HPI were apparently higher in miR-133a samples. 












































































Figure – 5.3.  Relative expression of ICP4 transcripts in differing conditions in a time-
dependent manner 
LMH cells were transfected with either a scrambled siRNA, ILTV-miR-I6-5p or gga-miR-133a-
3p alongside a mock control.  12 hours after, transfected cells were infected with live CSW-1 
ILTV at an MOI of 0.1.  Mock transfected cells were mock infected.  Cells were harvested at 1, 4, 
8, 12 and 24 HPI.  Extracted RNA was used for RT-qPCR analysis of ICP4 transcripts using the 
2ΔΔCT method with GAPDH used as control.  N = 3 biological replicates.  Error bars display 
standard error of the mean (SEM).  
P-values - * = <0.05, ** = <0.01, *** = <0.001  
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Table – 5.2. Relative expression of ICP4 transcripts in differing conditions in 









Post Hoc Tukey’s 
Grouping 
1 
Mock 0.00 0.00  A 
Scramble 0.01  0.01 A 
miR-I6-5p 0.00  0.00 A 
miR-133a 0.02  0.04 A 
4 
Mock 0.00  0.00 A 
Scramble 0.10  0.04 A 
miR-I6-5p 0.00  0.00 A 
miR-133a 0.03  0.03 A 
8 
Mock 0.02  0.01 A 
Scramble 0.24  0.05 A B 
miR-I6-5p 0.47  0.03   B 
miR-133a 0.72  0.09     C 
12 
Mock 0.02  0.01 A 
Scramble 2.94  0.22   B 
miR-I6-5p 3.90  1.00   B 
miR-133a 3.27  0.11   B 
24 
Mock 0.09  0.02 A 
Scramble 236.1  25.50 A B 
miR-I6-5p 278.1  86.01   B 
miR-133a 471  119.06   B 
Conditions that do not have the same letter are statistically significant from one 
and other. Experiment was carried out N = 3 Biological repeats  
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5.6.2 – Titres of ILTV following growth of virus in transfected cells 
Harvested supernatant was used for conventional plaque assays as described previously.  
Following fixing and staining, plaques were counted and the titre calculated (pfu/ml).  
Experiment was carried out in N = 7 biological repeats except for miR-133a which was N = 
6 due to one replicate unable to be counted.  Plaques were formed from supernatant 
harvested at 1 HPI and data analysis found there to be a significant difference between the 
scrambled siRNA and miR-133a (p =<0.05).  No significant difference could be determined 
between the scrambled siRNA or miR-I6-5p and miR-I6-5p and miR-133a (Figure – 5.5A).  
The reason for this production of plaques harvested from 1 HPI supernatant samples is 
unclear as virus replication will not have happened at 1 hour.  Both 4 and 8 HPI samples 
showed no statistical difference between the 3 conditions (Figure – 5.5B&C).  Similarly, in 
the 12 HPI there was no statistical evidence for difference between the 3 conditions however 
there was a trend towards lower virus titres in both I6-5p and miR-133a compared to the 
scrambled siRNA (Figure – 5.5D).  This trend continued at 24 HPI with even clearer 
difference in absolute pfu/ml.  Virus that was incubated in cells transfected with 133a 
showed a virus titre which was 66 % lower than that of the siRNA control or 42 % lower 
than that of I6-5p (Figure – 5.5E).  Furthermore, I6-5p showed a decreased viral titre 
compared to the siRNA control of around 25 %.  This was not statistically significant when 
tested using a one-way ANOVA combined with a post-hoc Tukey’s comparison test (Table – 
5.3E).  A summary of the viral titre including Post-Hoc statistical testing can be seen in 
Table 5.3.    
 
  
















Figure – 5.4.  Assessment of virus supernatant infectivity by plaque assay  
LMH cells were seeded out at 1x10
6 
cells per well and infected with supernatant harvested from 
transfected/infected cells.  Samples were left for 72 hours before been fixed by 10 % non-
buffered formalin (NBF) and stained with 0.1 % toluidine blue.  Plates shown here are 
representative of experiment.  Images with an asterisk are at 10
-2
 dilution whilst the rest are neat 
samples.   
* * * 















































Figure – 5.5.  Viral titres of ILTV incubated with a scrambled siRNA, ILTV-miR-I6-
5p or gga-miR-133a-3p 
Plaque plates as shown in Figure 5.4 were each individually counted.  From this, an 
average PFU/ml was calculated for each condition at every time point. N = 7 
biological repeats except for miR-133a which N = 6.  Error bars represent standard 
error of the mean (SEM).  
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Table – 5.3. Viral titres of ILTV incubated with a scrambled siRNA, ILTV-miR-I6-







Post Hoc Tukey’s 
Grouping 
1 
Mock 0 0.00 A 
Scramble 16 2.00   B 
miR-I6-5p 10.67 3.52   B C 
miR-133a 4.67 1.76     C 
4 
Mock 0 0.00 A 
Scramble 16 0.00   B 
miR-I6-5p 8.67 2.90 A B 
miR-133a 11.33 4.05   B 
8 
Mock 0 0.00 A 
Scramble 23.33 4.80 A B 
miR-I6-5p 17.33 5.81 A B 
miR-133a 30.67 9.33   B 
12 
Mock 0 0.00 A 
Scramble 40.67 9.95   B 
miR-I6-5p 30.67 5.20   B 
miR-133a 26 6.42 A B 
24 
Mock 0 0.00 A 
Scramble 6701 2573.50 A 
miR-I6-5p 5063 1880.26 A 
miR-133a 2217 1483.35 A 
Conditions that do not have the same latter are statistically significant from one and other.  
Experiment was carried out n=7*  
*133A at 24HPI was n=6 
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5.6.3 – Plaque size and morphology produced by ILTV harvested from transfected cells 
Plaque size was measured using Image J software.  A minimum of 10 plaques were counted 
per replicate per condition which were then combined to give an average plaque area per 
condition.  From this data set, statistical analysis was carried out using a one-way ANOVA 
with post-hoc Tukey’s comparisons test.  If ten plaques could not be counted per replicate, 
per condition, an n = 0 was put into the data set.  Times stated all refer to when the original 
virus was harvested (e.g. 1 HPI) and not how long plaque assays were incubated for.  For the 
1 HPI samples, not enough plaques could be counted for the miR-133a treated cells.  There 
was no significant difference between the siRNA scramble and miR-I6-5p however (Figure – 
5.6A).  No statistically significant difference was observed with the 4 HPI samples between 
the three conditions but there was a significant difference between all three conditions and 
the mock control (p =<0.001) (Figure – 5.6B).  For the 8 HPI samples however, a significant 
difference was observed between miR-133a and the siRNA control (p =<0.05) yet there was 
no difference between I6-5p and miR-133a (Figure – 5.6C).  At 12 HPI, the same pattern 
was observed with no difference between 133a and I6-5p but there was a significant 
difference between 133a and the siRNA scramble (p =<0.05) (Figure – 5.6D).  Analysis 
revealed a statistically significant reduction in plaque size (p =<0.001) with samples taken at 
24 HPI from 133a-transfected cells when compared to either I6-5p or the siRNA control 

















































































Figure – 5.6.  Average plaque area caused by ILTV after incubation with a scrambled 
siRNA, ILTV-miR-I6-5p or gga-miR-133a-3p 
Plaque assays were carried out as previously described.  Plates were scanned and 
images were then used to measure the plaque area of individual plaques using ImageJ 
software.  A minimum of 10 plaques was counted per plate per condition and replicate. 
Data comprises of two independent experiments with a total of n=7 biological 
replicates per condition (*n=6 for miR-133a at 24 HPI).  Average area was calculated 
from the combination of replicate plates for each condition.  A one-way ANOVA was 
used for analysis followed by a post-hoc Tukey’s test.  Error bars display the standard 
error of the mean (SEM). 
P-values - * = <0.05, ** = <0.01, *** = <0.001  














































Table – 5.4. Average plaque size caused by ILTV virus incubated in different 













Mock 0 0 0.00 A 
Scramble 21 53.43 5.31   B 
miR-I6-5p 13 47.00 7.52   B 
miR-133a 9 0 0.00 A 
4 
Mock 0 0 0.00 A 
Scramble 21 44.43 7.82   B 
miR-I6-5p 14 55.86 10.06   B 
miR-133a 16 55.44 8.20   B 
8 
Mock 0 0 0.00 A 
Scramble 34 93.94 7.10   B 
miR-I6-5p 19 81.36 8.43   B C 
miR-133a 46 67.26 5.44     C 
12 
Mock 0 0 0.00 A 
Scramble 33 56.36 4.07   B 
miR-I6-5p 29 48.86 5.13   B C 
miR-133a 29 37.00 2.73     C 
24 
Mock 0 0 0.00 A 
Scramble 297 59.28 2.00   B 
miR-I6-5p 305 53.02 1.25     C 
miR-133a 277 40.65 1.17       D 
Conditions within time points that do not have the same latter are statistically significant 
from one and other. 
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5.7 – Does miR-133a affect transcription or translation? 
Although a decrease in luciferase protein level was observed in the reporter assays, a 
concurrent decrease in ICP4 transcript levels was not measured in infected cells transfected 
with miR-133a.  The former was carried out using the plasmid Psi-Check 2 with the target 
sequence cloned into the 3’UTR multiple cloning site.  This is not the biological location of 
the target site and so moving the taget site to the 5’UTR mimics what is seen within ILTV.  
To investigate whether gga-miR-133a-3p affected the transcription or translation of ICP4.  
As there is currently no antibody available for ILTV ICP4 the full 5’UTR of ICP4 was 
cloned upstream of Firefly luciferase in the PGL3-Basic plasmid.  HEK293T cells were then 
transfected with this plasmid on its own (mock control) and then with the addition of either 
miR-133a or a scrambled siRNA.  After 48 hours, cells were harvested and RNA extracted.  
RT-qPCR was performed to determine relative levels of luciferase RNA transcript in the 
presence of miR-133a.  – RT samples were also run as internal controls to ensure only cDNA 
was investigated and not any residual DNA following RNA harvest (Data Not Shown). 
Relative RNA levels were normalised using the ΔΔCt method of analysis with GAPDH 
acting as an internal control (Livak and Schmittgen, 2001a).  Once relative expression levels 
were calculated, they were normalised to the mock control to give a relative expression level 
as a percentage (%).  A one-way ANOVA was performed on the ΔΔCt values, which also 
included a post-hoc Tukey’s test to look at the correlation between differing conditions. 
Data analysis revealed that there was a 55 % drop in relative RNA levels (%) compared to 
the mock control although this difference was not statistically significant (Figure – 5.7).  
Furthermore, the presence of a scrambled siRNA caused an 85 % drop in relative RNA 
levels compared to the mock control and a 30 % reduction compared to miR-133a although 
these differences were not statistically significant (Figure – 5.7). 
  





Figure – 5.7. Relative RNA levels (%) of a reporter plasmid containing a miR-133a-3p target 
sequence in the presence of miR-133a miRNA mimic or a scrambled siRNA control when 
compared to GAPDH 
A reporter plasmid containing the miR-133a-3p target sequence in the 5’UTR was cloned using 
PGL3b vector.  HEK293T cells were transfected with the plasmid on its own (mock) or with a 
mature miR-133a mimic or siRNA scramble control or were transfected on their own.  After 48 
hours, RNA was harvested and used for RT-qPCR to look at expression levels of luciferase.  The 
2ΔΔCT method of analysis was used with GAPDH as a control.  Error bars display standard error 
of the mean (SEM).  N = 7 (biological replicates)         
Chapter 5   Cellular miRNAs and ILTV 
157 
 
5.8 – miR-133a and the Interferon response pathway 
With an apparent reduction in virus titre and a statistically significant reduction in plaque 
size, it was not clear if this was due to a direct effect upon the virus or an indirect effect by 
carry over of any mimic induced interferon components that could initiate an antiviral 
response.  To test this, LMH cells transfected with either mimics or a scramble siRNA.  12 
hours post transfection, media was replaced with fresh complete media containing 2 % FBS 
and samples were left for a further 12 hours.  Concurrently, DF-1 cells in 12 well plates were 
transfected with a luciferase reporter plasmid driven by the ISG mX promoter (A kind gift 
from Prof Steve Goodbourn, St George’s, University of London) alongside an SV40 driven 
firefly luciferase as an internal control.  24 hours post transfection of the reporter plasmids, 
media was transferred from the LMH cells onto the DF-1 cells and left for a period of 24 
hours.  Samples were then harvested and luciferase assays carried out as previously 
described.  Data shown in Figure – 5.8 is the combined results of two independent assays 
with n = 4.  Data was at first normalised to the internal control to give a fold change level.  
This was then compared to the mock control as a percentage fold change.  Errors indicate the 
standard error of the mean (SEM).  Statistical analysis using a one-way ANOVA was carried 
out on the luciferase levels after normalisation to the internal control and any p values stated 
derive from this data.   
Data analysis showed that recombinant chicken interferon α/β protein was able to elicit a 50-
fold increase in luciferase expression when compared to the mock media control.  This was 
statistically significant from the mock control and all other conditions (p =<0.001).  A 
second control, Poly I:C was added directly into the media of transfected DF-1 cells and 
resulted in a 5-fold increase in luciferase activity compared to the mock control.  However, 
this was only statistically significant from recombinant chicken α/β protein (p =<0.001) and 
no significant difference was observed between Poly I:C and any of the other conditions.  
Analysis of the control siRNA scramble showed no difference in luciferase activity from the 
mock condition which was also not statistically significant.  In contrast, both gga-miR-133a-
3p and ILTV-miR-I6-5p showed decreased luciferase expression of ~73 % and 65 % 
compared to the mock.  Whilst luciferase expression (%) was lower, no significant difference 
was found upon statistical analysis.  Similarly, transfer of LMH mock media onto transfected 
cells and the introduction of a recombinant mouse IFN γ protein showed a reduction in 
luciferase expression compared to the mock, this was also found not to be statistically 
significant.       
 




Figure – 5.8.  The response of mX promoter, an IFN α/β immune stimulated gene (ISG) to 
transfection of miR-133a-3p 
LMH cells were transfected with a scrambled siRNA, ILTV-I6-5p or gga-miR-133a-3p and left for 12 
hours.  Media was then replaced on the cells, which were incubated for a further 24 hours.  DF-1 cells 
were transfected with a luciferase reporter plasmid driven by mX promoter.  Transfection media was left 
on for 24 hours and then replaced with media harvested from transfected LMH cells.  In addition to this, 
poly I:C, recombinant chicken IFN α/β protein or recombinant mouse IFN γ was added directly to DF-1 
media.  After 24 hours incubation, cell lysate was harvested for a luciferase reporter assay.  Renilla 
luciferase was measured against Firefly luciferase for normalization.  Data was then compared to the 
mock control to give an average fold change percentage (%).  Error bars represent the standard error of 
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5.9 – miR-133a-3p Expression in the Chicken and its relevance to ILTV 
5.9.1 – Confirming the sequence of miR-133a-3p in chickens  
To attempt to detect gga-miR-133a-3p in the chicken and confirm the sequence was the same 
as in other species, muscle tissue (breast and thigh) from two six week old Hyline birds was 
taken and RNA was extracted using the miRNeasy Kit (Qiagen).  RNA was then DNase 
treated and the MiScript II kit (Qiagen) was used for reverse transcription of RNA.  
Detection of mature miRNA sequences was then carried out using the MiScript SYBR green 
PCR kit (Qiagen).  Due to the nature of the reverse transcription using polyadenylation and a 
oligo-dT primer with a 3’ universal tag, DNA should not be detected and so minus reverse 
transcription (-RTs) controls were not necessary (as per section 3.4, Figure - 3.3).   
Resulting qPCR products were run on a 3 % agarose gel for visualisation.  According to the 
Qiagen MiScript PCR system handbook, mature miRNA sequences should produce a PCR 
product size of 85-87 bp. 
Breast and thigh muscle were tested using this method as muscle tissue has been shown to 
highly express miR-133a-3p in other species.  All three breast muscle samples and two out 
of three thigh muscle samples produced bands of between 50 and 100 bp, which fits with the 
expected product size.  In addition, two positive controls were included with cDNA 
synthesised from the mature miRNA mimic.  These also produced a similar product size of 
between 50 and 100 bp when visualised on a gel (Figure – 5.9A).  Following gel analysis, 
bands visualised were extracted, cloned and sent for sequencing.  Using this method, the 












+  +  NTC  Ladder 
Figure – 5.9. Detection of gga-miR-133a-3p in Chickens 
Samples of chicken tissue were taken from birds (1-3) and placed in RNA later prior to RNA 
extraction using the miRNeasy extraction kit (Qiagen).  cDNA was synthesised using the 
MiScript II kit before detection of gga-miR-133a-3p was carried out using the MiScript SYBR 
green kit (both Qiagen).  qPCR products were visualised on a 3 % agarose gel.  Bands detected 
were then cut out, DNA extracted and the product TOPO cloned for sequencing.  A – 
Detection of miR-133a-3p in muscle tissue. 
1  2  3  1  2  3  
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5.9.2 – Detection of ILTV genomic DNA in Dorsal Root Ganglia 
Chickens in the UK are vaccinated against ILTV using live-attenuated strains and so the 
virus is still able to set up a latent infection in the birds.  To investigate the distribution of 
latent ILTV DNA, 2x 8-month laying birds were obtained from the breeding stock at the 
National Avian research Facility (NARF) when surplus to requirements.  Spinal cord (SpC) 
and Dorsal Root Ganglia (DRG) were harvested.  From these tissues, DNA was extracted 
and used in a conventional PCR for ILTV genomic DNA (gDNA) and the cellular gene 
GAPDH. 
PCR products were analysed on a 2 % agarose gel and imaged.  Bands were visualised at 
approximately ~350 bp for ILTV gDNA and ~550 bp for GAPDH.  ILTV genomic DNA 
could detected in the DRG in one of the birds and not the other (Figure – 5.9A).  DNA could 
not be detected in either SpC sample.  GAPDH could be detected in both DRG samples but 
not in the spinal cord (Figure – 5.9B). 
 
  
























Figure – 5.10. Detection of ILTV DNA in the Dorsal Root Ganglia (DRG) of Vaccinated 
Chickens 
Tissue samples were taken from 2x 8-month old laying hen’s surplus to requirements at the 
National Avian Research Facility (NARF).  DRG and Spinal Cord (SpC) were harvested and from 
this DNA was extracted as per section 2.2.1.  DNA was used for conventional PCR with primers 
for ILTV genomic DNA (gDNA) (A) and GAPDH (B) along with appropriate controls. 
B1: Bird 1; B2: Bird 2  
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5.9.3 – Detection of miR-133a in tissues relevant to ILTV biology 
Once it was established that ILTV DNA could be detected in DRG, the expression of miR-
133a was investigated. To look at tissues of relevance to the biology of ILTV, 3x 18-month 
laying birds were obtained from the breeding stock at NARF when surplus to the facilities 
requirements.  Tissues harvested in the first instance were dorsal root ganglia (DRG) and 
Harderian gland (HG) alongside tissue samples taken from breast muscle (BM) of the birds.  
Samples were processed in the same manner as described previously and cDNA synthesised 
using the MiScript II RT Kit.  Upon analysis of the qPCR products using gel electrophoresis, 
bands were visualised at around 100 bp which fits with the predicted mature miRNA product 
size (Figure – 5.9B).  Bands were excised and TOPO cloned before been prepared and sent 
for sequencing.  Sequencing confirmed the presence of the mature miRNA gga-miR-133a-3p 
in the DRG, HG and BM in addition to the positive control.       
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Figure – 5.11. Detection of gga-miR-133a-3p in DRG, Harderian gland and Breast 
Muscle 
Samples of chicken tissue were taken from birds (1-3) and placed in RNA later prior to RNA 
extraction using the miRNeasy extraction kit (Qiagen).  cDNA was synthesised using the 
MiScript II kit before detection of gga-miR-133a-3p was carried out using the MiScript SYBR 
green kit (both Qiagen).  qPCR products were visualised on a 3 % agarose gel.  Bands detected 
were then cut out, DNA extracted and the product TOPO cloned for sequencing.   
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5.10 – Discussion 
Interactions between high confidence chicken miRNAs and viral transcripts were predicted 
using RNA Hybrid.  The data set was compiled from 79 viral transcripts and 54 mature 
miRNA sequences taken from MiRBase Release 21 (June, 2014).  In total, 103 miRNA 
target predictions were made using RNA Hybrid.  From these predictions, three targets were 
taken forward, cloned into a reporter plasmid and tested biochemically.  This led to the 
identification of one target showing a statistically significant decrease in luciferase 
expression when compared to the empty vector and siRNA scramble control.  Following on 
from this, the target site for gga-miR-133a-3p was shown to be contained within the 5’UTR 
of the expressed mRNA of ICP4.  Virus incubated in the presence of a mature miRNA 
mimic and subsequently used for conventional plaque assay analysis was shown to have 
defective growth morphology both in terms of resulting virus titre and plaque diameter.  
Whilst the viral load showed a large decrease between 133a and both I6-5p and siRNA 
scramble, this was not statistically significant when tested using a one-way ANOVA.  Plaque 
size diameter was however determined to be statistically significant (p =<0.001) between 
133a and both I6-5p and siRNA scramble.  Investigations in this study could not attribute 
this reduction to the IFN response triggered by the transfection of either mimic or control 
and this was shown to not be significantly different from mock cells whereas the 
introduction of recombinant chicken interferon α/β protein caused a statistically significant 
increase in MX promoter driven luciferase expression (p =<0.001).  The potential biological 
relevance of this interaction was then investigated by determining the tissue expression of 
the miRNA using a select panel of tissues.  First, using muscle tissue, the sequence of the 
mature miRNA was confirmed to be what is predicted in MiRBase.  Leading from this, 
tissues of potential biological relevance i.e. Dorsal root ganglia (DRG) and Harderian gland 
(HD) alongside a breast muscle tissue sample (BM) were selected and tested.  Results from 
this confirmed the presence of gga-miR-133a-3p within the DRG and HD; both sites 
important with regards to virus biology.  
The miR-133a family was first described in 2002 by cloning tissue specific 21 nt small 
RNAs from a panel of mouse tissues (Lagos-Quintana et al., 2002).  MiR-133, as it was then 
called, was first identified in heart muscle and the cortex of the mouse brain.  Naturally as 
technology has progressed, the identification of miRNAs by sequencing became the gold 
standard approach alongside other approaches such as in situ hybridisation.  Several separate 
studies identifying chicken miRNAs followed giving some insight into what miRNAs were 
expressed in the developing bird (Darnell et al., 2006, Xu et al., 2006, Glazov et al., 2008).  
More recently, miR-133a has been identified in a wide range of species ranging from the 
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common fruit fly (Drosophila melanogaster) through to painted turtles (Chrysemys picta).  A 
simple search of MiRBase for ‘133a’ reveals a total of 75 miRNAs across the animal 
kingdom highlighting the conservation of the miRNA.  Whilst the sequence of miR-133a 
was reported in the chicken, this was a predicted sequence and the results presented here are 
the first to confirm the sequence as the same as predicted in MiRBase.    
First reports of miR-133a specific targets were published around a decade ago.  Yin et al. 
(2008) reported the in vivo targeting of Mps1 kinase in Zebrafish (Danio rerio).  Artificial 
expression of miR-133a caused the abrogation of fin regeneration and conversely, 
antagonism of miR-133a accelerated tissue regeneration.  In the same year, Ivey et al. (2008) 
showed that miR-133a along with miR-1 were potent repressors of non-muscle genes during 
the regulation of cell linages from human and mouse embryonic stem cells.  Depending on 
the algorithms used, miR-133a is found to target 441 – 497 gene transcripts in the human 
genome (https://www.exiqon.com and http://www.targetscan.org, both accessed 20th May, 
2018).  To date, approximately 43 protein-coding genes have some experimental data in the 
literature to show that they are targeted by miR-133a-3p 
(http://mirtarbase.mbc.nctu.edu.tw/php/index.php).  Whilst these predictions were made 
based on human data and the confirmed targets are also based on humans, one can argue that 
the same targets are seen in the chicken if the gene homolog is encoded for in the bird.  
Incidences of miR-133a targeting viruses either directly or indirectly are more recent.  
Aujeszky’s disease is a highly important disease of the domestic pig (Sus scrofa domesticus).  
The aetiological agent is Suid Herpesvirus 1 (SuHV-1, pseudorabies virus) (Fenner et al., 
2011).  A study investigating the role of viral and host miRNAs during in vivo infection 
identified miR-133a as a differentially expressed miRNA following infection with a virulent 
strain of SuHV-1.  MiR-133a was up regulated 108 fold compared to the attenuated strain 
infected group.  Further analysis using gene interaction networks predicted a total of 33 viral 
gene interactions between SuHV-1 and miR-133a which included the regulatory genes; EP0, 
IE180, UL41 and UL48 (Timoneda et al., 2014).  IE180 of SuHV-1 is the homolog of ICP4, 
the major immediate-early gene identified in this study as a target of the miR-133a in the 
chicken.  Timoneda and colleagues suggested that miR-133a may play an active role in 
combating viral infection and they go on to state the importance of miR-133a due to its 
potential interaction with many structural and non-structural genes within SuHV-1.  In this 
study, the focus was primarily on the role of miR-133a and its regulation of ICP4 however in 
the initial bioinformatics screen, several other genes were identified as potential targets of 
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miR-133a in the ILTV genome and these included; UL48, UL36, UL20 and UL19 (a full list 
can be seen Appendix 7).   
A total of 12 viral targets were identified in this study, which whilst lower than that of the 
SuHv-1 study, suggests an important role for miR-133a in the infection process.  Two targets 
within ICP4 were tested in addition to the predicted target of UL20 and only one showed a 
statistically significant reduction (p =<0.001) in luciferase activity when compared to the 
siRNA scramble control and empty vector control.  The effect of this interaction was then 
abrogated upon mutation of the miRNA seed sequence.  First, it was shown that the miRNA 
target site is within the expressed mRNA of the ICP4 gene transcript.  Unusually, the target 
site was contained within the 5’UTR, whereas the vast majority of miRNA targets sites are 
found within the 3’UTR (Lewis et al., 2005).  Whilst uncommon, it has been reported that 
targeting of the 5’UTR is as efficient as targets contained within the 3’UTR (Lytle et al., 
2007).  Interestingly, miR-133a sites are found within ICP4 homologs of several other 
Alphaherpesvirinae family members including; Bovine Herpesvirus 1 (BoHV-1), Equine 
Herpesvirus 1 (EqHV-1) and HSV-1 (Appendix 8).  Equally, all of the species’ listed encode 
for a miR-133a homolog and the sequence is highly conserved (Appendix 8).  Whilst it was 
out of the remit of this project to investigate the function of miRNAs in other species’ and 
other viruses, the identification of the same target site within the same gene for each raises 
the possibility that this interaction is conserved and may play a role in virus-host 
interactions.      
Once the target was confirmed to be within the 5’UTR of the ICP4 mRNA transcript, the 
effect of miR-133a expression on virus infection was investigated.  Firstly, a time course of 
infection was set up to investigate the relative expression levels of ICP4 in the presence of 
miR-133a.  For this, two controls were used, one was a scrambled siRNA and the second, 
ILTV-miR-I6-5p, a miRNA shown previously to target ICP4 (Waidner et al., 2011).  
Relative RNA levels of ICP4 at both 8 and 24 HPI were significantly higher than that of the 
scrambled siRNA suggesting possibly that miR-133a was stabilising ICP4 RNA levels.  This 
is in contrast to the translational data shown in Figure – 5.1C that show a knockdown of 
luciferase protein suggesting that translation is affected.  Jopling et al. (2008) showed that 
the position of the miRNA target site has differing consequences.  Positioning of miR-122 
target sites within the 5’UTR of Hepatitis C virus causes an increase in viral RNA abundance 
whereas locating the miRNA site in the 3’UTR of a reporter mRNA resulted in a down 
regulation of mRNA expression suggesting binding site locations can affect gene regulation.  
Data presented in this thesis suggests that mRNA levels are indeed higher when the target 
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site of miR-133a in situated in the 5’UTR of ICP4 in both a reporter assay setting and also in 
the context of live virus (Figures – 5.7 and 5.3 respectively).   
It was hypothesised that by affecting ICP4 expression, miR-133a may help to block 
reactivation of virus from latency.  This is difficult to model in a tissue culture system and 
there is currently not a latency model available for ILTV and so this is something that could 
potentially be followed up on if the reagents and systems become available.  As there is 
currently no latency model of infection for ILTV, including reactivation models, the role of 
this interaction in latency was difficult to establish, however investigations focused on its 
possible involvement during latency.  As reviewed in Chapter 1, latency of ILTV is 
established within the DRG of the bird, similar to that of other Alphaherpesvirinae family 
members.  Furthermore, we know through previous studies that miRNAs have the ability to 
influence and maintain latency.  A study carried out by Pan et al. (2014), showed that miR-
138, a neuronal specific miRNA, was able to target ICP0 of HSV-1.  The study showed 
mutant viruses with disrupted miR-138 target sites exhibited increased expression of ICP0 
and other lytic proteins in neuronal cells.  Moreover, in vivo, mice infected with viruses 
containing the disrupted miR-138 sites displayed increased mortality and encephalitis 
symptoms alongside increased ICP0 and lytic gene transcripts within the DRG.  To 
determine whether miR-133a could potentially play a role in latency, two approaches were 
taken.  Firstly, what were the effects of the miRNA on the virus if the former was 
overexpressed in a permissive cell line and secondly, what is the biological relevance of this 
interaction.  The former focused upon what the effects of miR-133a were on virus 
replication.  The study found that virus harvested from cells transfected with miR-133a had a 
titre 66 % lower than that of virus grown in cells transfected with a siRNA scramble control.  
The siRNA control was used as a ‘mock’ in the sense that transfection can have an effect 
upon the cells and in addition, the transfection efficiency is not 100 % and so a virus only 
control would not have been an effective control.  Similarly, miR-133a transfected cells 
produced 42 % less virus than cells transfected with the virally encoded ILTV-miR-I6-5p.  In 
addition to the reduced viral titre, a statistically significant difference in plaque size diameter 
was observed at 8, 12 and 24 HPI between miR-133a and the siRNA control (p =<0.05).  
There was no significant difference between miR-133a plaque size and I6-5p at 8 and 12 HPI 
however at 24 HPI there was a statistically significant difference (p =<0.001).  This 
suggested that the effect miR-133a was having was greater than that of I6-5p, which is 
encoded antisense to ICP4. 
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One possible reason for this reduction in virus titre and plaque size area is the interferon 
response.  This pathway is triggered upon detection of invading viral DNA and initiates a 
signalling cascade to mount an antiviral response.  Included in this response is the interferon 
pathway that has the ability to prime neighbouring cells through secreted proteins and switch 
on the same anti-viral pathways (Perry et al., 2005).  As supernatant was used for plaque 
assay analysis of virus titre and subsequent plaque size area, it is feasible that if treatment 
with the dsRNA mimics induced a type I interferon response (IFN α/β) then IFN α/β present 
in the virus supernatants could induce an antiviral response in the plaque assay cultures.  To 
examine this possibility, a reporter plasmid driven by MX promoter, an IFN α/β induced 
gene was used.  In the presence of miR-133a, MX promoter levels were not 
induced/increased and there was no significant difference between miR-133a and the mock 
control.  This suggested that IFN was not directly responsible for the reduction in titre or 
plaque size.  
In this study ICP4 has been confirmed to be a target of miR-133a leading to a decrease in 
protein levels in a luciferase reporter system.  Another possible theory is that ICP4 is 
incorporated into the ILTV virion and the effects of miR-133a result in a decrease in copy 
number of this potential virion associated ICP4.  The composition of ILTV virions has not 
been reported in the literature but from looking at related viruses contained within the 
Alphaherpesvirinae family, we can infer what maybe contained within the particle.  Studies 
examining the virion composition of HSV-1 determined that ICP4 is contained within the 
particle and is strongly associated with the capsid of the virion (Loret et al., 2008, Loret and 
Lippe, 2012).  Likewise, ICP4 homologs have been found in other Alphaherpesvirus virions 
such as BoHV-1 (Barber et al., 2017).  It is therefore feasible to postulate that ICP4 is 
incorporated into the virion of ILTV and a reduced copy number is the cause of the 
decreased viral tires and small plaque size.  Due to the nature of ICP4 and its role in 
activating the lytic replication cascade, a reduced copy number contained within a particle 
may result in reduced fitness and thus a delay in initiation of the lytic replication cascade 
resulting in the smaller plaque size phenotype that is observed. 
As well as targeting ICP4, miR-133a has a further 8 predicted targets within ORFs of ILTV 
(laid out in Appendix – 6).  Included in the list are membrane proteins (UL43 and UL20), the 
large tegument protein (UL36) and also the major capsid protein encoded for by UL19 (Full 
list can be found in Appendix 6 of this thesis).  Manipulation of UL36 alone could have an 
effect upon virus replication and egress.  Studies elucidating the role of UL36 in HSV-1 
found that replication was affected when UL36 was deleted from the virus (Desai, 2000).  
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Likewise, work investigating UL31 HSV-1 mutants observed defective replication kinetics 
(Chang et al., 1997).  Taken together, it would be of interest to follow up on these potential 
targets which was not carried out during this study.  If any are found to be affected by miR-
133a, it may help to explain the phenotypes observed.         
Another explanation to this is the targeting of cellular genes that are required for lytic gene 
expression.  As previously stated, there are ~450 genes predicted to be targeted by miR-133a 
within the human genome and one can speculate that a similar number may be targeted in the 
chicken.   Viruses are obligate intracellular parasites that rely heavily upon the host cell to 
provide essential tools for efficient replication and a reduction of a required protein/pathway 
will inevitably have an effect on virus replication.  Interactions between cellular mRNAs and 
miR-133a would possibly have been identified using the CLASH procedure but this was not 
feasible due to the reasoning already outlined in chapter 3.  As stated, until a suitable cell 
line that is permissive to ILTV infection and replication is either identified or made using 
laboratory methods of cell line immortalisation, this follow up work is technically 
challenging.   
The last part of this study was to begin to investigate the biological relevance of the 
interaction identified.  Many miRNAs families are conserved between species’ allowing for 
the identification of miRNAs in livestock animals that have already been described in other 
animals (Shi et al., 2012).  Chicken embryos have been used for several years as a model for 
vertebrate developmental biology due the speed at which they develop alongside the well-
defined developmental process (Brown et al., 2003, Hamburger and Hamilton, 1992).  This 
has allowed for ‘gene-hunters’ to identify a large number of cellular miRNAs within the 
bird.  Currently, for the chicken, there are 1238 mature miRNA sequences from 904 
precursors according to miRBase (release 22, March 2018).  This compares with human, 
(2693 mature sequences from 1982 precursors), mouse (2013 mature miRNAs from 1303 
precursors) and rat (769 mature miRNAs from 510 precursors).  With the exception of rat, it 
suggests that there are many more miRNAs to be identified within chicken that may impact 
on all aspects of biology.  With the existing data set, it was suggested that miR-133a was in 
fact a miRNA restricted to muscle tissue however it has been shown to target neuronal 
polypyrimidine-tract binding protein (nPTB) which is expressed predominantly in neurons 
and testes (Boutz et al., 2007).  
To examine the expression of miR-133a, confirmation of the mature miRNA sequence was 
carried out by using muscle tissue that is known to express it at high levels (Ouyang et al., 
2015).  Using the commercially available MiScript II RT Kit (Qiagen) and sequencing, the 
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mature sequence was confirmed to be the same as predicted in MiRBase.  Following on from 
this, two tissues of biological relevance were tested, the DRG and Harderian gland.  The 
same method was applied and found that miR-133a was present in DRG, Harderian gland 
and Breast muscle tissue.  The latter of these is not of biological relevance and was used 
primarily as a control for the experiment.  As discussed earlier, DRG is the site of latency for 
ILTV and so the identification of miR-133a in this tissue has implications on latency and 
reactivation.  It is possible that the miRNA helps to maintain viral gene expression below the 
reactivation threshold thus helping to maintain latency.  This could be through targeting of 
just ICP4 or a combination of viral targets in addition to the possible targeting of cellular 
genes that help facilitate the reactivation of ILTV from latency.   
Furthermore, the identification of miR-133a in Harderian gland is also novel.  As reviewed 
in Chapter 1 of this thesis, the Harderian gland is a secondary lymphoid organ (SLO) of the 
avian immune system and is classed as the conjunctival associated lymphoid tissue (CALT) 
(Swayne et al., 2013).  As this monitors the orbital region of the eye and the upper 
respiratory tract of the bird, it implicates miR-133a as potentially been involved with lytic 
replication also as virus can be found in these areas. 
Whilst the study of the biological relevance identified miR-133a in tissues where virus is 
harboured, this study used birds that were 18 months old and so there is no temporal study to 
see if the miRNA is found in birds of different ages in addition to different breeds and 
gender.  It has been suggested to be a possible marker for the onset of puberty in birds, 
whereby the levels of miR-133a in serum drop significantly at the onset of puberty (Han et 
al., 2016) suggesting it is found in younger birds at high levels also.  Further work would 
ideally look at birds at different ages and more relevant to the poultry industry ages of birds.          
Overall, this part of the project has characterised the interaction between the 5’UTR of ICP4 
in ILTV and the endogenous miRNA gga-miR-133a-3p.  It has shown that virus incubated in 
the presence of miR-133a has a reduced virus titre and a smaller plaque size area, which is 
not due to the involvement of the interferon system.  The sequence of the mature miR-133a 
as predicted in MiRBase was also confirmed by sequencing.  This was found to be in tissues 
of biological relevance to the virus, primarily the dorsal root ganglia and Harderian gland.  
The findings were looked at from a latency perspective in relation to the DRG but 
identifying this miRNA within Harderian gland opens up the possibility that it is expressed 
in other tissues relevant to the virus biology during lytic replicaiton.  13 targets of miR-133a 
were predicted in this study and a total of 3 were tested leaving a possible 10 other targets to 
be looked at.  Some of the other predicted targets already defined roles in the virus 
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replication cycle as well as in addition to been antagonists of the host innate immunity.  The 
likelihood is that as more miRNAs in both animals and viruses are found and characterised, 
more interactions between miRNAs and target mRNAs will be identified thus expanding the 
field that is very much in its infancy still. 
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6.1 – Introduction 
Genome editing is a powerful tool that will shape the future of biomedical research in the 
following years and decades.  A relatively recent advancement, it allows for precise 
alterations to DNA using a number of methods outlined in Chapter One of this thesis.  
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome editing is the 
most recent of the approaches used and relies upon a cas9 nuclease protein guided by a small 
RNA, termed guide RNA (sgRNA) to direct the protein to a specific sequence through 
Watson-Crick base pair complementarity with target DNA (Ran et al., 2013).  Several repair 
mechanisms  can be employed as laid out in Figure 1.8 of Chapter One, however Homology 
directed repair (HDR) allows for precise changes to be made to DNA through the use of 
templates that have flanking sequences identical to the sequence you are wishing to change 
with the desired alterations incorporated into the template (Byrne et al., 2015). 
Mutations within large DNA viruses are infrequent, with the error rate calculated to be 
somewhere between 10-8 and 10-11 errors per incorporated nucleotide, giving rise to a 
mutation possibly once in several hundred to some thousands of genome copies 
(Fleischmann, 1996).  With this in mind, the application of homologous recombination has 
sought to speed up the process of mutations in herpesviruses with the classical approach 
using a repair template containing the desired changes, for example a deleted gene replaced 
with a fluorescent marker to aid in the selection process.  Numerous studies have used this 
approach as a means of producing gene-deletant viruses for characterisation of gene function 
and role in the virus lifecycle (Fuchs et al., 2003, Veits et al., 2003a, Devlin et al., 2007, 
Pavlova et al., 2010).  Whilst these approaches were, and are still, widely used, the number 
of recombination events resulting in the generation of a virus with the desired changes is 
low, estimated at less than 10 % of the overall virus population (Ryan and Shankly, 1996).   
Inducing double stranded breaks (DSBs) into DNA however can greatly improve the 
efficiency of targeted homologous recombination to around 75 %.  Studies carried out using 
SuHV-1 as a model genome showed that DSBs caused by a unique restriction enzyme site 
found within the genome could vastly improve targeted recombination (Ryan and Shankly, 
1996).  However, this approach relies upon a restriction enzyme site in the target area which 
limits its’ potential whereas CRISPR-Cas9 overcomes this limitation. 
Other methodologies have also been deployed such as the use of Bacterial Artificial 
Chromosomes (BACs) whereby the viral genome is cloned and the DNA construct becomes 
the artificial chromosome.  This approach was first shown using murine cytomegalovirus 
(MCMV) and since then several other herpesviruses have also had BACs created for them 
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(Messerle et al., 1997).  In contrast though, some herpesviruses including ILTV have not had 
BACs created due to several palindromic repeats which cause significant problems and result 
in unwanted mutations to the viral genome.  This therefore warrants a different approach 
which negates these issues.    
The first studies which combined genome editing using CRISPR-Cas9 and virology were 
carried out within the last decade.  Ebina et al. (2013) showed a loss in LTR driven 
expression of HIV-1 genes following stimulation when sgRNAs were designed to target the 
LTR.  Work on large double stranded DNA viruses that do not integrate into the host 
genome soon followed with work carried out in both adenovirus and HSV-1 (Bi et al., 2014).  
The findings of this paper suggested that the application of CRISPR-Cas9 increased 
efficiency of recombination to around 8 % in HSV-1.   
Since these first studies were carried out efficient genome editing using CRISPR-Cas9 has 
been shown in a number of different herpesviruses spanning the subfamilies and includes 
EBV, HCMV and HSV-1 in addition to several other members of these subfamilies (Russell 
et al., 2015, Yuen et al., 2015, van Diemen et al., 2016).  The future research in virology will 
almost certainly be shaped by the use of genome editing (Chen et al., 2018, Wang et al., 
2018).             
6.2 – Aims 
The aims of this part of the project were to explore the feasibility of using genome-editing 
technology to delete a cluster of five miRNAs from the viral genome.  This region was 
targeted as there are 5 miRNAs in a compact area (~1200 nt) and there is only a single copy 
of each miRNA.  To carry this out, sgRNAs targeting the region of interest were designed 
and tested alongside the creation of homology repair templates containing a fluorescent 
reporter to aid in the selection of any edited virus particles.  Cells were transfected and then 
infected with virus to induce double-stranded DNA breaks in the hope that upon DNA repair, 
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6.3 – Selection of sgRNAs to target the ILTV genome 
6.3.1 – Design of sgRNAs around the miRNA cluster 
In the first instance, sgRNAs were designed using the online CRISPR Design program 
(http://crispr.mit.edu).  These focused upon the right hand side of the last miRNA 
approximately ~1780 - 1800 bp from the left hand end of the viral genome following 
conversations with Dr. S. Lillico (The Roslin Institute).  In total, three sgRNAs were selected 
and taken forward.  A schematic diagram of the miRNA cluster and wider viral genome is 
shown in Figure - 6.1.  The program was set to have minimum off target effects in the human 
(default) due to the limitations of the free software not including the chicken genome.  Other 
online software programs were sought but the same limitation was seen.  Chosen sgRNAs 
are shown in Table 6.1 and highlighted in yellow.     
In addition, sgRNAs were also designed in collaboration with Dr W.S. Tan (The Roslin 
Institute, University of Edinburgh).  Here, a custom Python script (written by Dr Tan, 
unpublished) was used to scan the ILTV genome in the designated areas (512 – 514 nts for 
the left hand side of the cluster and 1741 – 1818 nts on the right hand side of the miRNA 
cluster) with the following criteria. 1) Potential sgRNAs must be followed by a PAM (NGG) 
motif, 2) They do not contain tetramers or above (e.g. AAA, TTT), 3) They do not contain 
any Bbs1 sites and 4) They have a GC content between 20 and 80 % inclusive.    Two areas 
of the ILTV genome flanking the miRNA cluster were chosen for sgRNA design.  Once a 
list of sgRNAs was compiled, the efficiency of the sgRNAs in directing cleavage of the 
DNA was tested using Azimuth 2.0 (Doench et al., 2016).  Once the efficiency was 
estimated, sgRNAs were ranked high to low.  A second package called Cas-OFFinder 
(http://www.rgenome.net/cas-offinder/) was then used to scan the sgRNAs for any potential 
off targeting within the ILTV genome (but not the chicken genome) with a maximum of 5 
mismatches allowed within the sgRNA sequence to the genome (Bae et al., 2014).  Another 
package called CFD was then used to estimate the efficiency of these off target sites with the 
lowest off target sgRNAs ranked the highest in this list.  Finally, from the two rankings, a list 
of sgRNAs for the left hand side of the miRNA cluster (designated the miRNA 5’, Table – 
6.2) and also the right hand side of the cluster (designated the miRNA 3’, Table – 6.1).  
From this list, the top two sgRNAs for the left and right hand side were taken forward into 
the study.  
Two methods of sgRNA were used to maximise the likelihood of designing sgRNAs that 
were efficient at directing cleavage of the DNA.  sgRNAs designed using the online program 
used the human genome as a threshold for off-targeting limiting the number of sgRNAs that 
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could direct cleavage in the viral genome.  In contrast, the sgRNAs designed in collaboration 
with Dr W.S. Tan used the viral genome as a threshold for off-targeting disregarding the 
chicken genome.   
Chosen sgRNAs were then ordered as sense/antisense primer sets with the inclusion of a 
Bbs1 endonuclease restriction site to allow for cloning.  Primers were annealed together and 
subsequently cloned into the Cas9 plasmid Px458 using Bbs1 endonuclease sites (Primers 
listed in Appendix 2 and Vector map in Appendix 1).  Clones were selected and sent for 
sequencing to confirm the correct sgRNA insertion.  Successfully cloned sgRNAs were then 
amplified and large DNA stocks were made and stored at – 20 °C until needed. 
 
6.3.2 – Design of sgRNAs around Glycoprotein G (US4) 
Glycoprotein G has been successfully deleted from ILTV previously using homologous 
recombination (Devlin et al., 2006).  Therefore to see if the approach designed to delete the 
miRNAs was feasible, knock out GΔG viruses were constructed in parallel as a positive 
control.  The design of sgRNAs directing cleavage of the gG region was carried out by Dr. I 










Figure – 6.1.  Schematic diagram of the miRNA cluster at the left hand 
end of the ILTV genome  
Diagrammatic representation of the first 2500 bp of the ILTV genome.  
Displayed are the 5 microRNAs found within the area.  Red arrows and letters 
refer to miRNAs and direction.  Green cross is where sgRNAs were picked at 
the left hand side of the miRNA cluster.  Blue cross is where sgRNAs were 
picked at the right hand side of the cluster.  Diagram not to scale.   
A – ILTV-miR-I1-5p starts at position 534  
B – ILTV-miR-I1-3p starts at position 568 
C – ILTV-miR-I2-5p starts at position 1425 
D – ILTV-miR-I3-3p starts at position 1634 
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Table – 6.1. List of sgRNAs targeting the right hand side of the miRNA cluster in the ILTV genome 







ILTV 0.774373 miRNA3’ 1737 1766 - TCCGTGATGAGGGAACCACA CGG 1746 1743 1763 Y 
ILTV 0.692173 miRNA3’ 1721 1750 + TATAGCGAGCAATGACCGTG TGG 1741 1725 1744 Y 
ILTV 0.6275 miRNA3’ 1735 1764 + ACCGTGTGGTTCCCTCATCA CGG 1755 1739 1758  
ILTV 0.614389 miRNA3’ 1763 1792 + TCGTTATGCATAGATGCCTG CGG 1783 1767 1786  
ILTV 0.612486 miRNA3’ 1747 1776 - TAACGAGCACTCCGTGATGA GGG 1756 1753 1773  
ILTV 0.584543 miRNA3’ 1748 1777 - ATAACGAGCACTCCGTGATG AGG 1757 1754 1774  
ILTV 0.542116 miRNA3’ 1764 1793 + CGTTATGCATAGATGCCTGC GGG 1784 1768 1787  
ILTV 0.540315 miRNA3’ 1780 1809 - GCAAGTGCGACCTAGCCCGC AGG 1789 1786 1806 Y 
ILTV 0.522977 miRNA3’ 1789 1818 + AGGTCGCACTTGCTGGGCAG CGG 1809 1793 1812  
ILTV 0.4588 miRNA3’ 1769 1798 + TGCATAGATGCCTGCGGGCT AGG 1789 1773 1792  
ILTV 0.453547 miRNA3’ 1783 1812 + CGGGCTAGGTCGCACTTGCT GGG 1803 1787 1806 Y 
ILTV 0.226674 miRNA3’ 1798 1827 + TTGCTGGGCAGCGGCTAAAC TGG 1818 1802 1821  
ILTV 0.195193 miRNA3’ 1782 1811 + GCGGGCTAGGTCGCACTTGC TGG 1802 1786 1805 Y 
Efficiency on a scale of 0 – 1 with 1 been the most efficient at cleaving the target. 
Start and end refer to the position of the target site in the ILTV genome 
Strand refers to the positive or negative strand of the ILTV genomic DNA 
Cut position is the specific point where the DSB is induced and the CRISPR start and end points are the sgRNA position 
Chosen refers to whether the sgRNA was chosen for the study  
Yellow highlighted rows refer to sgRNAs designed using the first method outlined in section 6.3. 
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Table – 6.2. List of sgRNAs targeting the left hand side of the miRNA cluster in the ILTV genome 




Start CRISPR End Chosen? 
ILTV 0.697143411 miRNA5’ 521 550 + TCCGCAGAGGAGACTGATTG GGG 541 525 544 Y 
ILTV 0.673674478 miRNA5’ 508 537 + GATTTCGCGAGGCTCCGCAG AGG 528 512 531 Y 
ILTV 0.559910063 miRNA5’ 503 532 - CGGAGCCTCGCGAAATCCAA CGG 512 509 529  
ILTV 0.433027156 miRNA5’ 519 548 + GCTCCGCAGAGGAGACTGAT TGG 539 523 542  
ILTV 0.377577048 miRNA5’ 520 549 + CTCCGCAGAGGAGACTGATT GGG 540 524 543  
Efficiency on a scale of 0 – 1 with 1 been the most efficient at cleaving the target. 
Start and end refer to the position of the target site in the ILTV genome 
Strand refers to the positive or negative strand of the ILTV genomic DNA 
Cut position is the specific point where the DSB is induced and the CRISPR start and end points are the sgRNA position 
Chosen refers to whether the sgRNA was chosen for the study 
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6.4 – Testing of sgRNA cutting ability In Vitro 
To determine if the sgRNAs had the ability to direct cleavage of the DNA sequence, they 
were tested in vitro.  DNA for both the template cutting sequence and the sgRNAs was 
amplified using conventional PCR (section 2.2.7, primers found in Appendix 2).  DNA to be 
used as a template cutting sequence was then purified and stored until the reactions were 
assembled.  DNA of the sgRNA sequences was purified and used for RNA synthesis as 
described in section 2.6.4.  sgRNA was purified and DNase treated to remove the DNA 
template.  Reactions were then assembled in vitro using a commercial recombinant Cas9 
protein as per section 2.6.5.  Samples were harvested at 1 and 24 hours post assembly and 
treated with both proteinase K and RNase A to degrade the Cas9 protein and sgRNA.  
Samples were separated on an agarose gel by electrophoresis and imaged.  Figure 6.2. shows 
the workflow of this experiment.   
  






Analyse on Gel  
(3 %) 
sgRNA Synthesis 
Amplify  guide DNA using 
conventional PCR 
RNase Treat 
Synthesis sgRNA from DNA 
Template 
DNase Treat  
PCR Clean Up 
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PCR Clean Up 
Template DNA Synthesis 
Analyse on a 
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denature both the sgRNA & Cas9 
protein 
Figure 6.2 – Overview of the testing of sgRNAs cutting ability in vitro 
In vitro transcription was used to synthesise sgRNAs from a DNA template amplified using conventional 
PCR.  sgRNAs were RNA extracted and DNase treated to remove any DNA contamination and then frozen at 
– 80 °C until needed.  Template DNA that contained the complimentary sgRNA site was amplified also by 
conventional PCR.  PCR products were cleaned up and RNase treated to move any contamination.  Template 
DNA was stored at – 20 °C until needed.  Cutting reactions were assembled with a 10:10:1 molar ratio of 
Cas9:sgRNA:template DNA and left for either 1 hour or 24 hours before analysis.  Prior to agarose gel 
electrophoresis, cas9 protein was degraded with proteinase K and the sgRNAs were degraded with RNase A.  
Red arrows represent optimisation steps whereas black arrows depict workflow.  
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6.4.1 – miRNA K/O sgRNAs testing in vitro using an online program 
Testing of the sgRNAs showed that the original sgRNAs designed were unable to direct 
cleavage of the template DNA after incubation of the reactions for either 1 hour or 24 hours 
in vitro (Figure 6.3A & B).  Due to this finding, the sgRNAs designed using this method 
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Figure 6.3. – Agarose gels of in vitro testing of sgRNAs designed to target the miRNA 
cluster using an online program 
sgRNAs designed using the online CRISPR program (found at: http://crispr.mit.edu) 
were tested using the methodology laid out in Figure 6.1. L = Ladder (50 bp generuler 
ladder), 1 = sgRNA 1, 2 = sgRNA 2, 3 = sgRNA 3, no sgRNA = no sgRNA added to 
sample   
A – Samples were left to incubate for 1 hour    
B – Samples were left to incubate for 24 hours 
 





6.4.2 – miRNA K/O sgRNAs testing in vitro set two 
In total, four sgRNAs designed in collaboration with Dr W.S. Tan (The Roslin Institute) 
were tested which consisted of two sgRNAs from the left hand side and two sgRNAs from 
the right hand side of the miRNA cluster.  Testing of the sgRNAs showed all four were able 
to direct the Cas9 protein to cleave the DNA template at both time points chosen in vitro 
(Figure 6.4A & B).  As these sgRNAs were able to facilitate cleavage of the DNA template, 
they were taken forward and used in experiments to create a miRNA deletant ILTV virus.  
6.4.3 – Testing the cutting ability of sgRNAs against a portion of GΔG DNA sgRNAs in 
vitro   
Two sgRNAs were tested in vitro for their ability to direct cleavage against a DNA template 
amplified from the ORF encoding for glycoprotein G (US4) GΔG.  One sgRNA was not 
recovered during the initial stages of the amplification of gDNA synthesis via PCR (Data 
Not Shown).  Of the two sgRNAs that were taken through the process, one showed cutting 
ability against the template DNA (Figure 6.5C & D).  This sgRNA was used in downstream 
experiments.   
 
 







Figure 6.4. – Agarose gels of in vitro testing of sgRNAs to direct cleavage at both 
sides of the miRNA cluster  
A second set of sgRNAs were designed in collaboration with Dr W.S. Tan (The 
Roslin Institute).  Guides were designed at both the left and right hand side of 
the miRNA cluster (designed sgRNAs listed in Tables – 6.1 & 6.2).  They used 
the viral genome as an off-target parameter and ignored the chicken genome.  
Guides were tested were tested using the methodology laid out in Figure 6.1.  
M = DNA marker   
Letters above lanes (L&R) refer to left or right hand side of the miRNA cluster whilst 
numbers refer to the sgRNA  
A – Samples were left to incubate for 1 hour    
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Figure 6.5. – Agarose gels of in vitro testing of sgRNAs to direct cleavage at 
Glycoprotein G (US4) 
Glycoprotein G has already been shown to be dispensable for in vitro ILTV 
replication (Devlin et al., 2006).  Guides were designed by Dr. I Dry (The 
Roslin Institute).  Guides were tested using the methodology laid out in Figure 6.1.  
Numbers above lanes refer to sgRNA  
A – Samples were left to incubate for 1 hour    
B – Samples were left to incubate for 24 hours 
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6.5 – Construction of Homology repair templates  
To increase the chances of recovering a recombinant virus with the miRNAs deleted, the 
approach taken used homology directed repair (HDR) coupled with a fluorescent reporter 
construct to allow for detection via microscopy.  This approach required a homology repair 
cassette that was constructed from the flanking sequences of the miRNA cluster with the 
reporter construct inserted into the miRNA region instead.  
6.5.1 – Creation of a Homology repair template 
Homology repair flanks were synthesised using a two-step process.  Primers were designed 
to amplify the left flank and right flank independently.  To allow for insertion of a 
fluorescent reporter construct, a common sequence was included at the end of the left reverse 
primer and the forward right primer.  This common sequence consisted of the restriction 
endonucleases Kpn1 and BamH1 in addition to a 4 bp consensus sequence.  Once both 
flanks were amplified by conventional PCR, there were analysed on an agarose gel before 
being extracted (Data Not Shown).  Resulting DNA was then used in an overlapping PCR to 
join the left and right flanks together.  This was achieved using the left flank forward primer 
and the right flank reverse primer.  PCR products were again visualised on an agarose gel 
and bands of the right size were extracted, TOPO cloned and sent for sequencing (Data Not 
Shown).  PCR products were confirmed to be the sequence of the expected flanks.  This 
same process was carried out for creation of the GΔG homology repair template (Data Not 
Shown).  Primers are listed in Appendix 2 for the above.  Workflow for the creation of a 
homology repair template is shown in Figure – 6.6. 
  









Figure – 6.6.  Schematic diagram depicting the construction of the Homology repair template 
used in the CRISPR experiment 
Two-step PCR was used to amplify flanking sections of ILTV genomic DNA around the miRNA 
cluster.  First round PCR amplified the left and right hand flanks separately (A- green and blue 
arrows).  The left reverse primer and right forward primer (marked with asterisks) contained a 
common sequence shown in (B) to allow for insertion of a reporter construct.  Second round PCR 
used the left forward primer and right reverse primer (A - dotted black arrows) to create a full 
length homology repair template with a common cloning sequence (B).     
Chapter 6  Genome-editing the ILTV Genome 
189 
 
6.5.2 – Creating of a fluorescent reporter construct 
To create a reporter construct, overlapping primers were designed to amplify the CBh 
promoter and eGFP.  Primers included the Kpn1 and BamH1 restriction endonuclease sites 
to allow for insertion into the homology repair template created in section 6.5.1.  The first 
round of PCR amplified the CBh promoter and eGFP separately.  These products were 
analysed on an agarose gel and bands were excised and purified for a second round of PCR 
to create a full fluorescent construct (Data Not Shown).  The full construct was then cloned 
into TOPO4 to allow for sequencing which confirmed the creation of a CBh driven eGFP 
(Data Not Shown).  Primers for this are listed in Appendix 2 and workflow for this is shown 
in Figure – 6.7. 
6.5.3 – Insertion of a reporter construct into the homology repair template 
Using the restriction endonucleases as outlined above, Kpn1/BamH1, the CBh-eGFP PCR 
product was inserted into the homology flanks (Figure – 6.8).  To check for its successful 
insertion, a diagnostic digest was set up with appropriate controls.  This confirmed the 
presence of CBh-eGFP within the homology flanks (Data Not Shown).   
  





Figure – 6.7.  Schematic diagram depicting the construction of the fluorescent reporter 
construct used in the CRISPR experiment 
Two-step PCR was used to amplify a CBh-driven eGFP reporter construct.  Primers were designed 
to amplify CBh promoter and eGFP separately and included a overlapping region on the CBh 
reverse and eGFP forward primer (A – red and purple primers).  PCR products were purified and 
used as templates for a second PCR using the CBh forward and eGFP reverse primer (A- black 
dotted arrows) to create a CBh-eGFP with unique restriction enzymes at either end for insertion into 
a homology repair template (B).   
A 
CBh Promoter eGFP 
Kpn1 -  
- BamH1 
B 
Kpn1 -  - BamH1 
CBh-eGFP 








Kpn1 -  - BamH1 
Figure – 6.8.  Schematic diagram showing the insertion of the reporter construct into the 
homology repair template 
The restriction endonucleases Kpn1 and BamH1 were used for insertion of the reporter construct 
into the homology repair template. Both homology repair template and reporter construct were 
digested with Kpn1 and BamH1 (A).  The reporter construct was then ligated into the homology 
repair template as described in section 2.3.3.  This produced a homology repair cassette containing 
a CBh-eGFP fluorescent reporter (B). 
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6.6 – Detection of Glycoprotein G recombinant viruses 
CRISPR experiments were carried out as described in section 2.6.6 of this thesis.  After 
harvesting of the samples, they were freeze-thawed a total of three times to disrupt any cells 
that were collected during the harvest process.  These samples were then used to infect new 
cells and were serially diluted.  Areas of green were picked using a 10 µl pipette tip and 
transferred onto fresh, naïve cells and picked virus was allowed to replicate for 48 hours 
before harvesting.  Samples were then harvested and frozen down with a small aliquot 
removed for DNA extraction and testing.  
Primers were designed to look for recombination events and should only detect mutant virus.  
A forward primer was designed against the eGFP sequence whilst a reverse primer was 
designed against the virus and sat outside of the flanking sequence.  Using extracted DNA 
from for conventional PCR and using extracted wild type virus and gDNA primers as 
controls, bands were detected in two of the four samples tested which also tested positive for 
gDNA.  No bands were detected in WT virus except for in the gDNA control PCR (Figure 
6.9A & B).  Experiments were then halted here to concentrate upon the miRNA deletant 
virus as a gΔg virus has previously been characterised and studied (Devlin et al., 2006).   
 











L 1 2 3 4 + NTC 
B 
Figure 6.9. – Detection of recombination events using CRISPR-Cas9 against Glycoprotein G of 
ILTV 
Primers were designed to only amplify recombination events with a forward primer situated in the eGFP 
portion of the reporter construct and a reverse primer located downstream of the right hand flank 
homology cassette.  In addition, primers termed gDNA were used to detect against another part of the 
viral genome.  PCR products were analysed using a suitable % agarose gel and imaged.  Numbers refer 
to PCR reaction.  NTC = No template control. ‘-‘ refers to a negative control using wild type  virus (A) 
whilst ‘+’ refers to a gDNA positive control (B).    
A – Primers designed to detect recombination events 
B – gDNA primers to check for virus presence 
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6.7 – Detection of miRNA K/O recombinant viruses 
CRISPR experiments were carried out as described in section 2.6.6.  For the detection of 
recombination events, primers were designed to amplify across the region of interest.  A 
forward primer was situated towards the terminal end of the left hand flank whilst a reverse 
primer was situated downstream of the right flank and into the viral genome.  Virus 
harbouring recombination events will have a larger PCR product produced compared to the 
wild type sequence.  Bands detected with a larger PCR product were excised, DNA extracted 
and cloned for sequencing.  Using these primer sets, several bands were visible at the correct 
product size in line with the positive control (Figure 6.10A).  Upon sequencing, two of the 
clones sent for sequencing were confirmed to be from recombinant virus (Figure 6.10A, 
lanes 2 & 9).  Sequencing from lane 8 (Figure – 6.10A) could not be achieved.  As whole 
virus samples were used for these PCR reactions, recovery of these viruses after detection 
could not be carried out.   
However, further testing of CRISPR virus stocks using a portion of the sample (the rest of 
sample was added to cells for virus infection) for recombination events detected partial 
recombination events in the virus (Figure – 6.10B, Lane 6).  This could have been a partial 
insertion of the GFP construct or a deletion event in the virus but this was unclear and so was 
not taken forward.  This PCR reaction had the addition of 6 % DMSO to allow for detection 
of wild type virus also.  Due to this, many non-specific bands were also detected upon 
visualisation on an agarose gel.  Bands of the correct size (~3000 bp) were excised, cloned 
and sent for sequencing.  Results from this confirmed the presence of recombination (Data 
Not Shown).   
The insertion of eGFP into the viral genome allowed for fluorescent microscopy imaging and 
analysis.  Samples were assessed at all stages of the process from initial 
transfection/infection of cells through to plaque purification of the recombinant viruses.  
Images taken during the initial transfection/infection are shown in Figure – 6.11.  The 
plasmid encoding for the Cas9 protein and the sgRNA also encodes for a red fluorescent 
protein (RFP) (Figure – 6.11C&D) whilst the homology repair template contains the eGFP 
(Figure – 6.11E&F).   
Whole well lysates were harvested and freeze thawed three times to release virus.  These 
lysates were used to infect naïve LMH cells. Samples were placed under a 0.5 % Avicell 
overlay to restrict virus spread.  Areas of green were selected and added to a second set of 
naïve LMH cells and numbered.  Images of cells under avicell overlay were taken 24 HPI.  
No images of RFP were taken due to lack of detection.  GFP could be seen under the Avicell 
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overlay in both GFP only and GFP + brightfield phases (Figure – 6.12B&C).  Taken 
together, these results pointed to the creation of a recombinant virus lacking the five 
miRNAs at the left hand end of the genome (laid out in Figure – 6.1).  Time constraints 
meant the purification of a pure population of recombinant virus could not be achieved 

























L 1 2 3 4 5 6 7 WT NTC  + 9 
B 
Figure - 6.10.  Detection of ILTV recombinants lacking five miRNAs from the genome 
after passage in cells 
Following plaque purification, genomic DNA was isolated from samples for use in PCR.  
Using primers spanning the miRNA cluster and appropriate controls, PCRs were carried out 
and visualised on an agarose gel (A).  Bands visualised at the correct size (~3000 bp) were 
excised and cloned for sequencing.  A second batch of recombinant viruses were tested (B) 
using the same method except with the addition of 6 % DMSO to the PCR reaction.  
Recombination events were detected and bands of the correct size (~3000 bp) were excised, 
cloned and sent for sequencing.     










Figure – 6.11.  Fluorescent microscope images of transfected and infected LMH cells 
LMH cells were seeded out at 1x10
5
 cells per well in a 6-well plate.  Cells were then 
transfected with a plasmid encoding for both the Cas9 protein and a sgRNA against the ILTV 
cluster and also a second plasmid which encoded for the homology repair cassette encoding the 
homology directed repair template.  After 12 hours, cells were infected with WT ILTV at an 
MOI = 0.001.  Untransfected LMH cells in brightfield phase and GFP phase (A&B). 
Expression of the sgRNA/Cas9 protein in brightfield + RFP and RFP only phases (C&D).  
Expression of the homology repair cassette in brightfield + GFP and GFP only phases (E&F).  
All images are taken 24 hours post infection of cells and are representative. 








Figure – 6.12.  Detection of eGFP following plaque purification of Recombinant ILTV 
virus 
LMH cells were seeded out at 1x10
5
 cells per well in a 6-well plate.  Cells were then infected 
with harvested lysates that had been freeze/thawed 3x and then placed under a 0.5 % Avicell 
overlay.  Images were taken 24 HPI.  No RFP images were taken due to lack of detection.  A – 
Brightfield phase only. B – Brightfield + GFP phase. C – GFP only.  Images are representative.   
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6.8 – Discussion 
This project aimed to employ the gene editing technology CRISPR-Cas9 to create a 
recombinant ILTV virus lacking a cluster of five miRNAs found at the left hand end of the 
genome.  To do this, sgRNAs were designed and tested in vitro to analyse their ability to 
direct a recombinant cas9 protein to cut the template DNA sequences.  Two attempts, using 
two different methods, were made to create sgRNAs that were able to direct cutting of the 
desired sequence.  It was found sgRNAs designed using an online algorithm were unable to 
direct the Cas9 protein to cause double stranded breaks however in contrast, sgRNAs 
designed in collaboration with Dr. Tan (The Roslin Institute) were able to direct and 
subsequently cause DNA cutting.  Concurrently, a homology repair template which 
harboured a fluorescent reporter gene was assembled through multiple PCRs and cloning.  
This was then used alongside the sgRNAs in an experiment to create recombinant virus.  
Upon testing of the recombinant virus, recombination events were discovered and confirmed 
through sequencing indicating that the experiment was successful.  Due to time limitations, 
further work to fully purify this virus and then characterise the virus in vitro for any possible 
growth/replication retardation has not been possible thus far.    
Recombinant viruses are a very useful tool to decipher the roles specific viral genes play in 
terms of pathogenesis, replication and overall virus biology.  To date, 19 genes have been 
knocked out of ILTV with two showing they are absolutely required for virus replication in 
vitro (Pavlova et al., 2013, Nadimpalli et al., 2017).  The most heavily research gene of 
ILTV is Glycoprotein G.  Deletion of the gene in vitro causes little effect upon replication 
kinetics whereas in vivo, significant attenuation is observed making such deleted viruses 
possible vaccine candidates (Coppo et al., 2011, Devlin et al., 2007, Devlin et al., 2006, 
Devlin et al., 2010).  These recombinant viruses have led to a deeper understanding of not 
only the role each individual gene plays in terms of virus biology but they have also 
advanced the knowledge of virus-host interactions.  In stark contrast though, there is very 
little research regarding the role of ILTV-encoded miRNAs.  Of the 10 known miRNAs, 
only one so far, ILTV-miR-I5 has been shown to have a function.  Waidner et al. (2011), 
showed that the miRNA was able to downregulate the protein expression of ICP4 by 
cleaving the mRNA transcript.  The study also observed ILTV-miR-I6 was able to 
downregulate ICP4 expression however this was not statistically significant.  Therefore, 
investigations into the role these miRNAs play during ILTV infection may uncover novel 
functions for them.  
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MicroRNAs can play a significant role in pathogenesis of virus infection.  In MDV-1 for 
example, miRNA MDV1-miR-M4-5p has been shown to be a functional homologue of the 
cellular encoded miR-155 and they share common targets (Zhao et al., 2009).  Further 
investigation involving the deletion of this miRNA from the viral genome observed the 
ablation of lymphoma formation as a result of MDV-1 infection in vivo (Zhao et al., 2011). 
Creation of recombinant viruses has relied mostly upon natural recombination or the use of a 
BAC to create the desired knockout/fusion protein.  Whilst the former has been extensively 
applied to ILTV, a BAC system has not successfully been created for ILTV.  There have 
been recent reports of a creation of a cosmid system using 3 plasmids that encode for the full 
ILTV genome that can be propagated in yeast (Spatz. et al., 2018).  With these limitations in 
mind, it was postulated that genome editing technology, in particular CRISPR-Cas9 may be 
of use to create recombinant viruses.   
CRISPR-Cas9 has been used successfully to modify the genomes of other herpesviruses and 
delete protein encoding genes as well as miRNAs (Bi et al., 2014, Yuen et al., 2015).  The 
study deleting UL23 from HSV-1 encountered issues regarding sgRNA targeting similar to 
this study.  The inherent problem of using a 20 bp sequence as a guide is that there are off 
target effects.  Whilst no mutations were found in the UL23 deletion studies when assessed 
by deep sequencing, the issue can be problematic (Bi et al., 2014).  In this project, two 
methods of sgRNA were employed to maximise the chances of finding suitable sgRNAs that 
were able to direct cleavage of the miRNA cluster (shown in Figure – 6.1.).   
Following conversations with Dr. S. Lillico (The Roslin Institute), sgRNAs were designed to 
target the right hand side of the miRNA cluster (shown in Figure – 6.1.).  The first system of 
sgRNA design used a freely available online program along with the region to be targeted.  
In this instance, the chicken genome could not be selected as a ‘target’ genome highlighting 
the issues regarding lack of reagents once again.  This was seen across several of the free 
sgRNA design tools and is problematic.  Therefore, suggested sgRNAs had to be chosen 
upon their supposed efficiency in targeting the specified area minus the off targeting scores 
calculated by an algorithm against the human genome.  From this, three sgRNAs were 
chosen at the top of the list with predicted efficiencies of 99 %, 99 % and 97 % in targeting 
the correct sequence.  These high scores are most likely due to the differences in the human 
and chicken genome sequence though this is unclear.  When these sgRNAs were tested in 
vitro (laid out in Figure – 6.2.), cleavage of template DNA by a Cas9 protein guided by these 
sgRNAs was undetectable at 1 and 24 hours post reaction assembly (Figure – 6.3A&B).   
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A second method of sgRNA design was also carried out in collaboration with Dr. W.S. Tan 
(The Roslin Institute).  As detailed in section 6.3.1, this method used a custom Python script 
along with several downstream steps to filter the results.  As well as designing sgRNAs to 
the right hand side of the miRNA cluster, sgRNAs were chosen at the left hand side of the 
cluster (highlighted in Figure – 6.1.).  This created two double stranded breaks in the region 
and hopefully increase the likelihood of a recombination event occurring.  The sgRNAs were 
then ranked on their combined scores of targeting the region (highest cutting efficiency to 
lowest) and their off targeting scores (lowest off targeting to highest) producing a list of 
sgRNAs for both the left and right hand side of the cluster (shown in Tables – 6.1 & 6.2).  
When these sgRNAs were tested in vitro, they were able to direct cleavage of the template 
DNA by the Cas9 protein (Figure – 6.4).  
The difference in sgRNA design is not particularly comparable as in the first approach, one 
is relying upon free software where as in the second approach, custom scripts were utilised 
in the first instance which were then supplemented by online algorithms.  The results of the 
approaches can however be compared.  In a black and white sense, sgRNAs picked from the 
second approach were able to successfully direct cleavage of a template DNA sequence in 
vitro whilst the former could not.  Not surprisingly, the sgRNAs from the first design attempt 
were identified in the second approach however their efficiencies were much lower than that 
of the sgRNAs chosen and taken forward (highlighted in Table – 6.1.  The first set of 
sgRNAs are shown in yellow).       
As well as having difficulty designing sgRNAs, which was overcome, the location of the 
miRNA cluster proved problematic.  As seen with homologous recombination and also HDR 
via CRISPR, the flanking homology arms are generally considered to be around 1000 bp or 
longer to ensure correct targeting and maximise the chances of a recombination event 
happening (Byrne et al., 2015).  This therefore proved a problem as the left hand flank was 
only 520 bp long in total which may have decreased the efficiency of recombination.  New 
approaches have been developed which may aid  future work and also increase the chances 
of recombination happening. These include using ssDNA donor templates as opposed to 
double stranded repair templates as they employ dramatically shorter homology repair arms 
whilst maintaining specificity (Yoshimi et al., 2016).  This approach has not been applied to 
viruses thus far though it may be of use in genomic areas that are constrained by the genome 
size.   
CRISPR-Cas9 modifications were first carried out using the Illinois strain of ILTV though 
this was soon replaced by the CSW-1 strain for a number of reasons.  Firstly, the CSW-1 
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strain is more virulent and also has a full genomic sequence available for it on NCBI.  
Secondly, the virus produces more cell-free particles which can be isolated.  This was seen 
as useful in the downstream purification steps to isolate a deletant virus.  Finally, the virus 
has been used extensively for previous deletant viruses both in vitro and in vivo showing that 
it can be manipulated (Devlin et al., 2007, Nadimpalli et al., 2017).  
The process of the transfection/infection was based upon the protocol from Russell et al. 
(2015).  This was modified though with the addition of Phosphonoacetic acid (PAA).  PAA 
has previously been to inhibit virus replication and can be washed out making it reversible 
(Elliott et al., 1980).  The theory was that by adding PAA to the virus media following 
infection, virus would not be able to replicate giving the CRISPR-Cas9 system chance to 
cleave the DNA and allow host cell machinery to carry out homology directed repair (HDR) 
thus increasing the chances of creating a recombinant virus.  This process was used through 
the project and no comparisons were made with the protocol lacking PAA but if the 
efficiency was increased, it may be worth noting for future work as it can be applicable to all 
other herpesviruses.   
Detection of recombination events was carried out by PCR.  Primers were designed to 
amplify the region spanning the miRNA cluster with a forward primer situated in the left 
flank region and a reverse primer downstream of the right homology arm.  This was done so 
that PCR products would not be detected from just the homology repair cassette.  The 
insertion of eGFP into the cluster caused PCR products to be ~300 bp bigger than the wild 
type sequence and so would be identifiable when separated by agarose gel electrophoresis.  
Moreover, the identification of a run of ~16 Cytosine’s (Cs) contained within the miRNA 
cluster caused problems during attempts to create a ‘revertant’ homology repair cassette 
(Data Not Shown).  Whilst unclear, the presence of this sequence possibly caused the 
amplification of the wild type to be difficult without the use of DMSO.  Therefore, the 
detection of PCR products at the correct size without DMSO was promising (Figure – 
6.10A).  Sequencing of these PCR products confirmed the presence of recombination events 
suggesting that a virus lacking the 5 miRNAs was successful.  This first PCR analysis used 
the full virus sample and so recovery of these viruses was not possible but it confirmed that 
the system was working.  
A follow up study using partial virus samples was carried out however this time 6 % DMSO 
was added to the PCR reaction.  This was done to amplify wild type virus also to give a 
comparison to the recombination events (Figure – 6.10B).  Recombination events were also 
detected in these samples at the correct predicted size which upon sequencing were 
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confirmed to be recombinant viruses.  There were also some other bandings that were 
unexpected.  These were most likely partial recombinants through partial insertion/deletion 
(indels) however in the interest of time they were not followed up on.   
As well as using PCR analysis to look for recombinant viruses, fluorescent microscopy was 
used.  This was carried out at all stages of the process from initial transfection/infection 
through to plaque purification steps.  The Cas9 plasmid which also encoded for the specific 
sgRNAs also encoded for a mCherry (RFP) marker allowing for detection (Figure – 
6.11C&D).  At first, a GFP plasmid containing the sgRNA and Cas9 protein was used 
however this could not be distinguished from the homology repair template as this contained 
eGFP to replace the miRNAs, this was then changed to allow for a clear difference between 
the two plasmids.   
During the plaque purification process, images were taken of the samples when they were 
infected with the virus samples.  Images were taken whilst cells were under an Avicell 
overlay and this hampered efforts in obtaining clear images.  GFP could still be detected in 
samples during the plaque purification process (Figure – 6.12) whilst no mCherry could be 
seen.  These results suggested that the eGFP was incorporated into the virus and allowed for 
passage as detection of the plasmids (Cas9 mCherry) was not observed.  The chance of the 
DNA plasmids surviving a freeze/thaw cycle 3x and then been able to get into naïve cells 
without a transfection reagent is very small.  This gave more confidence that the green that 
was observed was coming from a recombinant virus.     
Due to these difficulties, the ability to test this recombinant virus in vitro was not achieved 
however subsequent work should make this a priority.  As the virus was never separated 
from wild type virus following two rounds of plaque purification, one must also question 
whether the virus lacking the 5 miRNAs can replicate without a helper wild type virus.  The 
likelihood of this is slim but reports of this are seen in the literature, mainly through the 
deletion of protein coding genes however.  Deletion of UL-1 from ILTV and rescue of 
recombinant virus could never be fully established suggesting that the gene is essential 
during virus replication though the function of UL-1 is still to be elucidated (Nadimpalli et 
al., 2017).   Therefore, any future work should look to see if the two viruses can be separated 
from each other to create a pure population of recombinant virus.   
In summary, work presented in this chapter has shown the successful application of 
CRISPR-Cas9 genome editing technology.  This work has produced a virus that is lacking 5 
miRNAs as shown by the PCR analysis.  Future work must focus on purification of this virus 
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At the beginning of this project, there was one major aim, to use a biochemical technique 
CLASH to investigate miRNA:mRNA interactions during ILTV infection.  Following this, 
top targets were to be validated via a secondary laboratory method.  Early on in the project 
this was deemed to be not feasible due to a number of factors laid out below and so the aims 
of the project evolved whilst still focusing upon ILTV miRNA:mRNA interactions.  The 
modified aims of the project were to use bio-informatics to predict viral targets of ILTV-
encoded miRNAs and to explore the use of CRISPR-Cas9 as a tool to manipulate the ILTV 
genome by deleting a cluster of five miRNAs from the genome.  From this first modified 
aim, another project aim developed which investigated virus targets of high confidence 
cellular miRNAs. 
CLASH is a technically challenging procedure even with optimal reagents for each 
individual process in the experiment.  The difficulty in working with viruses that infect 
chickens is the current lack of reagents when compared to the human or mouse.  This is not 
just limited to antibodies but includes cell lines relevant to virus biology and well annotated 
genomes of both the virus and host.  The predominant cell line used for ILTV experiments 
are LMH cells which come with their own limitations.  In terms of getting the CLASH 
project off the ground, the first step would be to identify a new cell line that was 1 – capable 
of supporting ILTV replication and 2 – removed the limitations seen with LMH cells such as 
the use of gelatin for cell adherence.  Following this, for CLASH to work, this cell line 
would be need to be transduced with the same lentivirus expressing the tagged Ago2 to allow 
for the purification of RISC complexes.  However, as explored in Chapter 6 of this thesis, the 
use of genome editing to ‘tag’ the endogenous protein maybe be more preferable.  This has 
been shown to be feasible in chickens in a number of experiments (Oishi et al., 2016, Bai et 
al., 2016).  As eluded to in the discussion of Chapter 3, a more suitable basis for CLASH 
would be look at the virus in a latent state, but as this is already technically challenging in 
more well defined viruses of the alphaherpesvirus family, carrying this out in the chicken 
may be some years away though it is something that should be aimed for in the long term as 
this would be beneficial with respect to virus – host interactions and elucidating the role 
miRNAs play in the latent state of the virus.  
Due to the technical problems and limitations outline in Chapter 3 of this thesis, a new set of 
project aims were developed.  These included the use of bioinformatics to predict viral 
targets of ILTV-encoded miRNAs.  For the bioinformatic predictions, viral transcripts had to 
be made for each ORF in the viral genome which gave rise to another problem.  As 
mentioned previously, the reference genome for ILTV does not contain all of the details one 
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would find in another virus such as HSV-1.  Therefore, an arbitrary system was employed to 
ensure full coverage of the viral transcripts.  Whilst this worked and predicted transcripts 
were generated for each ORF, it complicated the downstream analysis.  This is highlighted in 
Chapter 4, section 4.4, with the viral target in UL29 first recognised in UL28.  Due to this, if 
a target showed knockdown, further investigation had to be under taken to examine which 
transcript was actually targeted.   
RNA Hybrid was used to make bioinformatic predictions for both Chapter 4 and Chapter 5 
of this thesis.  Previous members of the lab group have used this program successfully to 
predict miRNA targets (Riaz, 2014 , Nightingale, 2016).  There are many programs available 
to predict miRNA:mRNA interactions however some are constraint to specific species’ such 
as human targets making them unfeasible for this project.  Whilst this gave RNA Hybrid the 
advantage as it more flexible in terms of species’, it does produce a false positive 
predictions; something that is evident in Chapter 4.  Of the 28 novel targets tested, only 3 
showed a reduction in luciferase activity when tested in vitro.   
The method of testing predicted targets in vitro was using a luciferase based reporter plasmid 
with the predicted target site cloned into the 3’UTR of a Renilla luciferase gene.  It provided 
a direct link between the predicted miRNA target and the expression of a reporter gene.  Due 
to the large number of targets tested from the bioinformatic screen, around 110 bp portions 
were cloned into the multiple cloning site of the plasmid.  Using this approach, the context of 
the predicted target in the viral gene was lost and in some cases, moved the target site from 
the 5’UTR or coding region into the 3’UTR.  Because of this, a secondary method of 
validation had to be undertaken to see if the target site was indeed real and not artificial.   
In the case of the all of the targets that showed statistically significant knockdown in Chapter 
4, the targets sites were contained within the coding region of the target gene.  As there are a 
lack of reagents available to detect specific viral genes in ILTV, whole coding regions were 
cloned into an expression plasmid along with a small tag to allow for detection by western 
blotting.   
For chapter 4, several miRNA targets were investigated further following the initial 
luciferase screen.  These data results were inconclusive however there are several 
experiments that could be done in future that would answer the lingering questions from this 
part of the project.  In in the first instance, replacing the small 6x His tag on the UL29 
plasmid to another one such as HA or FLAG would possibly allow for the detection of the 
protein allowing for validation.  Whilst this would be a small change, it might be of use 
interest to use Locked Nucleic Acids (LNAs) as outline in chapter one of this thesis as a 
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possible alternative (Xu et al., 2017).  This could be used in conjunction with live virus 
allowing for RT-qPCR analysis of the interested transcripts.  On a similar ilk, the targeting of 
UL46/UL48 could also be investigated.  By using a scramble siRNA alongside the LNA of 
interest, one could look at the relative expression levels of the transcripts to determine if 
there was an enrichment in the presence of the LNA compared to the scramble control.  In 
theory, this approach could replace CLASH also as to date, there are only 10 known ILTV-
encoded miRNAs and this is unlikely to change.   
Moreover, thinking about the investigations into the UL46/UL48 targeting, the data garnered 
in this project still does not fully answer which transcript is targeted and so this would need 
to be elucidated also.  To do this, the employment of 5’ and 3’RACE for the two transcripts 
would definitively state the transcription start and termination sites.  There are several 
commercial kits available for this and any future work could use utilise these.  
The final part of Chapter 4 investigated the interplay between UL46, UL47, UL48 and the 
ICP4 promoter.  This work was very much in its infancy and there is a lot of scope for 
downstream experimentation.  In the first instance, the data needs repeating in another cell 
line, preferentially one that is permissive to ILTV infection such as LMH cells to see if the 
data is similar to the results presented in Figure – 4.8.  Secondly, one might investigate the 
sub-cellular localisation of the aforementioned proteins on their own and in the presence of 
one and other alongside the ICP4 promoter.  This could be carried out using the already 
existing plasmids as each one was cloned with a different small tag to allow for 
immunofluorescencent detection.  This could be done to see if the protein localisations are 
similar to their homologues from other herpesviruses.  One would argue that the importance 
of this is less than that of the points for chapter 4 above as the interplay between these 
proteins is well defined in other herpesviruses however the results are interesting in the fact 
that UL46 possibly acts as a negative regulator though this still needs to be investigated 
further.  Hypothetically, if this system was set up and was reliable, one could introduce the 
miRNAs that target the coding regions of these proteins to investigate their effects also but 
again, there are other methods that should be used first.  
Once the viral transcripts were identified they were also tested against high confidence 
cellular miRNAs as listed in MiRBase (release 21, June 2014).  This led to the creation of a 
new avenue of work that was investigated during the project (results outlined in Chapter 5).  
Reports of cellular miRNAs targeting herpesvirus transcripts are found in the literature but 
there are to date no reports with respects to ILTV (Pan et al., 2014).  The same approach as 
Chapter 4 was taken which presented the same technical issues such as the arbitrary mRNA 
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transcript methodology and the filtering of results with some minor adjustments.  Initial 
experiments focused on immediate-early genes as any effect on them is most likely to have 
an impact upon the virus biology.  The results laid out in Chapter 5 focus on ICP4 and the 
cellular miRNA gga-miR-133a-3p.  Similar to above, a secondary method of validation was 
not achieved and this is of up most importance.  The quickest method to validate this 
interaction would be employ LNAs similar to above and carry out RT-qPCRs to look for 
ICP4 enrichment.  At the time of writing this however, the approach taken was to clone both 
the 5’UTR and coding region of ICP4 in a plasmid with a small tag (HA) and validate the 
interaction via western blotting.  This line of enquiry was taken for two reasons, 1 – 
validation of the interaction could be achieved and 2 – the creation of a natural promoter 
driven ICP4 protein would be advantageous to the lab for other ILTV related experiments.   
This project has also been the first to formally identify the mature miRNA sequence of gga-
miR-133a-3p in the chicken.  One question that does need answering is how strongly 
expressed is this miRNA in the tissues of biological relevance.  This could be done either 
using the existing method with the Qiagen MiScript II/SYBR green kit to estimate the 
quantity of the miRNA in the tissue (not carried out in this project) or by carrying out RNA 
deep sequencing on the tissues of interest to look at number of counts for the miRNA.  The 
former of these approaches is feasible quickly and can be used with archived samples whilst 
the latter would require fresh samples in addition to expensive sequencing runs.   
In a similar fashion, it would be of interest to look at the levels of expression within LMH 
cells.  Coupled with this, the use of a miRNA sponge/anti-miR to remove the levels of miR-
133a in the cells and subsequently infecting the cells to look for a difference in viral 
transcript levels would be of interest.  This would probably mimic the levels seen naturally 
in the chicken as opposed to the overexpression of the miRNA as carried out in the project.  
Finally for this part of the project, work carried out during whilst writing this thesis 
identified this miRNA interaction in several other species of Alphaherpesviruses in ICP4 as 
well as the miR-133a sequence (details outlined in Appendix 6&7).  This opens up the 
possibility that this interaction is conserved within the alphaherpesvirus family however 
there is currently no experimental data to corroborate this suggestion.  It would be of interest 
to see if these interactions are indeed real and whether the miRNA is expressed in tissues 
relevant to the individual virus species biology.  Alongside this line of enquiry, work carried 
out by Dr I. Dry (The Roslin Institute) has shown that there is some differences in the 
sequence homology surrounding this miRNA site from different genotypes of ILTV 
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suggesting that this site may have higher incidences of mutation compared with other 
genomic regions of the virus (Personal communication, Data Not Shown).  
The final part of this project used CRISPR-Cas9 to create a mutant virus lacking 5 miRNAs.  
Results presented in this thesis suggest that a recombinant virus was successfully produced.  
Polyclonal populations of recombinant and wild type virus were frozen down as a pure 
population was not achieved by the end of the project.  Purification of the virus is of the up 
most importance to allow for downstream experimentation.  This could be done by further 
plaque purification as outlined in the project to create a monoclonal population.  
Following the creation of a monoclonal population, the first stage would be to make a 
revertant virus whereby the miRNAs are knocked back into the recombinant virus and then 
confirm this by sequencing.  Once the panel of viruses are made, they could then be tested in 
vitro for their growth kinetics.  This can be done through two means.  An outright look at the 
viral fitness by plaque assay using a set amount of input virus and measuring the output.  
This could look at both the absolute value of viral titre but also look at the plaque size 
phenotype akin to data presented in Chapter 5.  Secondly, one could look more in depth at 
the growth kinetics by RT-qPCR for viral transcript levels at different time points.  In theory 
the project could then go one of two ways dependent upon the data generated.  If a 
phenotypic difference was observed, this virus could then be used in vivo to study the effects 
within the host and measure clinical scores alongside the other parameters typically 
measured in vivo as laid out in Devlin et al. (2006).  Downstream of this, it could be a 
vaccine candidate which would open up a completely new avenue of research.  If no 
phenotypic difference was seen, the virus might be tested in vivo anyway as several papers 
have shown that recombinant viruses in vitro behave very different when used in vivo 
(Devlin et al., 2007, Garcia et al., 2016).   
As well as in vivo experiments, one might also create a series of single miRNA knockout 
viruses to look at the individual effects of each miRNA though this is something to only 
consider as the work laid out above would take precedence.   
Results described in this thesis present some novel findings with regards to ILTV biology 
and microRNAs as well as outlining a new method of manipulating the ILTV genome.  Data 
described goes some way to elucidating mechanisms of viral gene regulation by both ILTV-
encoded and cellular miRNAs.  Whilst the story is incomplete, mostly due to the technical 
hurdles outlined above and the time constraints, this thesis has created more questions than it 
has answered.  Future work will be able to build upon these findings and help elucidate the 
role of miRNAs during ILTV infection. 
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pLenti CMV Blast Empty 
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PLVX-Tight-Puro Vector  
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Appendix 2: Primers and Oligonucleotides 









miRNA name Sequence Annealing 
Temperature 
(°C) 
ILTV-miR-I1-5p GCGGCGAGACTGATTGGGGAAT 74 
ILTV-miR-I1-3p GCGGCGAATTCCATTCCTCTTTCT 72.4 
ILTV-miR-I2 GCGGCGGGAAGGCTGTGCGATAGG 81 
ILTV-miR-I3 GCGGCGTCTTGTCTCTGGGTGGG 78.3 
ILTV-miR-I4 GCGGCGATGTATAGCGAGCAATGA 74.1 
ILTV-miR-I5-5p GCGGCGCTTCTCGTCCCCGTCTTC 80.8 
ILTV-miR-I5-3p GCGGCGTGAAGAAGACGACGACGAG 78.7 
ILTV-miR-I6-5p GCGGCGGTCTCCTGTACCCTCA 75.3 
ILTV-miR-I6-3p GCGGCGACGCTGAGGGGCCATGA 84.4 
ILTV-miR-I7 GCGGCGTTTTAATACTGAGGTGC 69.2 
gga-miR-92a-3p GCGGCGTATTGCACTTGTCCC 72.6 
gga-miR-133a-3p GCGGCGTTGGTCCCCTTCAACC 77.8 
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1 I6-5p tttggCTCGAGgccaccgtggcggtcgcagccaccctcgtatgatgaggcaatgggggatggaccttttactacgactgggggtcgcgacctcgctcacgcGCGGCCGCaggcc  
 2 I6-3p ctgggGTTTAAACggtcgcgacctcgctcacgcaggccggtcgtcgccggtctcgaggtcgatctcggcgacgcaattggtgtgcagcaaagttgtgctcagaGCGGCCGCggca  
 3 I6-3p cacaaCTCGAGgcattggtgagtgcacaagctattagcagcatggtctctggctctgcttcctcagtgggcgtagaagtagactgtgggtacagtcagactGCGGCCGCcatat  
UL54 1 I6-3p ctttcCTCGAGtgtagaatgagatctgcggcgaatacaatgtgcttcgtggcgggattctgacctcagcgtgaacggccatccagggcgatcttttgtccgGCGGCCGCggccg 
UL48 1 I5-3p taataCTCGAGttggcgctgagttccagggaactcctaagccatcttttggctacaaatccttcttcattgagggaagtagccagctgcccgaaaatacttGCGGCCGCttcta  
 2 I6-5p accaaCTCGAGactcaagcgcagcatccctgccccctacacaaggctcaatgcaaacacaaaacaggagacgcgaacgacgcagtaacagtgtcgttatccGCGGCCGCgaaag 
UL46 1 I5-3p 
Same as UL48  2 I6-5p 
UL30 1 I6-5p cgtttCTCGAGggcttgaaatcagactctacagtaagcccccgtatgagaggagcgatggcgcaggagggctggtcttgacttttggcgcacagtatcttcGCGGCCGCcattc 
 2 I5-3p tttccCTCGAGgaagattgtagtgatgggataactgtatgcaaatgtggctctgagttcgagcttcttctgtgctttatgacttttttcaagcaatattcaGCGGCCGCcccga 
 3 I3 agccgCTCGAGgatttgaggattttgactgtcttccgagcggacttactaagcttggccggttgattgcagaggcaaggctagctattaccggcaacggacGCGGCCGCtaaac  
UL28 1 I2 gcggcCTCGAGaaccagagtcaaaaatgttccgttcttctgccatgccggccctaagatcagcctttaacgggatgctggacaaaggattcctttctggaaGCGGCCGCaatat 
 2 I5-5p ggagaCTCGAGcacaacctgtcacagaaggaactagtacaagcgacctgactgctaacctcagaggaactattgaaagggacgaggattcgatagaagttcGCGGCCGCttcta 
 3 I5-5p cctccCTCGAGacgaccctctagacgttactacaaggatgaggaggaggttgaggaggatagtgatgaggacgacaggatacttgccaccagagttctgaaGCGGCCGCaggcc 
UL24 1 I6-5p aatatCTCGAGcccctagagactgtaattgatgtcttggatgatttagcccagcgggccgtgcaggagaaggacattgttgggtcttataaaacactagacGCGGCCGCatccg 
 2 I1-5p tggatCTCGAGaatgcttagtattttcgcgatcgcgtctctgtttagacaataaaagggttatatctttctgatcagtccgtctgttttgtcagtgtgttGCGGCCGCgatac 
UL9 1 I6-3p atagtCTCGAGagtagccgctcattttctgcgctatgtgaattagcgcctacgtcgctcagcgggaggaacgatatgtcgccaaataattttgctcctggaGCGGCCGCgaaca  
 2 I6-3p ctggaCTCGAGgaacaactgtggttgtcgcccagcgtcggactcgcacgaagactgtacggatgcgatctcagcgatcgcctattatccaatccgacaatgGCGGCCGCagtag  
UL2 1 I2 aggttCTCGAGatcatccctcccctcgccatctagacgctcccctccacagctttcgccccaccacccctcgtctaattatgatggcgcagggcaaaatacGCGGCCGCgactg 




Antisense Viral Target Gene Long Oligonucleotide 
Gene Targeted by Sequence (antisense) 
ORF F 1 I6-5p ggcctGCGGCCGCgcgtgagcgaggtcgcgacccccagtcgtagtaaaaggtccatcccccattgcctcatcatacgagggtggctgcgaccgccacggtggcCTCGAGccaaa 
 2 I6-3p tgccGCGGCCGCtctgagcacaactttgctgcacaccaattgcgtcgccgagatcgacctcgagaccggcgacgaccggcctgcgtgagcgaggtcgcgaccGTTTAAACcccag 
 3 I6-3p atatgGCGGCCGCagtctgactgtacccacagtctacttctacgcccactgaggaagcagagccagagaccatgctgctaatagcttgtgcactcaccaatgcCTCGAGttgtg 
UL54 1 I6-3p cggccGCGGCCGCcggacaaaagatcgccctggatggccgttcacgctgaggtcagaatcccgccacgaagcacattgtattcgccgcagatctcattctacaCTCGAGgaaag 
 2 I6-5p gccgcCTCGAGaccatgtgatagtaattcgcgagataacggtgcgcgaattttcgggccgttgccatcgggagactactttgaaaatttgactgtgattatGCGGCCGCttaca 
 3 I2 atccgCTCGAGcaagatgtgcgtgttattatcgttgggcaagacccgtatcccacggaaggacacgcgcatggcttagctttcagtgtccctagggggtgcGCGGCCGCcgtat 
UL-1 1 I6-5p & I5-5p actctCTCGAGgagtacgacccaccgccggaaatggtggagggttggcatggagggggacagggcgggagggccgagagcccgcagccgctggctgatgtgGCGGCCGCcgtga 
 2 I6-5p & I5-5p SAME AS ABOVE AS THEY OVERLAP 
 3 I3 gcgtgCTCGAGaaatattacgcaatgtaggtttggacgatagaagaattgggcctcacaggggcagggatagataccagttaaggtccaggtctaggaaccGCGGCCGCgatcc 
US3 1 I2 agatgCTCGAGccgggcgcacgattaccgataatgtactcggacgatcgtaactcgccatagttttcactgcgtgaaccaattctttccatccagaatccgGCGGCCGCagagc 
 2 I4 ctcaaCTCGAGaacgcgtttgcgtattggatagtttctcacggacaatgtcattgcgcccctatgcagaaattttgccgaccgcggaaggcgtcgagcgccGCGGCCGCtcgcc 
 3 I6-5p ttatcCTCGAGtgcgacgtccgtcgctacaccgaggaagagcaacgtcgaagaggggttaacagtactaaccaggggaaatcaaaatgtaagcgcctgataGCGGCCGCgctaa 
sORF1 1 I5-5p aatggCTCGAGaacaagggcggcctctcagctggaaaatgaaattttggttctcgggcgcctaaatcacgagaatgttctcaagatccaggaaatccttcgGCGGCCGCgtacc 
ICP4 1 I6-5p & I6-3p agtaaCTCGAGtggacaggcgactcactgtctcatggcccctcagcgttgggaagaccgacaacgacgatgagggtacaggagacagagagaagtgtcctcGCGGCCGCccgtt  
 2 I5-5p & I5-3p tcttcCTCGAGgtcgtcttcctcttcctcatgctcctcgtcgtcgtcttcttcagactccagctcatctgaagaagacggggacgagaagaacgagaaagaGCGGCCGCagatc 
Note, ICP4 targets have both strands of corresponding miRNA in them. EG - both I5-3p and I5-5p 
Red = Xho1 and Blue = Not1 and Green = Pme1 
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UL48 1 I5-3p tagaaGCGGCCGCaagtattttcgggcagctggctacttccctcaatgaagaaggatttgtagccaaaagatggcttaggagttccctggaactcagcgccaaCTCGAGtatta 
 2 I6-5p ctttcGCGGCCGCggataacgacactgttactgcgtcgttcgcgtctcctgttttgtgtttgcattgagccttgtgtagggggcagggatgctgcgcttgagtCTCGAGttggt 
UL46 1 I5-3p 
Same as UL48  2 I6-5p 
UL30 1 I6-5p gaatgGCGGCCGCgaagatactgtgcgccaaaagtcaagaccagccctcctgcgccatcgctcctctcatacgggggcttactgtagagtctgatttcaagccCTCGAGaaacg 
 2 I5-3p tcgggGCGGCCGCtgaatattgcttgaaaaaagtcataaagcacagaagaagctcgaactcagagccacatttgcatacagttatcccatcactacaatcttcCTCGAGggaaa 
 3 I3 gtttaGCGGCCGCgtccgttgccggtaatagctagccttgcctctgcaatcaaccggccaagcttagtaagtccgctcggaagacagtcaaaatcctcaaatcCTCGAGcggct 
UL28 1 I2 atattGCGGCCGCttccagaaaggaatcctttgtccagcatcccgttaaaggctgatcttagggccggcatggcagaagaacggaacatttttgactctggttCTCGAGgccgc 
 2 I5-5p tagaaGCGGCCGCgaacttctatcgaatcctcgtccctttcaatagttcctctgaggttagcagtcaggtcgcttgtactagttccttctgtgacaggttgtgCTCGAGtctcc 
 3 I5-5p ggcctGCGGCCGCttcagaactctggtggcaagtatcctgtcgtcctcatcactatcctcctcaacctcctcctcatccttgtagtaacgtctagagggtcgtCTCGAGggagg 
UL24 1 I6-5p cggatGCGGCCGCgtctagtgttttataagacccaacaatgtccttctcctgcacggcccgctgggctaaatcatccaagacatcaattacagtctctaggggCTCGAGatatt 
 2 I1-5p gtatcGCGGCCGCaacacactgacaaaacagacggactgatcagaaagatataacccttttattgtctaaacagagacgcgatcgcgaaaatactaagcattCTCGAGatcca 
UL9 1 I6-3p tgttcGCGGCCGCtccaggagcaaaattatttggcgacatatcgttcctcccgctgagcgacgtaggcgctaattcacatagcgcagaaaatgagcggctactCTCGAGactat 
 2 I6-3p ctactGCGGCCGCcattgtcggattggataataggcgatcgctgagatcgcatccgtacagtcttcgtgcgagtccgacgctgggcgacaaccacagttgttcCTCGAGtccag 
UL2 1 I2 cagtcGCGGCCGCgtattttgccctgcgccatcataattagacgaggggtggtggggcgaaagctgtggaggggagcgtctagatggcgaggggagggatgatCTCGAGaacct 
 2 I6-5p tgtaaGCGGCCGCataatcacagtcaaattttcaaagtagtctcccgatggcaacggcccgaaaattcgcgcaccgttatctcgcgaattactatcacatggtCTCGAGgcggc 
 3 I2 atacgGCGGCCGCgcaccccctagggacactgaaagctaagccatgcgcgtgtccttccgtgggatacgggtcttgcccaacgataataacacgcacatcttgCTCGAGcggat 
UL-1 1 I6-5p & I5-5p tcacgGCGGCCGCcacatcagccagcggctgcgggctctcggccctcccgccctgtccccctccatgccaaccctccaccatttccggcggtgggtcgtactcCTCGAGagagt 
 2 I6-5p & I5-5p SAME AS ABOVE AS THEY OVERLAP 
 3 I3 ggatcGCGGCCGCggttcctagacctggaccttaactggtatctatccctgcccctgtgaggcccaattcttctatcgtccaaacctacattgcgtaatatttCTCGAGcacgc 
US3 1 I2 gctctGCGGCCGCcggattctggatggaaagaattggttcacgcagtgaaaactatggcgagttacgatcgtccgagtacattatcggtaatcgtgcgcccggCTCGAGcatct 
 2 I4 ggcgaGCGGCCGCggcgctcgacgccttccgcggtcggcaaaatttctgcataggggcgcaatgacattgtccgtgagaaactatccaatacgcaaacgcgttCTCGAGttgag 
 3 I6-5p ttagcGCGGCCGCtatcaggcgcttacattttgatttcccctggttagtactgttaacccctcttcgacgttgctcttcctcggtgtagcgacggacgtcgcaCTCGAGgataa 
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sORF1 1 I5-5p ggtacGCGGCCGCcgaaggatttcctggatcttgagaacattctcgtgatttaggcgcccgagaaccaaaatttcattttccagctgagaggccgcccttgttCTCGAGccatt 
ICP4 1 I6-5p & I6-3p aacggGCGGCCGCgaggacacttctctctgtctcctgtaccctcatcgtcgttgtcggtcttcccaacgctgaggggccatgagacagtgagtcgcctgtccaCTCGAGttact 





Mutant Viral Target Gene Long Oligonucleotides 
 
Gene Targeted by Orientation Sequence 
UL48 2 I6-5p 
Sense accaaCTCGAGcaagcgcagcatccctgccccctacacaaggctcaatgcaaacacaaacccaacaacgcgaacgacgcagtaacagtgtcgttaGCGGCCGCgaaag 
Antisense ctttcGCGGCCGCtaacgacactgttactgcgtcgttcgcgttgttgggtttgtgtttgcattgagccttgtgtagggggcagggatgctgcgcttgCTCGAGttggt 
ICP4 1 I6-5p & I6-3p 
Sense agtaaCTCGAGacaggcgactcactgtctcatggcccctcagcgttgggaagaccgacaacgacgatgagggtcccaacaacagagagaagtgtcGCGGCCGCccgtt  
Antisense aacggGCGGCCGCgacacttctctctgttgttgggaccctcatcgtcgttgtcggtcttcccaacgctgaggggccatgagacagtgagtcgcctgtCTCGAGttact 
UL29 1 I2 
Sense gcggcCTCGAGaaccagagtcaaaaatgttccgttcttctgccatgccggccctaagaAGCGCGTTCaacgggatgctggacaaaggattcctttctggaaGCGGCCGCaatat 
Antisense atattGCGGCCGCttccagaaaggaatcctttgtccagcatcccgttGAACGCGCTtcttagggccggcatggcagaagaacggaacatttttgactctggttCTCGAGgccgc 
NB - Purple colour shows mutation site 
Red and blue colours refer to the same restriction endonucleases as above 















Sense ttgtatCTCGAGttccaggagcggccgtggatcctacggcggcgtctgcttctggggaccaccctgtactcgttggcgccaggcgaatagcgcgtgccacGCGGCCGCgaggga  
Antisense tccctcGCGGCCGCgtggcacgcgctattcgcctggcgccaacgagtacagggtggtccccagaagcagacgccgccgtaggatccacggccgctcctggaaCTCGAGatacaa 
UL20 1 
Sense aataacCTCGAGgcagaccaagttccaacaatgtccgtcaaaatgtccctgctcaacgtgggggaccatcttgtcagcatagaagcactagagcgtgtttGCGGCCGCacacgc  
Antisense gcgtgtGCGGCCGCaaacacgctctagtgcttctatgctgacaagatggtcccccacgttgagcagggacattttgacggacattgttggaacttggtctgcCTCGAGgttatt 
 











Appendix 2  Primers and Oligonucleotides 
226 
 
UL46/48 RT-PCR Primers  
Gene Primer Sequence 
UL48 Universal Forward tagctgattccgcccttgat 
UL48 Reverse (Set 1) cgacttagctgtgttagctg 
UL48/46 Reverse (Set 2) and (UL46 Set 
1) 
cgacgcagtaacagtgtcgt 
UL46 Forward gctcggccagtcctactgaa 
 
ICP4 5’UTR RT-PCR Primers 
Gene Primer Sequence 
Universal Reverse attggagcggccaaattact 
ICP4-1000 Forward (Set 1) cttggcactcccaggaagcg 
ICP4-500 Forward (Set 2) taagtcatgaaaccaatatt 
ICP4-100 Forward (Set 3) ccaccagaaagcttcacgtt 
ICP4-475 Forward (Set 4) attaggtgggctgtcattatttga 
 
Protein and Promoter Cloning Primers 
Gene Primer Sequence 
ICP4p Forward GGTACCtgcttcccggtgtggccaataac 
ICP4p Reverse GGTACCCTCATCAACAATTGGAGCGG 





HA-UL46 Reverse AGTTATACACTCGAGGGCTTAATTCATTACTACGTAATG 
UL48-FLAG Forward ggttccaccATGGAAgaagaatcttccactggagcc 
UL48-FLAG Reverse tgtttagggcatCTTATCGTCGTCATCCTTGTAATCaggtgtatc 
FLAG-UL48 Forward ggttccaccATGGAAgattacaaggatgacgacgataaggaagaatcttccactggagcc 
FLAG-UL48 Reverse TTAGGGCATAGGTGTATCAAG 
6xHis-UL29 Forward gagataactcgcGGTACCGCCACCATGgaacatcatcaccatcaccacaagagttcatctggc 
6xHis-UL29 Reverse  gcgcagttaGCGGCCGCctgTTAacagaacagaatatcag 
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UL46 Outer Forward ggtgggaaagccaacagct 
UL46 Outer Reverse ttattggtccgggagcactt 
MUT-UL29 1 tttgtccagcatcccgttgaacgcgcttcttagggccggcatggcag 
MUT-UL29 2 ctgccatgccggccctaagaagcgcgttcaacgggatgctggacaaa 
MUT-UL46 1 tactgcgtcgttcgcggcgacgattttgtgtttgcattgagccttgtgtagggg 





Gene Primer Sequence 
ICP4 Forward TGTGGAGGAGTTCATGGTCC 
ICP4 Reverse CAGAGCTAATGACACACGGC 
ChCYP Forward GAGGGAGACAAGCCAAAGTT 
ChCYP Reverse GAGGGAGACAAGCCAAAGTT 
Firefly Luciferase Forward TCCATCTTGCTCCAACACCC 
Firefly Luciferase Reverse TGCGTCGAGTTTTCCGGTAA 
 




Gene Primer Sequence 
miR K/O gRNA 1 (Set 1) SENSE CACCGCGGGCTAGGTCGCACTTGCT 
miR K/O gRNA 1 (Set 1) ANTISENSE CGCCCGATCCAGCGTGAACGACAAA 
miR K/O gRNA 2 (Set 1) SENSE CACCGCGGGCTAGGTCGCACTTGC 
miR K/O gRNA 2 (Set 1) ANTISENSE CGCCCGATCCAGCGTGAACGCAAA 
miR K/O gRNA 3 (Set 1) SENSE CACCGCAAGTGCGACCTAGCCCGC 
miR K/O gRNA 3 (Set 1) ANTISENSE CGTTCACGCTGGATCGGGCGCAAA 
miR left side K/O 1 SENSE CACCTCCGCAGAGGAGACTGATTG 
miR left side K/O 1 ANTISENSE AGGCGTCTCCTCTGACTAACCAAA 
miR left side K/O 2 SENSE CACCGATTTCGCGAGGCTCCGCAG 
miR left side K/O ANTISENSE CTAAAGCGCTCCGAGGCGTCCAAA 
miR Right side K/O 1 SENSE CACCTCCGTGATGAGGGAACCACA 
miR Right side K/O 1 ANTISENSE AGGCACTACTCCCTTGGTGTCAAA 
miR Right side K/O 2 SENSE CACCTATAGCGAGCAATGACCGTG 
miR Right side K/O 2 ANTISENSE ATATCGCTCGTTACTGGCACCAAA 
GΔG gRNA 1 SENSE CACCGACGTACTCGTCCAGCGGAC  
GΔG gRNA 1 ANTISENSE CTGCATGAGCAGGTCGCCTGCAAA 
GΔG gRNA 2 SENSE CACCGGACCAGAGTAGTCGCTCCA 
GΔG gRNA 2 ANTISENSE CCTGGTCTCATCAGCGAGGTCAAA 
GΔG gRNA 3 SENSE CACCGACCCTTGGTAGTTACGTGTC 
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GΔG gRNA ANTISENSE CTGGGAACCATCAATGCACAGCAAA 
IVT miR K/O gRNA 1 (Set 1) Forward TTAATACGACTCACTATAGGCGGGCTAGGTCGCACTTGCTGTTTTAGAGCTAGAAAT 
IVT miR K/O gRNA 2 (Set 1) Forward TTAATACGACTCACTATAGGCGGGCTAGGTCGCACTTGCGTTTTAGAGCTAGAAAT 
IVT miR K/O gRNA 3 (Set 1) Forward TTAATACGACTCACTATAGGCAAGTGCGACCTAGCCCGCGTTTTAGAGCTAGAAAT 
IVT GΔG gRNA 1 Forward TTAATACGACTCACTATAGGACGTACTCGTCCAGCGGACGTTTTAGAGCTAGAAAT 
IVT GΔG gRNA 2 Forward TTAATACGACTCACTATAGGGACCAGAGTAGTCGCTCCAGTTTTAGAGCTAGAAAT 
IVT GΔG gRNA 3 Forward TTAATACGACTCACTATAGGACCCTTGGTAGTTACGTGTCGTTTTAGAGCTAGAAAT 
IVT Universal Reverse  AAAAGCACCGACTCGGTGCC  
IVT miR cut site (right side) Forward TTCGGAGAGTGCGGGATTTT 
IVT miR cut site (right side) Reverse CCACTGTTAAACTAACCGTTACT 
IVT GΔG cut site Forward  GCCACCGTTTCCCTAGTATG 
IVT GΔG cut site Reverse CGTCTAGATAAACAGACCCGGT 
IVT miR cut site (left side) Forward TTTTCCCAGAACCGAGGCG 
IVT miR cut site (left side) Reverse CAATTCAGCCGAGGATTTGG 
IVT miR left side K/O 1 Forward TTAATACGACTCACTATAGGTCCGCAGAGGAGACTGATTGGTTTTAGAGCTAGAAAT 
IVT miR left side K/O 2 Forward TTAATACGACTCACTATAGGATTTCGCGAGGCTCCGCAGGTTTTAGAGCTAGAAAT 
IVT miR right side K/O 1 Forward TTAATACGACTCACTATAGGTCCGTGATGAGGGAACCACAGTTTTAGAGCTAGAAAT 
IVT miR right side K/O 2 Forward TTAATACGACTCACTATAGGTATAGCGAGCAATGACCGTGGTTTTAGAGCTAGAAAT 
GΔG Left Flank Forward CACTCGATATCATGGACGCAGCC  
GΔG Left Flank Reverse GGATCCTCATGGTACCAGCTGAAGTTGTCTCTCTCCCCTC 
GΔG Right Flank Forward GGTACCATGAGGATCCCCACCCGAGAGTGTTTTT 
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GΔG Right Flank Reverse CGGAGTCCGCCGGCGAATAATTGG 
miR K/O Left Flank Forward GGATTCGAAACCCCTCGCGGCC 
miR K/O Left Flank Reverse GGATCCTCATGGTACCTCGCGAAATCCAACGGCGGGCGGTCC 
miR K/O Right Flank Forward GGTACCATGAGGATCCCTCATCACGGAGTGCTCGTTATGC 
miR K/O Right Flank Reverse  ATAGCACTTGCTCTCGTTCTGTATA 
CBH Promoter Forward  GGCTCTAGAGGTACCCGTTACATAACTTACGGTAAATGGC 
CBH Promoter Reverse (GFP overlap)  CAGCTCCTCGCCCTTGCTCACCATGGTGGCCCAACCTGAAAAAAAGTG   
GFP Forward (CBH overlap) GTTGGGCCACCATGGTGAGCAAGGGCGAGGAGCTG 
GFP Reverse CGGCCGCGGATCCTCCCCAGCATGCCTGCTATTC  
CMV Promoter Forward GGTACCATAGTAATCAATTACGGGGTCATT 
CMV Promoter Reverse (GFP overlap) CTCGCCCTTGCTCACGCTTATATAGAC 
GFP Forward (CMV overlap) GTGAGCAAGGGCGAG 
GFP Reverse (CMV) GGATCCACTAGAATGCAGTGAAAAAAATGC 
 




Gene Primer Sequence 
psiCHECK-2 Forward TGCTGAAGAACGAGCAGTAA 
psiCHECK-2 Reverse CGAGGTCCGAAGACTCATTT 
PX458 gRNA Forward GCCTATTTCCCATGATTCCT 
GFP Universal Forward (CRISPR) ACATGGTCCTGCTGGAGTTCGTGA 
GΔG-GFP Reverse (CRISPR) TTCCCTAAAGGCCGTAAACGCGAGGACGC 
miRΔ1-5-GFP Forward (CRISPR) CTTAGGCGCGGTGTTGCTAAG 
miRΔ1-5-GFP Reverse (CRISPR) TTCGTGTCAGTGCAGTTTCGC 
M13 Forward ACTGGCCGTCGTTTTAC 
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Appendix 4 – RNA Hybrid analysis of viral targets of ILTV-encoded 
miRNAs 
Gene miRNA Position MFE (Kcal/Mol) 
ORF F 
ILTV-miR-I1-3p 1497 -16.7 
ILTV-miR-I2 1295 -27.7 
ILTV-miR-I2 2043 -23.9 
ILTV-miR-I3 240 -26.0 
ILTV-miR-I3 812 -25.7 
ILTV-miR-I4 1560 -28.1 
ILTV-miR-I4 1771 -21.9 
ILTV-miR-I5-5p 251 -28.2 
ILTV-miR-I5-5p 184 -23.3 
ILTV-miR-I5-3p 2728 -16.4 
ILTV-miR-I6-5p 601 -30.3 
ILTV-miR-I6-5p 2059 -24.8 
ILTV-miR-I6-3p 2458 -33.3 
ILTV-miR-I6-3p 677 -33.0 
ILTV-miR-I7 1752 -21.2 
UL54 ILTV-miR-I6-3p 1543 -33.7 
UL52 
ILTV-miR-I1-5p 3106 -25.3 
ILTV-miR-I6-5p 2524 -25.7 
ILTV-miR-I6-3p 5091 -21.7 
ILTV-miR-I7 4434 -15.9 
UL50 
ILTV-miR-I1-3p 1162 -18.6 
ILTV-miR-I3 1310 -30.7 
ILTV-miR-I4 647 -25.9 
ILTV-miR-I4 1243 -20.6 
ILTV-miR-I5-3p 370 -32.0 
ILTV-miR-I6-3p 1852 -18.7 
UL48 
ILTV-miR-I5-3p 3376 -18.4 
ILTV-miR-I6-5p 3716 -21.5 
UL46 
ILTV-miR-I5-3p 2126 -18.4 
ILTV-miR-I6-5p 2466 -21.5 
UL23 
ILTV-miR-I1-3p 4697 -16.0 
ILTV-miR-I2 867 -33.2 
ILTV-miR-I2 134 -28.3 
ILTV-miR-I3 5097 -20.9 
ILTV-miR-I4 3567 -20.1 
ILTV-miR-I4 3227 -17.4 
ILTV-miR-I6-5p 154 -20.8 
UL26 
ILTV-miR-I1-5p 935 -22.9 
ILTV-miR-I1-5p 991 -18.2 
ILTV-miR-I1-3p 23 -25.1 
ILTV-miR-I1-3p 798 -21.5 
ILTV-miR-I2 2012 -26.7 
ILTV-miR-I2 1947 -23.1 
ILTV-miR-I3 425 -22.0 
ILTV-miR-I3 1063 -23.9 
ILTV-miR-I4 2288 -19.3 
ILTV-miR-I4 2491 -18.4 
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ILTV-miR-I5-5p 1071 -21.8 
ILTV-miR-I5-5p 2013 -18.0 
ILTV-miR-I5-3p 2804 -24.2 
UL26 
ILTV-miR-I5-3p 1246 -15.8 
ILTV-miR-I6-5p 372 -23.4 
ILTV-miR-I6-5p 2654 -21.6 
ILTV-miR-I6-3p 679 -19.2 
ILTV-miR-I7 1488 -17.2 
UL26.5 
ILTV-miR-I1-5p 65 -22.9 
ILTV-miR-I1-5p 121 -18.2 
ILTV-miR-I2 1142 -26.7 
ILTV-miR-I2 1077 -23.1 
ILTV-miR-I3 193 -23.9 
ILTV-miR-I3 749 -18.0 
ILTV-miR-I4 1418 -19.3 
ILTV-miR-I4 1621 -18.4 
ILTV-miR-I5-5p 201 -21.8 
ILTV-miR-I5-5p 1143 -18.0 
ILTV-miR-I5-3p 1934 -24.2 
ILTV-miR-I5-3p 376 -15.8 
ILTV-miR-I6-5p 1784 -21.6 
ILTV-miR-I7 618 -17.2 
UL28 
ILTV-miR-I1-5p 409 -27.6 
ILTV-miR-I1-5p 2772 -22.3 
ILTV-miR-I1-3p 1374 -19.2 
ILTV-miR-I1-3p 3926 -17.9 
ILTV-miR-I2 57 -30.3 
ILTV-miR-I2 3040 -26.9 
ILTV-miR-I3 2376 -25.1 
ILTV-miR-I3 5666 -24.1 
ILTV-miR-I4 1582 -23.2 
ILTV-miR-I4 1155 -20.6 
ILTV-miR-I5-5p 2389 -30.5 
ILTV-miR-I5-5p 5696 -29.3 
ILTV-miR-I5-3p 5973 -19.2 
ILTV-miR-I5-3p 2867 -18.4 
ILTV-miR-I6-5p 1522 -22.6 
ILTV-miR-I6-5p 5362 -21.7 
ILTV-miR-I6-3p 733 -28.1 
ILTV-miR-I6-3p 1590 -21.5 
ILTV-miR-I7 287 -23.9 
ILTV-miR-I7 2381 -20.9 
UL29 
ILTV-miR-I1-5p 3486 -27.6 
ILTV-miR-I1-5p 1549 -23.1 
ILTV-miR-I2 3134 -30.3 
ILTV-miR-I2 2759 -22.2 
ILTV-miR-I3 2668 -24.4 
ILTV-miR-I3 1848 -23.6 
ILTV-miR-I4 2544 -22.2 
ILTV-miR-I4 1814 -19.2 
ILTV-miR-I5-5p 3873 -26.8 
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ILTV-miR-I5-5p 2176 -18.4 
ILTV-miR-I5-3p 2096 -16.0 
ILTV-miR-I6-5p 3856 -21.7 
UL29 
ILTV-miR-I6-5p 3676 -20.6 
ILTV-miR-I6-3p 3810 -28.1 
ILTV-miR-I6-3p 916 -23.4 
ILTV-miR-I7 3364 -23.9 
ILTV-miR-I7 1052 -16.2 
UL30 
ILTV-miR-I1-5p 2415 -15.0 
ILTV-miR-I1-3p 2107 -20.7 
ILTV-miR-I1-3p 3199 -18.7 
ILTV-miR-I2 107 -24.2 
ILTV-miR-I2 3974 -20.9 
ILTV-miR-I3 3747 -29.7 
ILTV-miR-I3 432 -20.1 
ILTV-miR-I4 2681 -22.1 
ILTV-miR-I4 2637 -17.5 
ILTV-miR-I5-5p 2302 -19.1 
ILTV-miR-I5-5p 630 -16.6 
ILTV-miR-I5-3p 2162 -25.2 
ILTV-miR-I5-3p 1787 -20.0 
ILTV-miR-I6-5p 645 -25.8 
ILTV-miR-I6-5p 2548 -24.1 
ILTV-miR-I6-3p 1600 -24.6 
ILTV-miR-I6-3p 673 -21.7 
ILTV-miR-I7 1473 -16.9 
ILTV-miR-I7 1234 -16.1 
UL39 
ILTV-miR-I1-5p 3919 -27.0 
ILTV-miR-I1-5p 1374 -20.7 
ILTV-miR-I1-3p 2754 -22.2 
ILTV-miR-I1-3p 845 -19.2 
ILTV-miR-I2 752 -29.1 
ILTV-miR-I2 552 -26.5 
ILTV-miR-I3 609 -26.9 
ILTV-miR-I3 1152 -26.0 
ILTV-miR-I4 2260 -20.1 
ILTV-miR-I4 418 -17.0 
ILTV-miR-I5-5p 1117 -27.6 
ILTV-miR-I5-5p 586 -22.4 
ILTV-miR-I5-3p 2366 -23.7 
ILTV-miR-I5-3p 3839 -22.8 
ILTV-miR-I6-5p 3875 -22.4 
ILTV-miR-I6-5p 2910 -20.0 
ILTV-miR-I6-3p 2511 -24.2 
ILTV-miR-I6-3p 1762 -24.0 
ILTV-miR-I7 2514 -24.2 
UL40 
ILTV-miR-I1-5p 1556 -27.0 
ILTV-miR-I1-5p 992 -17.3 
ILTV-miR-I1-3p 391 -22.2 
ILTV-miR-I4 1950 -15.3 
ILTV-miR-I5-5p 117 -19.9 
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ILTV-miR-I5-5p 499 -18.9 
ILTV-miR-I5-3p 3 -23.7 
ILTV-miR-I5-3p 1476 -22.8 
UL40 
ILTV-miR-I6-5p 1512 -22.4 
ILTV-miR-I6-5p 547 -20.0 
ILTV-miR-I6-3p 148 -24.2 
ILTV-miR-I6-3p 549 -17.8 
ILTV-miR-I7 151 -24.2 
UL12 
ILTV-miR-I5-5p 1982 -23.5 
ILTV-miR-I5-5p 688 -16.2 
UL9 
ILTV-miR-I6-3p 1068 -26.3 
ILTV-miR-I6-3p 972 -24.0 
UL5 
ILTV-miR-I2 505 -25.1 
ILTV-miR-I6-5p 849 -23.6 
ILTV-miR-I6-5p 3859 -23.0 
ILTV-miR-I7 1973 -18.1 
UL4 ILTV-miR-I6-5p 1249 -23.0 
UL3.5 
ILTV-miR-I2 779 -24.3 
ILTV-miR-I5-3p 776 -19.1 
ILTV-miR-I6-5p 528 -21.9 
ILTV-miR-I6-3p 1268 -16.8 
UL2 
ILTV-miR-I1-5p 1155 -22.5 
ILTV-miR-I2 164 -31.7 
ILTV-miR-I2 1423 -24.5 
ILTV-miR-I3 1330 -22.7 
ILTV-miR-I3 1379 -22.1 
ILTV-miR-I4 953 -22.5 
ILTV-miR-I4 1021 -14.9 
ILTV-miR-I5-5p 230 -19.2 
ILTV-miR-I5-5p 1176 -14.2 
ILTV-miR-I5-3p 883 -19.7 
ILTV-miR-I6-5p 614 -19.2 
ILTV-miR-I6-5p 747 -23.9 
ILTV-miR-I6-3p 1275 -15.9 
ILTV-miR-I6-3p 1441 -26.4 
UL0 ILTV-miR-I5-3p 2855 -19.7 
UL-1 
ILTV-miR-I2 2 -28.2 
ILTV-miR-I2 157 -23.4 
ILTV-miR-I3 2541 -30.1 
ILTV-miR-I3 2249 -25.5 
ILTV-miR-I4 126 -20.8 
ILTV-miR-I4 1961 -19.6 
ILTV-miR-I5-5p 2292 -33.9 
ILTV-miR-I5-5p 1126 -30.3 
ILTV-miR-I5-3p 80 -23.4 
ILTV-miR-I5-3p 1217 -16.6 
ILTV-miR-I6-5p 616 -29.8 
ILTV-miR-I6-5p 2286 -29.6 
ILTV-miR-I6-3p 2651 -15.5 
US10 
ILTV-miR-I2 832 -28.7 
ILTV-miR-I5-3p 614 -24.6 




ILTV-miR-I1-5p 578 -24.4 
ILTV-miR-I3 544 -23.8 
US2 ILTV-miR-I1-5p 1485 -24.4 
US2 
ILTV-miR-I3 1451 -23.8 
ILTV-miR-I5-3p 845 -27.5 
US3 
ILTV-miR-I1-3p 2220 -20.6 
ILTV-miR-I2 773 -28.5 
ILTV-miR-I2 32 -26.9 
ILTV-miR-I3 643 -26.7 
ILTV-miR-I3 383 -25.8 
ILTV-miR-I4 1108 -29.5 
ILTV-miR-I4 1683 -21.7 
ILTV-miR-I5-5p 2054 -20.7 
ILTV-miR-I5-5p 1585 -20.4 
ILTV-miR-I5-3p 213 -24.8 
ILTV-miR-I5-3p 1365 -18.7 
ILTV-miR-I6-5p 1489 -27.5 
ILTV-miR-I6-5p 2064 -26.8 
ILTV-miR-I6-3p 496 -18.3 
ILTV-miR-I6-3p 966 -18.3 
ILTV-miR-I7 1064 -20.5 
sORF1 (UL47) ILTV-miR-I5-5p 74 -20.4 
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Appendix 5: High Confidence Chicken miRNAs from MiRBase Release 
21 (June 2014) 
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Appendix 6 – Alternative Targets of gga-miR-133a-3p in the ILTV 
Genome  






Possible Gene  
Function? † 
UL31 134 -27.7 Nuclear matrix protein 
UL32 1873 - 27.7 Envelope glycoprotein 
UL36 418 -26.7 Large tegument protein 
UL37 3712 -26.7 Capsid assembly  
UL42 1929 -29.8 DNA Polymerase processivity factor  
UL43 546 -29.8 Membrane protein 
UL20 2902 -26.1 Membrane protein 
UL19 2122 -26.1 VP5 – Major capsid protein 
ICP4as* 586 -30.3 
Essential Immediate-Early gene which is absolutely 
required for lytic gene replication 
ICP4as* 2563 -28.5 
ICP4s 584 -30.3 
ICP4 2563 -28.5 
 
*ICP4 rows are direct copies of each other due to there been two copies of ICP4 in the ILTV 
genome, one been in the inverted repeat region hence ‘as’ for antisense orientation.  These 
two were tested as laid out in Chapter 5 of this thesis. 
†Data taken from HSV-1 genome as it is the most annotated of the Alphaherpesviruses and 
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Appendix 7: miR-133a-3p Targeting of ICP4 in different herpesvirus 
species 
Alignment of miR-133a-3p from different animal species 
gga-miR-133a-3p   :  98 
hsa-miR-133a-3p   :  98 
eca-miR-133a      :  98 
ssc-miR-133a-3p   :  97 
bta-miR-133a      :  96 
cons              :  98 
 
gga-miR-133a-3p   -UUGGUCCCCUUCAACCAGCUGU 
hsa-miR-133a-3p   UUUGGUCCCCUUCAACCAGCUG- 
eca-miR-133a      UUUGGUCCCCUUCAACCAGCUG- 
ssc-miR-133a-3p   -UUGGUCCCCUUCAACCAGCUG- 
bta-miR-133a      UUUGGUCCCCUUCAACCAGCUG- 
 




gga = Chicken 
hsa = Human 
eca = Horse 
ssc = Pig 
bta = Cow 
 
RNA Hybrid analysis of miR-133a-3p Targeting ICP4 in different Herpesvirus species 
Target: BOHV-1_ICP4_L14320.1 
MiRNA: gga-miR-133a-3p 
MFE: -29.4 kcal/mol 
Position: 4033 
Target 5'  A   C  GAC  GG CC        A 3' 
            GGC GG   UG  G  GGGACCAG     
            UCG CC   AC  C  CCCUGGUU     




MFE: -28.7 kcal/mol 
Position: 2918 
Target 5' C     CGC  CCGCUCC         G 3' 
           GCGGC   GG       GGGGACCAG     
           UGUCG   CC       CCCCUGGUU     










MFE: -30.6 kcal/mol 
Position: 3724 
Target 5' G     C  GC  CGGCCUC        C 3' 
           ACGGC GG  GG       GGGGACCA     
           UGUCG CC  CU       CCCCUGGU     




MFE: -23.6 kcal/mol 
Position: 7320 
Target 5'   C     CCCGGCCUUCUC  UUUC       C 3' 
             GCUGG            GA    GGGACCA     
             CGACC            CU    CCCUGGU     




MFE: -30.3 kcal/mol 
Position: 584 
Target 5'  G     UCAUUAU             C 3' 
            GGCUG       UUG AGGGGACCA     
            UCGAC       AAC UCCCCUGGU     




MFE: -28.5 kcal/mol 
Position: 2563 
Target 5' U     G C  C  CUUCU        C 3' 
           ACGGC G GU UG     GGGGACCA     
           UGUCG C CA AC     CCCCUGGU     
miRNA  3'       A       UU           U 5' 
 
Virus Species included in screen: 
 
BOHV-1 = Bovine alphaherpesvirus-1 
EQHV-1 = Equine alphaherpesvirus-1 
HSV-1  = Human Simplex virus-1 
MDV-1  = Marek’s Disease Virus-1 
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